{
  "questions": [
    {
      "id": "63f03006f36125a426000018",
      "type": "summary",
      "body": "What were the results of the DESTINY-Breast04 Trial?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32395945",
          "text": "offering an MRI scan to women with very dense glandular breast tissue and normal results on screening mammography reduces the number of interval cancers by 50%. In the women who agreed to undergo an MRI (59%), this reduction was 80% (from 5 per 1000 to 1 per 1000 participants).",
          "offsetInBeginSection": 38,
          "offsetInEndSection": 316,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17690310",
          "text": " 30-day mortality and 6- and 12-month functional outcomes from the DESTINY trial.\n\n\nMETHODS\nDESTINY (ISRCTN01258591) is a prospective, multicenter, randomized, controlled, clinical trial based on a sequential design that used mortality after 30 days as the first end point. When this end point was reached, patient enrollment was interrupted as per protocol until recalculation of the projected sample size was performed on the basis of the 6-month outcome (primary end point=modified Rankin Scale score, dichotomized to 0 to 3 versus 4 to 6). All analyses were based on intention to treat.\n\n\nRESULTS\nA statistically significant reduction in mortality was reached after 32 patients had been included: 15 of 17 (88%) patients randomized to hemicraniectomy versus 7 of 15 (47%) patients randomized to conservative therapy survived after 30 days (P=0.02).",
          "offsetInBeginSection": 195,
          "offsetInEndSection": 1047,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31039047",
          "text": "In total, 45 samples were positive with breath testing and the number of positives with established forensic methods was 46.",
          "offsetInBeginSection": 1411,
          "offsetInEndSection": 1535,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9422017",
          "text": "The probability of a vaginal delivery among these women was 69% (95% CI 63-75%).",
          "offsetInBeginSection": 611,
          "offsetInEndSection": 691,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31039047",
          "text": "Results: The total number of cases used for this investigation was 67. In 54 of these cases (81%) the results regarding a positive or negative drug test result agreed and in 13 they disagreed. Out of these, the report from the forensic investigation of blood/urine was negative in 21 cases.",
          "offsetInBeginSection": 813,
          "offsetInEndSection": 1103,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36386213",
          "text": " and $155,757), which causes the ICER for T-DXd to be $296,873, $318,944, and $197,355 per QALY. The cost of T-DXd and the patient's weight were the m",
          "offsetInBeginSection": 1459,
          "offsetInEndSection": 1609,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35666611",
          "text": "Findings from the phase III DESTINY-Breast04 trial indicate that the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) is effective for patients with inoperable/metastatic HER2-low breast cancer.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17690310",
          "text": "With 32 patients included, the primary end point failed to demonstrate statistical superiority of hemicraniectomy, and the projected sample size was calculated to 188 patients.",
          "offsetInBeginSection": 1315,
          "offsetInEndSection": 1491,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501453",
          "text": "Two of the LiST estimates overestimated the mortality reductions by 6.1 and 4.2 percentage points (33% and 35% relative to the measured estimates), while two underestimated the mortality reductions by 4.7 and 6.2 percentage points (22% and 25% relative to the measured estimates).",
          "offsetInBeginSection": 1356,
          "offsetInEndSection": 1636,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35665782",
          "text": "CONCLUSIONS\nIn this trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy.",
          "offsetInBeginSection": 2191,
          "offsetInEndSection": 2414,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17690310",
        "http://www.ncbi.nlm.nih.gov/pubmed/35666611",
        "http://www.ncbi.nlm.nih.gov/pubmed/21501453",
        "http://www.ncbi.nlm.nih.gov/pubmed/35665782",
        "http://www.ncbi.nlm.nih.gov/pubmed/36386213",
        "http://www.ncbi.nlm.nih.gov/pubmed/9422017",
        "http://www.ncbi.nlm.nih.gov/pubmed/31039047",
        "http://www.ncbi.nlm.nih.gov/pubmed/32395945"
      ]
    },
    {
      "id": "641ad941690f196b5100003d",
      "type": "yesno",
      "body": "Are LOQ and LOD the same?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28911409",
          "text": "tion is important for the analysis of aflatoxin in hazelnuts. The limit of detection (LOD) and limit of quantification (LOQ) are two important paramet",
          "offsetInBeginSection": 364,
          "offsetInEndSection": 514,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8013092",
          "text": "3 the magnitude of the corresponding statistical LODs. The empirical LODs and LOQs are identical for these GC-MS assays. The observations made here ab",
          "offsetInBeginSection": 972,
          "offsetInEndSection": 1122,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25907667",
          "text": "Moreover, LOD and LOQ decrease with decrease of data acquisition frequency (DAF).",
          "offsetInBeginSection": 641,
          "offsetInEndSection": 722,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31108780",
          "text": "Besides, LOD and LOQ of glycidyl ester were 0.024 and 0.06\u202fmg/kg respectively.",
          "offsetInBeginSection": 656,
          "offsetInEndSection": 734,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21603916",
          "text": "Real-time PCR (qPCR) is the principal technique for the quantification of pathogen biomass in host tissue, yet no generic methods exist for the determination of the limit of quantification (LOQ) and the limit of detection (LOD) in qPCR.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 236,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18996077",
          "text": " Results showed no significant discrepancy between LOD/LOQ obtained by the different techniques. Validation experiments corroborated the calculated LOQ. The results indicate that any single technique can provide meaningful values for the LOD and LOQ.",
          "offsetInBeginSection": 578,
          "offsetInEndSection": 828,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1783594",
          "text": "LOD and LOQ are equivalent to 3 and 10 times, respectively, the background signal contributed by a sample matrix blank.",
          "offsetInBeginSection": 687,
          "offsetInEndSection": 806,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1783594",
          "text": "LOD and LOQ are equivalent to 3 and 10 times, respectively, the background signal contributed by a sample matrix blank.",
          "offsetInBeginSection": 687,
          "offsetInEndSection": 806,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32308686",
          "text": "mparable with a selected HPLC reference method. Both methods displayed same precision and credibility. Reaction stoichiometry between tryptophan and g",
          "offsetInBeginSection": 624,
          "offsetInEndSection": 774,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21662779",
          "text": "Limits of detection (LOD) and quantitation (LOQ) for UV detection are 1 and 2 mg/L, respectively.",
          "offsetInBeginSection": 490,
          "offsetInEndSection": 587,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30086968",
        "http://www.ncbi.nlm.nih.gov/pubmed/21662779",
        "http://www.ncbi.nlm.nih.gov/pubmed/28911409",
        "http://www.ncbi.nlm.nih.gov/pubmed/14647939",
        "http://www.ncbi.nlm.nih.gov/pubmed/20220523",
        "http://www.ncbi.nlm.nih.gov/pubmed/15936163",
        "http://www.ncbi.nlm.nih.gov/pubmed/25907667",
        "http://www.ncbi.nlm.nih.gov/pubmed/27690394",
        "http://www.ncbi.nlm.nih.gov/pubmed/29105560",
        "http://www.ncbi.nlm.nih.gov/pubmed/1783594"
      ]
    },
    {
      "id": "642a029d57b1c7a315000011",
      "type": "summary",
      "body": "Histone acetyltransferases (HATs) transfer acetyl groups from acetyl CoA to lysine residues on histones. What is the purpose of this transfer?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19577000",
          "text": "Different subtypes of histone acetyl transferases (HATs) catalyze the acetylation of histones on specific lysine residues.",
          "offsetInBeginSection": 149,
          "offsetInEndSection": 271,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11112280",
          "text": "residues in the N-terminal tails of nucleosomal histones to promote transcriptional activation. Recent structural and enzymatic work on the GCN5/PCAF ",
          "offsetInBeginSection": 91,
          "offsetInEndSection": 241,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12368900",
          "text": "me A (CoA) to acetylate specific Lys residues within histones to regulate gene expression. The structure of an ESA1-CoA complex reveals structural sim",
          "offsetInBeginSection": 106,
          "offsetInEndSection": 256,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21057107",
          "text": "Most histone acetyltransferases (HATs) function as multisubunit complexes in which accessory proteins regulate substrate specificity and catalytic efficiency.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15313419",
          "text": "The group of enzymes, histone acetyltransferases (HATs), involved in this crucial step of gene regulation, covalently modifies the N-terminal lysine residues of histones by the addition of an acetyl group from acetyl coenzyme A. Dysfunction of these enzymes is often associated with several diseases, ranging from neurodegenerative disorders to cancer.",
          "offsetInBeginSection": 83,
          "offsetInEndSection": 435,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21908798",
          "text": "Histone acetyltransferases (HATs) catalyze the transfer of an acetyl group from an acetyl-coenzyme A donor molecule to specific lysine residues within proteins.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32764680",
          "text": "Histone acetyltransferases (HATs) catalyze the transfer of an acetyl group from acetyl-CoA to lysine residues of histones and play a central role in transcriptional regulation in diverse biological processes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32157780",
          "text": "ansfer acetyl groups onto histones and thereby regulate both gene expression and chromosomal structures. Previous work has shown that the activation o",
          "offsetInBeginSection": 63,
          "offsetInEndSection": 213,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26065557",
          "text": "Histone acetyltransferases (HATs) mediate the transfer of an acetyl group from the cofactor, acetyl-CoA, to the side chain amino group of specific lysines in diverse protein substrates, most notably nuclear histones.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 216,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12624111",
          "text": "These enzymes covalently modify the N-terminal lysine residues of histones by the addition of acetyl groups from acetyl-CoA.",
          "offsetInBeginSection": 124,
          "offsetInEndSection": 248,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27231488",
        "http://www.ncbi.nlm.nih.gov/pubmed/12391296",
        "http://www.ncbi.nlm.nih.gov/pubmed/15313419",
        "http://www.ncbi.nlm.nih.gov/pubmed/12624111",
        "http://www.ncbi.nlm.nih.gov/pubmed/32695779",
        "http://www.ncbi.nlm.nih.gov/pubmed/32157780",
        "http://www.ncbi.nlm.nih.gov/pubmed/11112280",
        "http://www.ncbi.nlm.nih.gov/pubmed/10790315",
        "http://www.ncbi.nlm.nih.gov/pubmed/28240169",
        "http://www.ncbi.nlm.nih.gov/pubmed/26065557"
      ]
    },
    {
      "id": "6432fc0457b1c7a31500001f",
      "type": "factoid",
      "body": "Which gene is most frequently mutated in hereditary angioedema ?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33780405",
          "text": "used by either a C1 esterase inhibitor deficiency (type 1) or mutation (type 2). This leads to overproduction of bradykinin resulting in vasodilation,",
          "offsetInBeginSection": 80,
          "offsetInEndSection": 230,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19477491",
          "text": "women), and tranexamic acid (1 woman). No difference between mutation p.Thr309Arg and p.Thr309Lys was found.\n\n\nCONCLUSIONS\nFacial swelling is a cardin",
          "offsetInBeginSection": 1419,
          "offsetInEndSection": 1569,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8586465",
          "text": "d protein 4.1. Recent mutation analyses have revealed that the NF2 tumor suppressor gene is frequently mutated not only in vestibular schwannomas and ",
          "offsetInBeginSection": 1248,
          "offsetInEndSection": 1398,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20667118",
          "text": "Recently, in some families mutations in the coagulation factor XII (Hageman factor) gene were detected in the affected persons.",
          "offsetInBeginSection": 528,
          "offsetInEndSection": 655,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19477491",
          "text": "BACKGROUND\nHereditary angioedema caused by mutations in the factor XII gene is a recently described disease entity that occurs mainly in women.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27826968",
          "text": "mally low C1-INH activity (less than 25%; normal range: 70%-130%). The SERPING1 gene mutation was confirmed in this patient. She was treated with prop",
          "offsetInBeginSection": 1064,
          "offsetInEndSection": 1214,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28601681",
          "text": "e genetic\u00a0disease usually caused by mutation in the C1 inhibitor or the coagulation Factor XII gene. However, in a series of patients with HAE, no cau",
          "offsetInBeginSection": 47,
          "offsetInEndSection": 197,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16634360",
          "text": "It is caused by heterozygous defects in the C1 inhibitor gene located on chromosome 11q, and it has an autosomal dominant inheritance pattern.",
          "offsetInBeginSection": 198,
          "offsetInEndSection": 340,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27826968",
          "text": "ct in the C1 esterase inhibitor (C1-INH) consequent to mutation in the SERPING1 gene, which encodes C1-INH. This disease manifests as recurrent, non-p",
          "offsetInBeginSection": 78,
          "offsetInEndSection": 228,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34065094",
          "text": "he hands, feet, limbs, face, intestinal tract, or airway. Mutations in SERPING1, the gene that encodes C1-INH (C1 esterase inhibitor), are responsible",
          "offsetInBeginSection": 185,
          "offsetInEndSection": 335,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16634360",
        "http://www.ncbi.nlm.nih.gov/pubmed/19477491",
        "http://www.ncbi.nlm.nih.gov/pubmed/19656474",
        "http://www.ncbi.nlm.nih.gov/pubmed/33593719",
        "http://www.ncbi.nlm.nih.gov/pubmed/28601681",
        "http://www.ncbi.nlm.nih.gov/pubmed/23282866",
        "http://www.ncbi.nlm.nih.gov/pubmed/36417927",
        "http://www.ncbi.nlm.nih.gov/pubmed/33442779",
        "http://www.ncbi.nlm.nih.gov/pubmed/36203343",
        "http://www.ncbi.nlm.nih.gov/pubmed/24176211"
      ]
    },
    {
      "id": "64178edb690f196b51000025",
      "type": "summary",
      "body": "What is casimersen's mechanism of action?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
          "text": "However, the cell type that senses O2 (the O2 sensor) and the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear.",
          "offsetInBeginSection": 201,
          "offsetInEndSection": 381,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29178131",
          "text": "However, the presumptive mechanism of action, inhibition of NMDA (N-methyl-D-aspartate) receptors, has recently been challenged.",
          "offsetInBeginSection": 191,
          "offsetInEndSection": 319,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18642372",
          "text": "AIMS\nThe mechanism of action of injection therapy is virtually unknown. Urethral Pressure Reflectometry (UPR) is a novel technique for measuring press",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18633828",
          "text": "The representations are therefore shared between self and other (shared representations of action, SRA).",
          "offsetInBeginSection": 92,
          "offsetInEndSection": 196,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
        "http://www.ncbi.nlm.nih.gov/pubmed/29178131",
        "http://www.ncbi.nlm.nih.gov/pubmed/18642372",
        "http://www.ncbi.nlm.nih.gov/pubmed/18633828"
      ]
    },
    {
      "id": "6402bf2b201352f04a000007",
      "type": "summary",
      "body": "What is the mechanism of action of tiragolumab?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19719780",
          "text": "The mechanism of the long duration of action of salmeterol at beta(2)-adrenoceptors has long been a matter of debate, and is still unresolved.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32576590",
          "text": "The TIGIT inhibitor tiragolumab, alone or in combination with the PD-L1 inhibitor atezolizumab, may be effective against solid cancers.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
          "text": "However, the cell type that senses O2 (the O2 sensor) and the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear.",
          "offsetInBeginSection": 201,
          "offsetInEndSection": 381,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32576590",
        "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
        "http://www.ncbi.nlm.nih.gov/pubmed/19719780"
      ]
    },
    {
      "id": "641d8fd6690f196b51000041",
      "type": "list",
      "body": "What are the serum biomarkers that have been proposed in Neuromyelitis Optica Spectrum Disorders (NMOSD) to monitor disease activity?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35401423",
          "text": "These include antibody titers, cytokine profiles, complement factors, and markers of neuronal (e.g., neurofilament light chain) or astroglial (e.g., glial fibrillary acidic protein) damage.",
          "offsetInBeginSection": 1340,
          "offsetInEndSection": 1529,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31471502",
          "text": "OBJECTIVE\nTo test the hypothesis that serum levels of glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL), which are an intermediate astrocyte and neuron filaments, respectively, are clinically useful biomarkers of disease activity and disability in neuromyelitis optica spectrum disorders (NMOSD).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 321,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32961928",
          "text": "We highlight short chain fatty acids, lipoproteins, amino acids, and lactate as candidate diagnostic biomarkers.",
          "offsetInBeginSection": 875,
          "offsetInEndSection": 987,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25468778",
          "text": "The serum levels of IL-21, IL-6, IL-17, TNF-\u03b1 and IL-10 were analyzed by ELISA assays.",
          "offsetInBeginSection": 465,
          "offsetInEndSection": 551,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36378751",
          "text": "ing remission may be predictive of future disease activity. Serial serum GFAP measurements are emerging as a biomarker to monitor disease activity in ",
          "offsetInBeginSection": 1234,
          "offsetInEndSection": 1384,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35938660",
          "text": "As our understanding regarding the immune pathophysiology of NMOSD expands, emerging biomarkers, including serum neurofilament light chain and glial fibrillary acidic protein (GFAP), may facilitate earlier relapse detection and inform long-term treatment decisions.",
          "offsetInBeginSection": 1216,
          "offsetInEndSection": 1481,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35887254",
          "text": "This review aims to provide an update on recent studies regarding issues related to NMOSD, including the pathophysiology of the disease, the potential use of serum and cerebrospinal fluid cytokines as disease biomarkers, the clinical utilization of ocular coherence tomography, and the comparison of different animal models of NMOSD.",
          "offsetInBeginSection": 549,
          "offsetInEndSection": 882,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35401423",
          "text": "These include antibody titers, cytokine profiles, complement factors, and markers of neuronal (e.g., neurofilament light chain) or astroglial (e.g., glial fibrillary acidic protein) damage.",
          "offsetInBeginSection": 1340,
          "offsetInEndSection": 1529,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32547558",
          "text": "Exosomal microRNAs (miRNAs) are emerging biomarkers for demyelinating diseases.",
          "offsetInBeginSection": 147,
          "offsetInEndSection": 226,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29478727",
          "text": "Serum immunoglobulin G autoantibodies (NMO-IgG) are identified in the majority of NMOSD patients.",
          "offsetInBeginSection": 123,
          "offsetInEndSection": 220,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36378751",
        "http://www.ncbi.nlm.nih.gov/pubmed/31664710",
        "http://www.ncbi.nlm.nih.gov/pubmed/33019871",
        "http://www.ncbi.nlm.nih.gov/pubmed/25468778",
        "http://www.ncbi.nlm.nih.gov/pubmed/32961928",
        "http://www.ncbi.nlm.nih.gov/pubmed/31471502",
        "http://www.ncbi.nlm.nih.gov/pubmed/35887254",
        "http://www.ncbi.nlm.nih.gov/pubmed/29478727",
        "http://www.ncbi.nlm.nih.gov/pubmed/35401423",
        "http://www.ncbi.nlm.nih.gov/pubmed/32547558"
      ]
    },
    {
      "id": "6429d5c557b1c7a315000006",
      "type": "list",
      "body": "What are the major thrombotic complications in patients with COVID-19?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34060217",
          "text": "The aim of our study was to determine the incidence of late thrombotic complications (deep vein thrombosis, pulmonary embolism, stroke, new-onset vascular access thrombosis) in maintenance hemodialysis patients after recovery from COVID-19.",
          "offsetInBeginSection": 215,
          "offsetInEndSection": 455,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34271813",
          "text": "Most of these complications are associated with venous thromboembolism and pulmonary embolism; and arterial thrombosis is rare.",
          "offsetInBeginSection": 89,
          "offsetInEndSection": 216,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34110529",
          "text": "Patients were evaluated for major adverse cardiovascular events (MACE: cardiovascular death, myocardial infarction, stroke, transient ischemic attack, venous thromboembolism) and bleeding complications [according to Bleeding Academic Research Consortium (BARC) definition] during in-hospital stay.",
          "offsetInBeginSection": 702,
          "offsetInEndSection": 999,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36430724",
          "text": "These complications are thought to be driven by endothelial activation and tissue damage promoted by the systemic hyperinflammation associated with COVID-19.",
          "offsetInBeginSection": 124,
          "offsetInEndSection": 281,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32829885",
          "text": "Thrombotic complications due to COVID-19 are likely to occur due to a pro-coagulant pattern encountered in some of these patients or to a progressive endothelial thrombo-inflammatory syndrome causing microvascular disease.",
          "offsetInBeginSection": 500,
          "offsetInEndSection": 722,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35967591",
          "text": "These include microvascular and macrovascular thrombotic complications such as arterial and venous thromboembolism, myocardial injury or inflammation resulting in infarction, heart failure, and arrhythmias.",
          "offsetInBeginSection": 94,
          "offsetInEndSection": 300,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35110028",
          "text": "(COVID-19) is the leading cause of acute respiratory distress syndrome (ARDS), multiple organ failure, and mortality. Extracorporeal membrane oxygenat",
          "offsetInBeginSection": 64,
          "offsetInEndSection": 214,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33569525",
          "text": "DISCUSSION\nOne-third of COVID-19 patients show major thrombotic events, mostly pulmonary emboli.",
          "offsetInBeginSection": 782,
          "offsetInEndSection": 878,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34724155",
          "text": "gulable state in COVID-19, including thrombotic microangiopathy, endothelial dysfunction, bleeding disorder, and thrombosis. However, large specialise",
          "offsetInBeginSection": 318,
          "offsetInEndSection": 468,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34066226",
          "text": "In this review, we summarize the current understanding of relationships between SARS-CoV-2 infection, endothelial dysfunction, and pulmonary and extrapulmonary complications in patients with COVID-19.",
          "offsetInBeginSection": 1250,
          "offsetInEndSection": 1450,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35967591",
        "http://www.ncbi.nlm.nih.gov/pubmed/35110028",
        "http://www.ncbi.nlm.nih.gov/pubmed/34724155",
        "http://www.ncbi.nlm.nih.gov/pubmed/33296828",
        "http://www.ncbi.nlm.nih.gov/pubmed/34060217",
        "http://www.ncbi.nlm.nih.gov/pubmed/33569525",
        "http://www.ncbi.nlm.nih.gov/pubmed/33414129",
        "http://www.ncbi.nlm.nih.gov/pubmed/34884354",
        "http://www.ncbi.nlm.nih.gov/pubmed/34271813",
        "http://www.ncbi.nlm.nih.gov/pubmed/34104443"
      ]
    },
    {
      "id": "6433012b57b1c7a315000022",
      "type": "summary",
      "body": "What is Cinryze?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22282695",
          "text": "he United States was limited to androgen therapy. The human plasma-derived C1 esterase inhibitor (Cinryze\u2122), distributed by Lev Pharmaceuticals, was a",
          "offsetInBeginSection": 734,
          "offsetInEndSection": 884,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20627701",
          "text": "Treatments approved by the Food and Drug Administration for routine prophylaxis include danazol given orally and the nanofiltered human C1 esterase inhibitor, CINRYZE, which is approved for intravenous administration.",
          "offsetInBeginSection": 110,
          "offsetInEndSection": 327,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29279063",
          "text": "ts, and the mean age was 50.1 years. Cinryze and Berinert (both C1-esterase inhibitors) had the highest median scores (5.0) for patient confidence, fo",
          "offsetInBeginSection": 986,
          "offsetInEndSection": 1136,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31592791",
          "text": "Cinryze has FDA approval only for prophylaxis for children as young as 6 years old.",
          "offsetInBeginSection": 1021,
          "offsetInEndSection": 1104,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29569504",
          "text": "a blocking the production or function of bradykinin. Cinryze\u00ae is a nanofiltered C1-INH, approved in Europe for the acute treatment, preprocedure preve",
          "offsetInBeginSection": 406,
          "offsetInEndSection": 556,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21895469",
          "text": "Cinryze is a pasteurized, nanofiltered plasma derived concentrate of C1-inhibitor (pdC1-INH) licensed for the prophylactic treatment of hereditary angioedema.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31592791",
          "text": "Available agents include plasma-derived C1 esterase inhibitors (C1-INH) (Berinert, Haegarda, Cinryze), recombinant C1-INH (Ruconest), bradykinin B2 receptor inhibitor (Icatibant), and kallikrein inhibitors (Ecallantide and lanadelumab).",
          "offsetInBeginSection": 383,
          "offsetInEndSection": 619,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26756974",
          "text": "ched to long-term prophylaxis consisting in an individual dose of intravenous C1-INHc (Cinryze). None of the patients had been previously treated with",
          "offsetInBeginSection": 776,
          "offsetInEndSection": 926,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23282867",
          "text": " C1 inhibitor derived from pooled human plasma has been available for decades in Europe, and 2 preparations have been recently introduced into the United States. Both have been efficacious in carefully controlled double-blind studies. One preparation, Cinryze, was approved by the U.S. Food & Drug Administration (FDA) for prophylaxis of HAE attacks in October 2008, and the second, Berinert, was approved by the FDA for treatment of acute attacks in October 2009.",
          "offsetInBeginSection": 561,
          "offsetInEndSection": 1025,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33485376",
          "text": "She was treated with Cinryze\u00ae replacement therapy throughout the pregnancy 1000 IU i.v.",
          "offsetInBeginSection": 701,
          "offsetInEndSection": 788,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29279063",
        "http://www.ncbi.nlm.nih.gov/pubmed/20627701",
        "http://www.ncbi.nlm.nih.gov/pubmed/21895469",
        "http://www.ncbi.nlm.nih.gov/pubmed/22282695",
        "http://www.ncbi.nlm.nih.gov/pubmed/31592791",
        "http://www.ncbi.nlm.nih.gov/pubmed/23282867",
        "http://www.ncbi.nlm.nih.gov/pubmed/33485376",
        "http://www.ncbi.nlm.nih.gov/pubmed/29569504",
        "http://www.ncbi.nlm.nih.gov/pubmed/26756974"
      ]
    },
    {
      "id": "64179337690f196b51000034",
      "type": "yesno",
      "body": "Do machine learning-based methods outperform statistical methods for survival analysis?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24573170",
          "text": "Most of the rule quality measures outperform Kaplan-Meier estimate and perform at least equally well as tree-based algorithms.",
          "offsetInBeginSection": 1137,
          "offsetInEndSection": 1263,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34910160",
          "text": "Deep learning outperformed Cox proportional hazards models on the basis of proportion of explained variance (R2: 0.468 vs 0.425 in women and 0.383 vs 0.348 in men), calibration and discrimination (all P\u2009<0.0001).",
          "offsetInBeginSection": 1380,
          "offsetInEndSection": 1592,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36028137",
          "text": "CONCLUSION\nMachine learning algorithms such as the random forest were superior to conventional Cox regression and previously reported survival scores for predicting 1-month, 3-month, and 12-month survival following liver transplantation.",
          "offsetInBeginSection": 2443,
          "offsetInEndSection": 2680,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35571512",
          "text": "Furthermore, RF, SVM, DT, AdaBoost, DT, and KNN outperform other machine learning algorithms in predicting the survival or death of COVID-19 patients.",
          "offsetInBeginSection": 986,
          "offsetInEndSection": 1136,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36233640",
          "text": "The ensemble methods RF and XGB outperform other methods when data are less balanced, while SVM, LR, LASSO, and DFNN outperform other methods when data are more balanced.",
          "offsetInBeginSection": 2044,
          "offsetInEndSection": 2214,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31888507",
          "text": "We demonstrate superior performance relative to standard random forest methods for survival data.",
          "offsetInBeginSection": 1352,
          "offsetInEndSection": 1449,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30155234",
          "text": "ross-validation strategy. We found (1) that deep learning methods significantly outperform all competing methods and (2) that the predictive performan",
          "offsetInBeginSection": 924,
          "offsetInEndSection": 1074,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27042700",
          "text": "Results suggest that LSVR is at a minimum competitive with favored machine learning methods and is able to outperform those methods in predicting ALS score one month in advance.",
          "offsetInBeginSection": 764,
          "offsetInEndSection": 941,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36227551",
          "text": "Our results reveal that machine-learning-based models such as random survival forests, gradient boosted survival model, and survival support vector machine can outperform the traditional statistical methods, i.e., Cox proportional hazard model.",
          "offsetInBeginSection": 847,
          "offsetInEndSection": 1091,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34862545",
          "text": " and within neurosciences, including neurosurgery. ML methods regularly outperform classical methods and have been successfully applied to, inter alia",
          "offsetInBeginSection": 568,
          "offsetInEndSection": 718,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33313792",
        "http://www.ncbi.nlm.nih.gov/pubmed/36227551",
        "http://www.ncbi.nlm.nih.gov/pubmed/35143521",
        "http://www.ncbi.nlm.nih.gov/pubmed/30155234",
        "http://www.ncbi.nlm.nih.gov/pubmed/34845416",
        "http://www.ncbi.nlm.nih.gov/pubmed/34910160",
        "http://www.ncbi.nlm.nih.gov/pubmed/24573170",
        "http://www.ncbi.nlm.nih.gov/pubmed/20153956",
        "http://www.ncbi.nlm.nih.gov/pubmed/31888507",
        "http://www.ncbi.nlm.nih.gov/pubmed/21368918"
      ]
    },
    {
      "id": "63f03c47f36125a42600001e",
      "type": "factoid",
      "body": "ZF2001 is used for which disease?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35596222",
          "text": "To investigate the protective efficacy and mechanism of ZF2001 (a protein subunit vaccine with conditional approval in China) to SARS-CoV-2 Delta variant-induced severe pneumonia, the lethal challenge model of K18-hACE2 transgenic mice was used in this study.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 259,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34021265",
          "text": "odies (NAbs) elicited by CoronaVac (inactivated vaccine), ZF2001 (RBD-subunit vaccine) and natural infection. Among 86 potent NAbs identified by high-",
          "offsetInBeginSection": 268,
          "offsetInEndSection": 418,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36146661",
          "text": "binding domain (RBD) subunit vaccine with emergency use authorization in China, was used for comparison. L2, with adjuvant compatibility with RBD, ele",
          "offsetInBeginSection": 514,
          "offsetInEndSection": 664,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34877393",
          "text": "es (NAbs) elicited by CoronaVac (inactivated vaccine) and ZF2001 (RBD-subunit vaccine) against B.1.617 and B.1.1.7 variants. Our results showed that, ",
          "offsetInBeginSection": 598,
          "offsetInEndSection": 748,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35507481",
          "text": "The primary end point was the occurrence of symptomatic coronavirus disease 2019 (Covid-19), as confirmed on polymerase-chain-reaction assay, at least 7 days after receipt of the third dose.",
          "offsetInBeginSection": 777,
          "offsetInEndSection": 967,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36158819",
          "text": "eceiving the first dose of the ZF2001 RBD-subunit vaccine against coronavirus disease 2019 (COVID-19). Autopsy showed severe interstitial myocarditis,",
          "offsetInBeginSection": 106,
          "offsetInEndSection": 256,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35507481",
          "text": "BACKGROUND\nThe ZF2001 vaccine, which contains a dimeric form of the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 and aluminum hydroxide as an adjuvant, was shown to be safe, with an acceptable side-effect profile, and immunogenic in adults in phase 1 and 2 clinical trials.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 303,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36146661",
        "http://www.ncbi.nlm.nih.gov/pubmed/35596222",
        "http://www.ncbi.nlm.nih.gov/pubmed/34877393",
        "http://www.ncbi.nlm.nih.gov/pubmed/36158819",
        "http://www.ncbi.nlm.nih.gov/pubmed/35507481",
        "http://www.ncbi.nlm.nih.gov/pubmed/34021265"
      ]
    },
    {
      "id": "642c82c557b1c7a315000012",
      "type": "factoid",
      "body": "What mammal has the lowest known chromosome number?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31879909",
          "text": "We believe that we can significantly broaden this scenario by establishing a unique placental mammal model system that combines the powerful genetic tools and low chromosome number of fission yeast and Drosophila melanogaster, with the exceptional cytological features of a rat kangaroo cell.",
          "offsetInBeginSection": 1012,
          "offsetInEndSection": 1304,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24500949",
          "text": "kelihood-inferred changes in chromosome numbers among close relatives. Typhonium, the focal genus, includes species with 2n = 65 and 2n = 8, the lowes",
          "offsetInBeginSection": 486,
          "offsetInEndSection": 636,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31879909",
          "text": "This system is based on hTERT-immortalized fibroblasts from a female Indian muntjac, a placental mammal with the lowest known chromosome number (n\u00a0=\u00a03).",
          "offsetInBeginSection": 1305,
          "offsetInEndSection": 1457,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14608465",
          "text": "ty, with diploid numbers ranging from 2n=50 to 2n=16. We report on Callicebus lugens, which has the lowest diploid number (2n=16) yet found in the pri",
          "offsetInBeginSection": 171,
          "offsetInEndSection": 321,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32843950",
          "text": "o-2-phenylindole) staining. The karyotype analyses show that the male B. sinicus possesses the lowest chromosome number (2n = 15) ever observed in Mec",
          "offsetInBeginSection": 145,
          "offsetInEndSection": 295,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30296783",
          "text": "e. In total, 2,758 spermatocytes and over 170,000 COs were examined. Suffolk rams exhibited the lowest mean number of COs (61.1 \u00b1 0.15) compared to Ic",
          "offsetInBeginSection": 533,
          "offsetInEndSection": 683,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17189914",
          "text": "Among marine mammals, a C-value has been estimated only for the bottlenose dolphin (Tursiops truncatus).",
          "offsetInBeginSection": 408,
          "offsetInEndSection": 512,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33089966",
          "text": "and the X-chromosome scaffold, with a scaffold N50 of 115\u00a0Mb. Genome-wide heterozygosity is the lowest (0.01%) of any mammalian species analysed to da",
          "offsetInBeginSection": 707,
          "offsetInEndSection": 857,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/5444269",
          "text": "The Indian muntjac (Muntiacus muntjak) has a diploid chromosome number of 7 in the male and 6 in the female, the lowest number yet described in a mammal.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29706521",
          "text": "Here we used the unique cytological attributes of female Indian muntjac, the mammal with the lowest known chromosome number (2n\u00a0= 6), to characterize and track individual chromosomes with distinct kinetochore size throughout mitosis.",
          "offsetInBeginSection": 615,
          "offsetInEndSection": 848,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27186334",
        "http://www.ncbi.nlm.nih.gov/pubmed/17799482",
        "http://www.ncbi.nlm.nih.gov/pubmed/32843950",
        "http://www.ncbi.nlm.nih.gov/pubmed/21563069",
        "http://www.ncbi.nlm.nih.gov/pubmed/29706521",
        "http://www.ncbi.nlm.nih.gov/pubmed/14608465",
        "http://www.ncbi.nlm.nih.gov/pubmed/31879909",
        "http://www.ncbi.nlm.nih.gov/pubmed/17189914",
        "http://www.ncbi.nlm.nih.gov/pubmed/22105874",
        "http://www.ncbi.nlm.nih.gov/pubmed/33089966"
      ]
    },
    {
      "id": "6429b41757b1c7a315000004",
      "type": "list",
      "body": "When modifying histones with either activating or repressing marks, such as with acetyl and methyl groups, histone acetyltransferases and histone methyltransferases normally modify which amino acids?",
      "snippets": [],
      "documents": []
    },
    {
      "id": "643305b257b1c7a315000025",
      "type": "factoid",
      "body": "Which company produces Ruconest?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26250409",
          "text": "This article will focus on the results of ten clinical studies demonstrating the efficacy and safety of Ruconest(\u00ae) (Pharming Group NV, Leiden, the Netherlands), which is now approved for use in Europe, Israel and the USA.",
          "offsetInBeginSection": 821,
          "offsetInEndSection": 1043,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19455773",
          "text": "This study of Raleigh Industries, one of the leading bicycle manufactures in the world in the immediate post-war years, argues that its business strategy was in part shaped by a managerial commitment to a dominant company culture which was deeply embedded in Raleigh's history.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 277,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32197675",
          "text": "This contribution from a pharmaceuticals company describes WW assessment and management principles, the search for pretreatment options and several case studies on WW (pre)treatment at some pharma production sites of the Roche Group.",
          "offsetInBeginSection": 401,
          "offsetInEndSection": 634,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25210412",
          "text": "Belinostat (Beleodaq) for peripheral T-cell lymphoma; C1-esterase inhibitor (Ruconest) for acute attacks in hereditary angioedema; and tedizolid phosphate (Sivextro) for acute bacterial skin and skin structure infections.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 221,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26250409",
        "http://www.ncbi.nlm.nih.gov/pubmed/19455773",
        "http://www.ncbi.nlm.nih.gov/pubmed/32197675",
        "http://www.ncbi.nlm.nih.gov/pubmed/25210412"
      ]
    },
    {
      "id": "641635fa690f196b5100001c",
      "type": "factoid",
      "body": "What is usually the age of diagnosis in Duchenne muscular dystrophy?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21482750",
          "text": "Caregivers (21 mothers and 6 fathers; mean age, 40.04 years) of 27 Duchenne muscular dystrophy patients (mean age, 11.26 years) completed the validated Children Health Questionnaire-Parent Form 50 and the Family Strain Questionnaire.",
          "offsetInBeginSection": 286,
          "offsetInEndSection": 519,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2347279",
          "text": "A needle muscle biopsy through a fetoscope for the antenatal diagnosis of Duchenne muscular dystrophy (DMD) was reported the mother was a carrier of 30 years old with a family history of Duchenne muscular dystrophy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 215,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16322188",
          "text": "ood muscular dystrophies. The disease is typically diagnosed between 3 and 7 years of age and follows a predictable clinical course marked by progress",
          "offsetInBeginSection": 76,
          "offsetInEndSection": 226,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16638505",
          "text": "ctioning of 25 Dutch males with Duchenne muscular dystrophy (mean age 10.1 years) were systematically assessed. This study relied on the use of a new ",
          "offsetInBeginSection": 237,
          "offsetInEndSection": 387,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19394035",
          "text": "tine kinase was 4.7 years. Mean age at definitive diagnosis of DMD was 4.9 years.\n\n\nCONCLUSIONS\nThere is a delay of about 2.5 years between onset of D",
          "offsetInBeginSection": 850,
          "offsetInEndSection": 1000,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10436681",
          "text": "n age of 3 years, but the accurate diagnosis was made at a mean age of 5.7 years. In only 15% of children, the disease was diagnosed in the first four",
          "offsetInBeginSection": 402,
          "offsetInEndSection": 552,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2476078",
          "text": "A total of 33 young boys (mean age 3.4 years) with Duchenne muscular dystrophy and 21 normal controls (mean age 3.5 years) were assessed using the Griffiths's mental development scales and the Reynell language scales.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 217,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12206794",
          "text": "lly and includes three cohorts of three patients each. Patients must be at least 15 years of age. Diagnosis of Duchenne and Becker muscular dystrophy ",
          "offsetInBeginSection": 502,
          "offsetInEndSection": 652,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23357214",
          "text": "Survival analysis revealed a median age at onset of lower urinary tract symptoms of 23 years (95% CI 17.7-23.9).",
          "offsetInBeginSection": 682,
          "offsetInEndSection": 794,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19449433",
          "text": "rophy of calf muscles, and muscle weakness, which became evident at 3 years of age. In addition, she had multiple congenital anomalies including atria",
          "offsetInBeginSection": 764,
          "offsetInEndSection": 914,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25977513",
        "http://www.ncbi.nlm.nih.gov/pubmed/12026234",
        "http://www.ncbi.nlm.nih.gov/pubmed/10436681",
        "http://www.ncbi.nlm.nih.gov/pubmed/19394035",
        "http://www.ncbi.nlm.nih.gov/pubmed/33012180",
        "http://www.ncbi.nlm.nih.gov/pubmed/21482750",
        "http://www.ncbi.nlm.nih.gov/pubmed/2476078",
        "http://www.ncbi.nlm.nih.gov/pubmed/2347279",
        "http://www.ncbi.nlm.nih.gov/pubmed/31311695",
        "http://www.ncbi.nlm.nih.gov/pubmed/7557060"
      ]
    },
    {
      "id": "6402c868201352f04a00000b",
      "type": "yesno",
      "body": "Was erythropoietin effective for optic neuritis in the TONE trial?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27706045",
          "text": "Although effective in terms of retinal nerve fiber layer protection, erythropoietin treatment of acute isolated optic neuritis did not influence further evolution of MRI lesions in the brain when comparing absolute numbers.",
          "offsetInBeginSection": 1062,
          "offsetInEndSection": 1285,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10340796",
          "text": "CONCLUSIONS\nPulse treatment does not appear effective for idiopathic optic neuritis even though visual function in the pulse treatment group of this trial recovered more quickly during the initial phase compared to the controls.",
          "offsetInBeginSection": 1099,
          "offsetInEndSection": 1327,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26932144",
          "text": "In a phase II trial performed in preparation of this study, we have shown that erythropoietin protects global retinal nerve fibre layer thickness (RNFLT-G) in acute optic neuritis; however, the preparatory trial was not powered to show effects on visual function.",
          "offsetInBeginSection": 299,
          "offsetInEndSection": 562,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25877841",
          "text": "As with other MS relapses, treatment with corticosteroids has little or no impact on the extent to which vision eventually recovers after an attack of optic neuritis.",
          "offsetInBeginSection": 154,
          "offsetInEndSection": 320,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27165274",
          "text": "BACKGROUND\nTo date, high-dose corticosteroids constitute the only established treatment of acute optic neuritis (ON); however, steroids cannot prevent the loss of retinal nerve fibers.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7821473",
          "text": "Ivermectin does not appear to precipitate or exacerbate optic neuritis at a period of 7-14 days.",
          "offsetInBeginSection": 1527,
          "offsetInEndSection": 1623,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30713249",
          "text": "s. Intravenous immunoglobulin (IVIg) has been reported to be effective for steroid-resistant patients. However, there is no report investigating the histopathological efficacy of IVIg in optic neuritis models. In this study, we examined the effects of IVIg on optic neuritis of experimental autoimmune encephalomyelitis (EAE) and experimental autoimmune optic neuritis (EAON). Inflammation, demyelination and axonal loss were assessed in the optic nerve sections. IVIg showed dose-dependent prevention of clinical symptoms in EAON. IVIg provided an anti-inflammatory effect in both EAE and EAON, associated with improved demyelination",
          "offsetInBeginSection": 89,
          "offsetInEndSection": 723,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15601662",
          "text": "Functional and histo pathological data of retinal ganglion cells and optic nerves revealed that neuron and axon protection was most effective when erythropoietin treatment that was started at immunization was combined with high-dose methylprednisolone therapy given from days 1 to 3 of MOG-induced experimental autoimmune encephalomyelitis.",
          "offsetInBeginSection": 1147,
          "offsetInEndSection": 1487,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8719696",
          "text": "that at the time of the acute attack of optic neuritis, the majority of selective color defects were blue/yellow defects, whereas at 6 months, more of the selective defects were red/green defects, though both types of defects (as well as nonselective defects) were seen acutely and at 6 months. Despite the rigorous inclusion criteria of the ONTT, the large number of patients we studied, correlation of color vision with visual acuity, and longitudinal follow up, this study showed that no single type of color defect was consistently associated with optic neuritis",
          "offsetInBeginSection": 2120,
          "offsetInEndSection": 2686,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27706045",
          "text": "Therefore, patients with acute optic neuritis were assigned to receive either 33,000 IU of recombinant human erythropoietin (IV) daily for three days, or a placebo, as an add-on to methylprednisolone.",
          "offsetInBeginSection": 241,
          "offsetInEndSection": 441,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/7821473",
        "http://www.ncbi.nlm.nih.gov/pubmed/30713249",
        "http://www.ncbi.nlm.nih.gov/pubmed/10340796",
        "http://www.ncbi.nlm.nih.gov/pubmed/25877841",
        "http://www.ncbi.nlm.nih.gov/pubmed/26932144",
        "http://www.ncbi.nlm.nih.gov/pubmed/25605544",
        "http://www.ncbi.nlm.nih.gov/pubmed/34800417",
        "http://www.ncbi.nlm.nih.gov/pubmed/27706045",
        "http://www.ncbi.nlm.nih.gov/pubmed/8719696",
        "http://www.ncbi.nlm.nih.gov/pubmed/8293145"
      ]
    },
    {
      "id": "6424154d690f196b5100004a",
      "type": "summary",
      "body": "What is the R value with respect to hepatoxicity",
      "snippets": [],
      "documents": []
    },
    {
      "id": "64299b6a57b1c7a315000001",
      "type": "yesno",
      "body": "Is COVID-19 caused by the Omicron variant less severe than infection caused by other variants?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36285226",
          "text": "ble complication associated with Omicron variant. Despite preliminary reports of less severe disease clinicians should be vigilant for potential delet",
          "offsetInBeginSection": 1643,
          "offsetInEndSection": 1793,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36339233",
          "text": "On the other hand, our data suggest that vaccination is less effective in preventing infection by the Omicron variant.",
          "offsetInBeginSection": 1150,
          "offsetInEndSection": 1268,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35411288",
          "text": "s in its virulence\u00a0and disease severity. Most reports have shown that the Omicron variant causes mild illness. Little is known about the impact of Omi",
          "offsetInBeginSection": 308,
          "offsetInEndSection": 458,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35595662",
          "text": "Vaccine effectiveness is lower and wanes faster against infection and symptomatic disease caused by the omicron variant of SARS-CoV-2 than was observed with previous variants.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 175,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35404391",
          "text": "Omicron variant infection (vs Delta) was associated with significantly lower odds of moderate or severe/critical disease (adjusted odds ratio [AOR], 0.12; 95% confidence interval [CI], .07-.18).",
          "offsetInBeginSection": 1386,
          "offsetInEndSection": 1580,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35869843",
          "text": "CONCLUSIONS\nWhile the mortality in immunocompromised patients infected with Omicron was low, hospital admission was frequent and the duration of symptoms often prolonged.",
          "offsetInBeginSection": 1532,
          "offsetInEndSection": 1702,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35014038",
          "text": "ity and mortality in last two years. The rate of infectivity of Omicron variant is much higher than Delta variant and in a very quick time Omicron has",
          "offsetInBeginSection": 236,
          "offsetInEndSection": 386,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35143466",
          "text": "In mid-December 2021, the B.1.1.529 (Omicron) variant of SARS-CoV-2, the virus that causes COVID-19, surpassed the B.1.617.2 (Delta) variant as the predominant strain in California.\u00a7 Initial reports suggest that the Omicron variant is more transmissible and resistant to vaccine neutralization but causes less severe illness compared with previous variants (1-3).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 363,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35835638",
          "text": "revealed multiple cystic cavitations.\n\n\nCONCLUSION\nAlthough COVID-19 is not severe in most children, life-threatening conditions such as COVID-19-asso",
          "offsetInBeginSection": 1178,
          "offsetInEndSection": 1328,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36090988",
          "text": "In summary, the current COVID-19 vaccines could effectively protect COVID-19 caused by Delta and Omicron variants but was less effective against Omicron variant infection.",
          "offsetInBeginSection": 1909,
          "offsetInEndSection": 2080,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36339233",
        "http://www.ncbi.nlm.nih.gov/pubmed/35143466",
        "http://www.ncbi.nlm.nih.gov/pubmed/35961786",
        "http://www.ncbi.nlm.nih.gov/pubmed/35835638",
        "http://www.ncbi.nlm.nih.gov/pubmed/36285226",
        "http://www.ncbi.nlm.nih.gov/pubmed/36146584",
        "http://www.ncbi.nlm.nih.gov/pubmed/36090988",
        "http://www.ncbi.nlm.nih.gov/pubmed/36453218",
        "http://www.ncbi.nlm.nih.gov/pubmed/36417338",
        "http://www.ncbi.nlm.nih.gov/pubmed/36298593"
      ]
    },
    {
      "id": "6432ffdf57b1c7a315000021",
      "type": "summary",
      "body": "What is hereditary angioedema?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22227095",
          "text": "Hereditary angioedema is a rare disease, often diagnosed with delay because of a heterogeneous clinical presentation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22195758",
          "text": "Hereditary angioedema is a rare disorder, and patients frequently endure long duration of symptoms, frequent physician visits, and unnecessary procedures prior to a diagnosis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 175,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24880254",
          "text": "Hereditary angioedema is a genetic disorder typically related to insufficient or dysfunctional C1-esterase inhibitor.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11194524",
          "text": "Hereditary angioedema (HAE) is a rare autosomal dominant disorder, which is caused by congenital deficiency of functional C1-inhibitor (C1-INH).",
          "offsetInBeginSection": 284,
          "offsetInEndSection": 428,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21251443",
          "text": "Hereditary angioedema is a rare genetic disorder resulting from an inherited deficiency or dysfunction of the C1 inhibitor.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21137180",
          "text": "Hereditary angioedema caused by C1 esterase inhibitor deficiency is a rare autosomal dominant inherited disorder.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2371584",
          "text": "Hereditary angioedema is a rare autosomal dominant disorder due to the deficiency of functionally active C1-inhibitor.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726426",
          "text": "Hereditary angioedema is a disease associated with acute complement-mediated inflammation and swelling of the airway and other vital organs.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18329867",
          "text": "The cause is a quantitative or qualitative congenital deficit in C1 inhibitor.",
          "offsetInBeginSection": 71,
          "offsetInEndSection": 149,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32178893",
          "text": "Hereditary angioedema is an autosomal dominant disorder, presenting as sudden and recurring episodes of variable severity of subcutaneous and mucosa edema that may occur spontaneously or in response to triggers.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19526954",
        "http://www.ncbi.nlm.nih.gov/pubmed/21137180",
        "http://www.ncbi.nlm.nih.gov/pubmed/24865240",
        "http://www.ncbi.nlm.nih.gov/pubmed/22179171",
        "http://www.ncbi.nlm.nih.gov/pubmed/22227095",
        "http://www.ncbi.nlm.nih.gov/pubmed/23625675",
        "http://www.ncbi.nlm.nih.gov/pubmed/22014012",
        "http://www.ncbi.nlm.nih.gov/pubmed/24880254",
        "http://www.ncbi.nlm.nih.gov/pubmed/33233873",
        "http://www.ncbi.nlm.nih.gov/pubmed/26819784"
      ]
    },
    {
      "id": "64178ec2690f196b51000024",
      "type": "summary",
      "body": "What is viltolarsen's mechanism of action?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
          "text": "However, the cell type that senses O2 (the O2 sensor) and the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear.",
          "offsetInBeginSection": 201,
          "offsetInEndSection": 381,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29178131",
          "text": "However, the presumptive mechanism of action, inhibition of NMDA (N-methyl-D-aspartate) receptors, has recently been challenged.",
          "offsetInBeginSection": 191,
          "offsetInEndSection": 319,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18633828",
          "text": "The representations are therefore shared between self and other (shared representations of action, SRA).",
          "offsetInBeginSection": 92,
          "offsetInEndSection": 196,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
        "http://www.ncbi.nlm.nih.gov/pubmed/29178131",
        "http://www.ncbi.nlm.nih.gov/pubmed/18633828"
      ]
    },
    {
      "id": "64040bd8201352f04a00000e",
      "type": "yesno",
      "body": "Should be used bexarotene for relapsing-remitting multiple sclerosis?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34418398",
          "text": "INTERPRETATION\nWe do not recommend the use of bexarotene to treat patients with multiple sclerosis because of its poor tolerability and negative primary efficacy outcome.",
          "offsetInBeginSection": 2844,
          "offsetInEndSection": 3014,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34418398"
      ]
    },
    {
      "id": "6422e7f0690f196b51000045",
      "type": "list",
      "body": "Hepcidin is a key regulator of what processes?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25852110",
          "text": "Hepcidin is a key regulator of iron homeostasis and plays a role in the pathogenesis of anaemia of chronic disease.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21136948",
          "text": "Hepcidin, a key regulator of iron homeostasis, is known to have three isoforms: hepcidin-20, -22, and -25.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19681654",
          "text": "Hepcidin, a key regulator of iron metabolism, plays a crucial role in the pathogenesis of anemia of chronic disease.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18936232",
          "text": "The discovery of hepcidin as a key regulator of iron homeostasis has advanced our current knowledge of this field.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16497104",
          "text": "Hepcidin, a key regulator of iron metabolism, decreases intestinal absorption of iron and its release from macrophages.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15797999",
          "text": "Hepcidin, a key regulator of iron metabolism, is synthesized by the liver. Hepcidin binds to the iron exporter ferroportin to regulate the release of ",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24356737",
          "text": "central role in hepcidin regulation. Hepcidin is a key regulator ofiron homeostasis and has now been suggested as a central mediator ofiron metabolism",
          "offsetInBeginSection": 70,
          "offsetInEndSection": 220,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30798808",
          "text": "Hepcidin is a main regulator of iron metabolism, of which abnormal expression affects intestinal absorption and reticuloendothelial sequestration of iron by interacting with ferroportin.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24123375",
          "text": "The expression of hepcidin is significantly induced by iron overload, inflammation, and infection of pathogens.",
          "offsetInBeginSection": 48,
          "offsetInEndSection": 159,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30374287",
          "text": "Hepcidin is the major regulator of systemic iron metabolism, while the role of this peptide in the brain has just recently been elucidated.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/12433676",
        "http://www.ncbi.nlm.nih.gov/pubmed/17557118",
        "http://www.ncbi.nlm.nih.gov/pubmed/33820875",
        "http://www.ncbi.nlm.nih.gov/pubmed/18951868",
        "http://www.ncbi.nlm.nih.gov/pubmed/30469435",
        "http://www.ncbi.nlm.nih.gov/pubmed/19338078",
        "http://www.ncbi.nlm.nih.gov/pubmed/18333366",
        "http://www.ncbi.nlm.nih.gov/pubmed/21136948",
        "http://www.ncbi.nlm.nih.gov/pubmed/17768112",
        "http://www.ncbi.nlm.nih.gov/pubmed/24356737"
      ]
    },
    {
      "id": "6429ee7457b1c7a31500000b",
      "type": "yesno",
      "body": "Can analgesics or antipyretics be taken for side effects following COVID-19 vaccination?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35759219",
          "text": "The most frequently reported side effects were sore arm at the injection site (84.65%), fatigue (84.48%), discomfort (65.43%), muscles/joint pain (61.38%), drowsiness (58.73%), and headache (58.38%).",
          "offsetInBeginSection": 987,
          "offsetInEndSection": 1186,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35738594",
          "text": "The COVID-19 vaccination can cause specific side-effects, such as axillary lymph node swelling; therefore, breast oncologists should pay attention to such occurrences.",
          "offsetInBeginSection": 144,
          "offsetInEndSection": 311,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35236842",
          "text": "Analgesics or antipyretic medications are often used to alleviate vaccine side effects, but their effect on immunogenicity remains uncertain.",
          "offsetInBeginSection": 137,
          "offsetInEndSection": 278,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36294440",
          "text": "Based on side effects, each subject was assigned to Group N (no side effects), Group CV (cardiac or vascular side effects), Group C (cardiac side effects only), or Group V (vascular side effects only).",
          "offsetInBeginSection": 687,
          "offsetInEndSection": 888,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36184535",
          "text": "Several cases of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) following COVID-19 vaccination have been reported.",
          "offsetInBeginSection": 106,
          "offsetInEndSection": 244,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35334998",
          "text": "CONCLUSIONS\nThe reported side effects following COVID-19 vaccination among Arab populations are usually non-life-threatening; flu-like symptoms and injection site pain.",
          "offsetInBeginSection": 2151,
          "offsetInEndSection": 2319,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34522089",
          "text": "The most common post-vaccination symptoms reported by the participants were fever, myalgia, malaise, fatigue, muscle and joint pain, and headache.",
          "offsetInBeginSection": 1371,
          "offsetInEndSection": 1517,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35666609",
          "text": "COVID-19 vaccination may also be associated with flares of pre-existing dermatoses and delayed inflammatory reactions to tissue filler.",
          "offsetInBeginSection": 1711,
          "offsetInEndSection": 1846,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34940894",
          "text": "The most common observed side effects were mild to moderate pain at the injection site (40%), followed by fatigue (24%).",
          "offsetInBeginSection": 1062,
          "offsetInEndSection": 1182,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34707073",
          "text": "However, the COVID-19 mRNA vaccines frequently cause systemic side effects shortly after the injection, such as fever, headache and generalized fatigue.",
          "offsetInBeginSection": 110,
          "offsetInEndSection": 262,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34940894",
        "http://www.ncbi.nlm.nih.gov/pubmed/34197678",
        "http://www.ncbi.nlm.nih.gov/pubmed/35236842",
        "http://www.ncbi.nlm.nih.gov/pubmed/34073382",
        "http://www.ncbi.nlm.nih.gov/pubmed/34707073",
        "http://www.ncbi.nlm.nih.gov/pubmed/36366292",
        "http://www.ncbi.nlm.nih.gov/pubmed/35334998",
        "http://www.ncbi.nlm.nih.gov/pubmed/36184535",
        "http://www.ncbi.nlm.nih.gov/pubmed/35775049",
        "http://www.ncbi.nlm.nih.gov/pubmed/35952506"
      ]
    },
    {
      "id": "6433050157b1c7a315000024",
      "type": "factoid",
      "body": "Which drug was the first recombinant human C1 inhibitor protein (C1INH) for the treatment of acute attacks of hereditary angioedema (HAE)?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22171564",
          "text": "BACKGROUND\nRecombinant human C1-inhibitor (rhC1INH; Ruconest\u00ae) has been developed for treatment of acute angioedema attacks in patients with hereditary angioedema (HAE) due to heterozygous deficiency of C1INH.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30021471",
          "text": " an established treatment for both on demand and prophylaxis of HAE. Conestat alfa is a recombinant form of human C1-INH (rhC1-INH) produced in transg",
          "offsetInBeginSection": 219,
          "offsetInEndSection": 369,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29569504",
          "text": "tor (C1-INH) or via blocking the production or function of bradykinin. Cinryze\u00ae is a nanofiltered C1-INH, approved in Europe for the acute treatment, ",
          "offsetInBeginSection": 388,
          "offsetInEndSection": 538,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17559913",
          "text": " likely mediator of the swelling and pain characterizing HAE attacks. Ecallantide, a novel, recombinant protein, potently inhibits kallikrein. This is",
          "offsetInBeginSection": 396,
          "offsetInEndSection": 546,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22995741",
          "text": "ion and the complement system. C1INH isolated from human blood plasma (pd-hC1INH) is used for the management of hereditary angioedema (HAE), a disease",
          "offsetInBeginSection": 110,
          "offsetInEndSection": 260,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23282867",
          "text": "A third preparation, the recombinant human C1 inhibitor Rhucin, is completing clinical trials.",
          "offsetInBeginSection": 1026,
          "offsetInEndSection": 1120,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20441418",
          "text": "to treat HAE in selected countries, mostly in Europe. Berinert P (CSL Behring, Marburg, Germany), a human plasma-derived C1-INH, was studied in the In",
          "offsetInBeginSection": 249,
          "offsetInEndSection": 399,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36408587",
          "text": "EXPERT OPINION\nThe availability of the first targeted oral prophylactic drug, the kallikrein inhibitor berotralstat, in 2021, is a milestone in the treatment of patients with hereditary angioedema.",
          "offsetInBeginSection": 1014,
          "offsetInEndSection": 1211,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22691903",
          "text": "ed formula received FDA approval in October 2009 for treating attacks. Ecallantide, a plasma kallikrein inhibitor, and icatibant, a bradykinin recepto",
          "offsetInBeginSection": 904,
          "offsetInEndSection": 1054,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23282867",
          "text": "icacious in carefully controlled double-blind studies. One preparation, Cinryze, was approved by the U.S. Food & Drug Administration (FDA) for prophyl",
          "offsetInBeginSection": 741,
          "offsetInEndSection": 891,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24556385",
        "http://www.ncbi.nlm.nih.gov/pubmed/22691903",
        "http://www.ncbi.nlm.nih.gov/pubmed/17524093",
        "http://www.ncbi.nlm.nih.gov/pubmed/30021471",
        "http://www.ncbi.nlm.nih.gov/pubmed/16334540",
        "http://www.ncbi.nlm.nih.gov/pubmed/23282867",
        "http://www.ncbi.nlm.nih.gov/pubmed/22171564",
        "http://www.ncbi.nlm.nih.gov/pubmed/26091744",
        "http://www.ncbi.nlm.nih.gov/pubmed/24468257",
        "http://www.ncbi.nlm.nih.gov/pubmed/22995741"
      ]
    },
    {
      "id": "6417900b690f196b5100002a",
      "type": "factoid",
      "body": "What type of DMD can viltolarsen be used for?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401027",
          "text": "Phosphorodiamidate morpholino oligomer (PMO)-mediated exon skipping is a therapeutic approach that applies to many Duchenne muscular dystrophy (DMD) patients harboring out-of-frame deletion mutations in the DMD gene.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 216,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33285037",
          "text": "n gene, and could be an effective treatment for patients with Duchenne muscular dystrophy (DMD). We investigated viltolarsen's ability to induce dystr",
          "offsetInBeginSection": 101,
          "offsetInEndSection": 251,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34097287",
          "text": "The debilitating neuromuscular disorders Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA), which harm 1 in 5000 newborn males and 1 in 11,000 newborns, respectively, are marked by progressive muscle wasting among other complications.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 252,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34569969",
          "text": "ies -Eteplirsen, Golodirsen, Viltolarsen, and Casimersen -for Duchenne Muscular Dystrophy (DMD). However, these treatments have only demonstrated vari",
          "offsetInBeginSection": 102,
          "offsetInEndSection": 252,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34092651",
          "text": "achieving spectacular success in treating these diseases. For Duchenne muscular dystrophy (DMD), the state-of-the-art is an exon skipping therapy usin",
          "offsetInBeginSection": 661,
          "offsetInEndSection": 811,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23637366",
          "text": "A digital micromirror device (DMD) is an array of individually switchable mirrors that can be used in many advanced optical systems as a rapid spatial light modulator.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32947786",
          "text": "en for DMD exon 51 skipping and golodirsen and viltolarsen for DMD exon 53 skipping, have been approved in the last 4 years. We are witnessing the sta",
          "offsetInBeginSection": 420,
          "offsetInEndSection": 570,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32519222",
          "text": "nter of Neurology and Psychiatry (NCNP), for the treatment of Duchenne muscular dystrophy (DMD). Viltolarsen binds to exon 53 of the dystrophin mRNA p",
          "offsetInBeginSection": 167,
          "offsetInEndSection": 317,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401022",
          "text": "Viltolarsen is a phosphorodiamidate morpholino antisense oligonucleotide (PMO) designed to skip exon 53 of the DMD gene\u00a0for the treatment of Duchenne muscular dystrophy (DMD), one of the most common lethal genetic disorders characterized by progressive degeneration of skeletal muscles and cardiomyopathy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 305,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25198739",
          "text": "In DMD, angiotensin converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) are used as the first line drugs.",
          "offsetInBeginSection": 461,
          "offsetInEndSection": 600,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34097287",
        "http://www.ncbi.nlm.nih.gov/pubmed/1971151",
        "http://www.ncbi.nlm.nih.gov/pubmed/33610829",
        "http://www.ncbi.nlm.nih.gov/pubmed/34092651",
        "http://www.ncbi.nlm.nih.gov/pubmed/32483212",
        "http://www.ncbi.nlm.nih.gov/pubmed/36401022",
        "http://www.ncbi.nlm.nih.gov/pubmed/28430230",
        "http://www.ncbi.nlm.nih.gov/pubmed/32519222",
        "http://www.ncbi.nlm.nih.gov/pubmed/36401026",
        "http://www.ncbi.nlm.nih.gov/pubmed/23637366"
      ]
    },
    {
      "id": "63f57ea133942b094c000005",
      "type": "list",
      "body": "What is the triad of the Cat eye syndrome?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33465332",
          "text": "The classic triad of iris coloboma, anorectal malformations, and auricular abnormalities is present in 40% of patients.",
          "offsetInBeginSection": 127,
          "offsetInEndSection": 246,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24833922",
          "text": "The Female Athlete Triad (Triad) represents a syndrome of three interrelated conditions that originate from chronically inadequate energy intake to compensate for energy expenditure; this environment results in insufficient stored energy to maintain physiological processes, a condition known as low energy availability.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 320,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32362975",
          "text": "The triad of one or more episodes of unilateral orbital pain, paresis of one or more of the cranial nerves, and granulomas by magnetic resonance imaging (MRI) or biopsy is 95-100% sensitive at diagnosing the syndrome; however, our patient did not present with the \"classic\" triad.",
          "offsetInBeginSection": 1215,
          "offsetInEndSection": 1495,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9641748",
          "text": "McCune-Albright syndrome consists of the triad polyostotic fibrous dysplasia, caf\u00e9-au-lait spots and autonomous hyperfunction of one or more endocrine systems.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19551563",
          "text": "We report a child presenting with a triad of congenital third nerve palsy, cerebellar hypoplasia and facial capillary hemangioma.",
          "offsetInBeginSection": 397,
          "offsetInEndSection": 526,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19491639",
          "text": "The original description of the Foster Kennedy syndrome included the clinical triad of optic disc pallor in one eye, optic disc edema in the other eye, and reduced olfaction caused by space-occupying anterior fossa masses.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 222,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11332976",
          "text": "riable pattern of multiple congenital anomalies of which coloboma of the iris and anal atresia are the best known. CES is cytogenetically characterise",
          "offsetInBeginSection": 46,
          "offsetInEndSection": 196,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9759431",
          "text": "This triad is known as SICRET Syndrome (Small Infarction of Cochlear, Retinal and Encephalic Tissue).",
          "offsetInBeginSection": 157,
          "offsetInEndSection": 258,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25648072",
          "text": "Individuals with cat-eye syndrome are characterized by the presence of preauricular pits and/or tags, anal atresia, and iris coloboma.",
          "offsetInBeginSection": 67,
          "offsetInEndSection": 201,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23928108",
          "text": "e 22, with a variable phenotype comprising anal atresia, coloboma of the iris and preauricular tags or pits. We report a girl with cat eye syndrome, p",
          "offsetInBeginSection": 129,
          "offsetInEndSection": 279,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/9759431",
        "http://www.ncbi.nlm.nih.gov/pubmed/19551563",
        "http://www.ncbi.nlm.nih.gov/pubmed/11332976",
        "http://www.ncbi.nlm.nih.gov/pubmed/24833922",
        "http://www.ncbi.nlm.nih.gov/pubmed/23928108",
        "http://www.ncbi.nlm.nih.gov/pubmed/35911297",
        "http://www.ncbi.nlm.nih.gov/pubmed/32362975",
        "http://www.ncbi.nlm.nih.gov/pubmed/19491639",
        "http://www.ncbi.nlm.nih.gov/pubmed/17352276",
        "http://www.ncbi.nlm.nih.gov/pubmed/33465332"
      ]
    },
    {
      "id": "64281a47690f196b5100004f",
      "type": "yesno",
      "body": "Is OXLUMO (lumasiran) used for the treatment of primary hyperoxaluria?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35071135",
          "text": "ones, kidney failure and systemic oxalosis. Lumasiran, is a liver-directed RNA interference therapeutic agent. It has been shown to reduce hepatic oxa",
          "offsetInBeginSection": 154,
          "offsetInEndSection": 304,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33789010",
          "text": "Lumasiran, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase.",
          "offsetInBeginSection": 202,
          "offsetInEndSection": 341,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31580236",
          "text": "Liver transplant has been suggested as a treatment for primary hyperoxaluria type 1 since the defective enzyme is expressed in the liver.",
          "offsetInBeginSection": 136,
          "offsetInEndSection": 273,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35843439",
          "text": "Lumasiran is an RNA interference therapeutic that is administered subcutaneously for the treatment of PH1.",
          "offsetInBeginSection": 2565,
          "offsetInEndSection": 2671,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33985991",
          "text": "Lumasiran, an RNA interference therapeutic, suppresses glycolate oxidase, reducing hepatic oxalate production.",
          "offsetInBeginSection": 194,
          "offsetInEndSection": 304,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33852222",
          "text": "There is an urgent need for drugs able to inhibit the liver production of oxalate and to prevent the disease progression; lumasiran, an innovative molecule based on RNAi interference, is one of the most promising drugs.",
          "offsetInBeginSection": 183,
          "offsetInEndSection": 402,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33852222",
          "text": "Lumasiran allows to significantly reduce the levels of oxalate both in blood and in urine, halting the course of the disease and preventing serious renal and systemic complications, if the therapy is started at an early stage of the disease.",
          "offsetInBeginSection": 1419,
          "offsetInEndSection": 1660,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35237473",
          "text": "Lumasiran is an RNA interference (RNAi) therapeutic agent that reduces hepatic oxalate production, which has been recently approved for the treatment of PH1.",
          "offsetInBeginSection": 315,
          "offsetInEndSection": 472,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35592620",
          "text": "Supportive treatment for primary hyperoxaluria type 1 (PH1) focuses on high fluid intake and crystallization inhibitors.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35924494",
          "text": "d. The only etiological treatment has long been combined liver-kidney transplantation because it restaures enzymatic function and replaces pathological kidneys. However, for a few years now, numerous studies are carried out on this subject and promising results have already been published with a new drug, lumasiran",
          "offsetInBeginSection": 510,
          "offsetInEndSection": 826,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35731461",
        "http://www.ncbi.nlm.nih.gov/pubmed/34906487",
        "http://www.ncbi.nlm.nih.gov/pubmed/35237473",
        "http://www.ncbi.nlm.nih.gov/pubmed/35843439",
        "http://www.ncbi.nlm.nih.gov/pubmed/35779234",
        "http://www.ncbi.nlm.nih.gov/pubmed/35015123",
        "http://www.ncbi.nlm.nih.gov/pubmed/33985991",
        "http://www.ncbi.nlm.nih.gov/pubmed/35592620",
        "http://www.ncbi.nlm.nih.gov/pubmed/9604807",
        "http://www.ncbi.nlm.nih.gov/pubmed/33852222"
      ]
    },
    {
      "id": "6429cfb557b1c7a315000005",
      "type": "yesno",
      "body": "Should patients using inhaled glucocorticoids for asthma or COPD be advised to stop these medications to prevent COVID-19?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33248363",
          "text": "However, patients with asthma or COPD should continue all prescribed inhaled medications.",
          "offsetInBeginSection": 204,
          "offsetInEndSection": 293,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12877818",
          "text": "Although inhaled glucocorticoids are highly effective in controlling airway inflammation in asthma, they are ineffective in the small group of patients with glucocorticoid-dependent and -resistant asthma.",
          "offsetInBeginSection": 127,
          "offsetInEndSection": 331,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33812494",
          "text": "COVID-19 in people with asthma is relatively small. People with COPD and interstitial lung disease appear to have a modestly increased risk of severe ",
          "offsetInBeginSection": 2848,
          "offsetInEndSection": 2998,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32554082",
          "text": "Similarly, the use of inhaled corticosteroids with or without systemic corticosteroids was not associated with COVID-19-related hospitalization.",
          "offsetInBeginSection": 1663,
          "offsetInEndSection": 1807,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7596005",
          "text": "This might indicate that for certain groups of patients with mild asthma or COPD, periodic treatment schedules with inhaled steroids is the treatment policy for the future.",
          "offsetInBeginSection": 2073,
          "offsetInEndSection": 2245,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33276252",
          "text": " There was no significant association between inhaled corticosteroid use and testing positive for COVID-19. Interestingly, systemic corticosteroid use was associated with a lower odds ratio (0.95, 95% CI: 0.91-0.99) of testing positive for COVID-19. Similar results were noted when the analysis was restricted to those with any chronic pulmonary diseases, with asthma or with chronic obstructive pulmonary disease (COPD).\n\n\nCONCLUSIONS\nOur study supports the recommendation that patients with chronic pulmonary diseases, including asthma and COPD who require treatment with either inhaled or systemic corticosteroids, should continue their use during the COVID-19 pand",
          "offsetInBeginSection": 1053,
          "offsetInEndSection": 1721,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10741768",
          "text": "Because of the lack of proven treatments for COPD and because inhaled corticosteroids can prevent airway inflammation and permanent lung damage in patients with asthma, it has become common practice to prescribe inhaled corticosteroids for patients with COPD despite a lack of data suggesting that these agents have any long-term benefit in these patients.",
          "offsetInBeginSection": 222,
          "offsetInEndSection": 578,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33357281",
          "text": "Additionally, the use of systemic or inhaled glucocorticoids does not appear to increase the risk of severe COVID-19, but there is no evidence guiding the use of biologic therapy.",
          "offsetInBeginSection": 1044,
          "offsetInEndSection": 1223,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32779943",
          "text": "All prescribed medications, especially inhaled corticosteroids, should be continued, and, where indicated, oral corticosteroids and biologic therapies should still be used.",
          "offsetInBeginSection": 845,
          "offsetInEndSection": 1017,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33276252",
          "text": "CONCLUSIONS\nOur study supports the recommendation that patients with chronic pulmonary diseases, including asthma and COPD who require treatment with either inhaled or systemic corticosteroids, should continue their use during the COVID-19 pandemic.",
          "offsetInBeginSection": 1477,
          "offsetInEndSection": 1726,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32979987",
        "http://www.ncbi.nlm.nih.gov/pubmed/36450371",
        "http://www.ncbi.nlm.nih.gov/pubmed/32348052",
        "http://www.ncbi.nlm.nih.gov/pubmed/34926333",
        "http://www.ncbi.nlm.nih.gov/pubmed/33276252",
        "http://www.ncbi.nlm.nih.gov/pubmed/10741768",
        "http://www.ncbi.nlm.nih.gov/pubmed/34476396",
        "http://www.ncbi.nlm.nih.gov/pubmed/32843175",
        "http://www.ncbi.nlm.nih.gov/pubmed/21899999",
        "http://www.ncbi.nlm.nih.gov/pubmed/12877818"
      ]
    },
    {
      "id": "6432f75757b1c7a31500001d",
      "type": "yesno",
      "body": "Is Zanubrutinib a first-generation BTK inhibitor approved by US Food and Drug Administration (FDA)?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34248972",
          "text": "Ibrutinib and acalabrutinib are approved by the US Food and Drug Administration for the treatment of CLL and other B-cell lymphomas, and zanubrutinib, for patients with mantle cell lymphoma.",
          "offsetInBeginSection": 394,
          "offsetInEndSection": 584,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35159041",
          "text": "Ibrutinib was the first irreversible BTK inhibitor approved by the U.S. Food and Drug Administration in 2013 as a breakthrough therapy in CLL patients.",
          "offsetInBeginSection": 360,
          "offsetInEndSection": 511,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34858810",
          "text": "Zanubrutinib, a selective next-generation covalent BTK inhibitor, is approved by the FDA to treat adult patients with MCL who have received \u22651 prior therapy, and is under investigation for the treatment of patients with CLL.",
          "offsetInBeginSection": 1156,
          "offsetInEndSection": 1380,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
          "text": "Zanubrutinib is currently approved for use for treatment of adult patients with MCL who have received at least one prior therapy, for adults with WM, and for adults with MZL who have received at least one anti-CD20-based therapy.",
          "offsetInBeginSection": 3210,
          "offsetInEndSection": 3439,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33613932",
          "text": "Ibrutinib was the first-in-class drug which was initially approved by the US Food and Drug Administration (FDA) for the treatment of patients with relapsed/refractory and later for patients with treatment-na\u00efve CLL.",
          "offsetInBeginSection": 338,
          "offsetInEndSection": 553,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32207333",
          "text": "Zanubrutinib is a next-generation BTK inhibitor with minimal off-target effects, sustained BTK occupancy in peripheral blood mononuclear cells and lymph nodes from patients with B-cell malignancies and promising responses in patients with CLL.",
          "offsetInBeginSection": 297,
          "offsetInEndSection": 540,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35973973",
          "text": "ueling the growth of BTK inhibitors (BTKis) and landmark approval of first-generation BTKi, ibrutinib. However, ibrutinib's side effect profile left a",
          "offsetInBeginSection": 181,
          "offsetInEndSection": 331,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
          "text": "ewer patients experience side effects and quit treatment. Zanubrutinib is currently approved for use for treatment of adult patients with MCL who have",
          "offsetInBeginSection": 3152,
          "offsetInEndSection": 3302,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32484067",
          "text": "Zanubrutinib an oral irreversible Bruton's tyrosine kinase (BTK) inhibitor, is under development for the treatment of a variety of B-cell malignancies and has received accelerated approval by the US Food and Drug Administration for treatment of adult patients with mantel cell lymphoma who have received at least one prior therapy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 331,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32231778",
          "text": "A second-generation BTK inhibitor, acalabrutinib, has also been studied in CLL, and has recently been granted breakthrough designation by the United States Food and Drug Administration.",
          "offsetInBeginSection": 437,
          "offsetInEndSection": 622,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34858810",
        "http://www.ncbi.nlm.nih.gov/pubmed/32484067",
        "http://www.ncbi.nlm.nih.gov/pubmed/35770040",
        "http://www.ncbi.nlm.nih.gov/pubmed/33025948",
        "http://www.ncbi.nlm.nih.gov/pubmed/35404729",
        "http://www.ncbi.nlm.nih.gov/pubmed/35159041",
        "http://www.ncbi.nlm.nih.gov/pubmed/34248972",
        "http://www.ncbi.nlm.nih.gov/pubmed/34123480",
        "http://www.ncbi.nlm.nih.gov/pubmed/35966045",
        "http://www.ncbi.nlm.nih.gov/pubmed/32231778"
      ]
    },
    {
      "id": "64178fea690f196b51000028",
      "type": "factoid",
      "body": "What types of DMD can eteplirsen be used for?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32947786",
          "text": "However, several new personalized therapies, including antisense oligonucleotides eteplirsen for DMD exon 51 skipping and golodirsen and viltolarsen for DMD exon 53 skipping, have been approved in the last 4 years.",
          "offsetInBeginSection": 330,
          "offsetInEndSection": 544,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33075081",
          "text": "Most patients with exon 51 skip-amenable mutations should be offered eteplirsen, before or with a corticosteroid.",
          "offsetInBeginSection": 662,
          "offsetInEndSection": 775,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30526286",
          "text": "Eteplirsen was approved for the treatment of eligible patients with Duchenne muscular dystrophy (DMD) in September 2016 in one of the most, if not the most, controversial approvals ever made by the Food and Drug Administration of the United States.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 248,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35715998",
          "text": "Eteplirsen is a United States-approved treatment for patients with DMD and exon 51 skip-amenable mutations.",
          "offsetInBeginSection": 105,
          "offsetInEndSection": 212,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30171538",
          "text": "Exon skipping through the use of antisense oligonucleotides (AOs) is currently one of the most promising approaches for treating Duchenne muscular dystrophy (DMD).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32483212",
          "text": "Eteplirsen and golodirsen, AONs for DMD exons 51 and 53 skipping, have been recently approved by the FDA.",
          "offsetInBeginSection": 377,
          "offsetInEndSection": 482,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807823",
          "text": "Eteplirsen has orphan drug designation in the USA and EU, and rare paediatric disease designation in the USA for use in DMD.",
          "offsetInBeginSection": 347,
          "offsetInEndSection": 471,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23637366",
          "text": "With a DMD, several implementations of confocal microscopy, hyperspectral imaging, and fluorescence lifetime imaging can be realized.",
          "offsetInBeginSection": 168,
          "offsetInEndSection": 301,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28280301",
          "text": "Eteplirsen is applicable for approximately 14% of patients with DMD mutations.",
          "offsetInBeginSection": 663,
          "offsetInEndSection": 741,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34797383",
          "text": "Applicable to approximately 14% of DMD patients, a phosphorodiamidate morpholino oligomer (PMO) antisense oligonucleotide eteplirsen received accelerated approval by the US Food and Drug Administration (FDA) in 2016.",
          "offsetInBeginSection": 469,
          "offsetInEndSection": 685,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35715998",
        "http://www.ncbi.nlm.nih.gov/pubmed/33075081",
        "http://www.ncbi.nlm.nih.gov/pubmed/27807823",
        "http://www.ncbi.nlm.nih.gov/pubmed/30171533",
        "http://www.ncbi.nlm.nih.gov/pubmed/30526286",
        "http://www.ncbi.nlm.nih.gov/pubmed/34797383",
        "http://www.ncbi.nlm.nih.gov/pubmed/23995279",
        "http://www.ncbi.nlm.nih.gov/pubmed/23637366",
        "http://www.ncbi.nlm.nih.gov/pubmed/32947786",
        "http://www.ncbi.nlm.nih.gov/pubmed/30621068"
      ]
    },
    {
      "id": "63eef94ff36125a426000010",
      "type": "yesno",
      "body": "Is Cinpanemab effective for Parkinson\u2019s Disease?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29874003",
          "text": "The present therapeutic drugs for PD can only alleviate the patients\u2019 symptoms, but cannot prevent or delay progression of the disease.",
          "offsetInBeginSection": 114,
          "offsetInEndSection": 249,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32338488",
          "text": "Levodopa is less effective in DLB than in PDD and may increase the risk of psychosis.",
          "offsetInBeginSection": 1306,
          "offsetInEndSection": 1391,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35921450",
          "text": "The trial was stopped after the week 72 interim analysis owing to lack of efficacy.",
          "offsetInBeginSection": 1215,
          "offsetInEndSection": 1298,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34618556",
          "text": "Deep brain stimulation (DBS) improves Parkinson\u2019s disease symptoms acutely but does not differentiate between neuronal circuits, and its effects decay rapidly if stimulation is discontinued.",
          "offsetInBeginSection": 178,
          "offsetInEndSection": 368,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26236796",
          "text": "Current treatment cannot stop the progression of the disease, although there is definite therapeutic effect.",
          "offsetInBeginSection": 308,
          "offsetInEndSection": 416,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26464310",
          "text": "The current drug treatment for PD is palliative and does not meet the clinical challenges of the disease, such as levodopa-induced dyskinesia, non-motor symptoms, and neuroprotection.",
          "offsetInBeginSection": 147,
          "offsetInEndSection": 330,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23223310",
          "text": "In advanced stages of PD, D2R agonists are often effective in delaying the appearance and the extent of motor complications.",
          "offsetInBeginSection": 915,
          "offsetInEndSection": 1039,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31731332",
          "text": "Conclusion\nAs detected by a survey performed by telephone calls with good interrater reliability, patients with PD improve with LCIG treatment in many aspects of the disease.",
          "offsetInBeginSection": 1067,
          "offsetInEndSection": 1241,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23223310",
          "text": "Nevertheless, this well established therapeutic intervention loses efficacy with the progression of the disease and patients develop invalidating side effects, known in their complex as L-DOPA-induced dyskinesia (LID).",
          "offsetInBeginSection": 105,
          "offsetInEndSection": 323,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32718129",
          "text": "Background/aim\nLevodopa-carbidopa intestinal gel (LCIG) is an effective treatment modality in the management of advanced Parkinson\u2019s disease (PD) despite frequent adverse events and different rates of dropouts.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 210,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34618556",
        "http://www.ncbi.nlm.nih.gov/pubmed/28468476",
        "http://www.ncbi.nlm.nih.gov/pubmed/23223310",
        "http://www.ncbi.nlm.nih.gov/pubmed/27000036",
        "http://www.ncbi.nlm.nih.gov/pubmed/26464310",
        "http://www.ncbi.nlm.nih.gov/pubmed/31731332",
        "http://www.ncbi.nlm.nih.gov/pubmed/32718129",
        "http://www.ncbi.nlm.nih.gov/pubmed/29874003",
        "http://www.ncbi.nlm.nih.gov/pubmed/35921450",
        "http://www.ncbi.nlm.nih.gov/pubmed/32338488"
      ]
    },
    {
      "id": "6426d131690f196b5100004e",
      "type": "factoid",
      "body": "In what organ would you find the Ashwell receptor?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27207430",
          "text": "This review will focus on the mechanisms of platelet senescence with specific emphasis on the role of post-translational modifications in platelet life-span and thrombopoietin production downstream of the hepatic Ashwell-Morrell receptor.",
          "offsetInBeginSection": 241,
          "offsetInEndSection": 479,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20816169",
          "text": "The Ashwell-Morell receptor (AMR) of hepatocytes, originally termed the hepatic asialoglycoprotein receptor, was the first cellular receptor to be identified and isolated and the first lectin to be detected in mammals.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18488037",
          "text": "The Ashwell receptor, the major lectin of hepatocytes, rapidly clears from blood circulation glycoproteins bearing glycan ligands that include galactose and N-acetylgalactosamine.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20816169",
          "text": "Among these components, clearance by the liver's AMR is enhanced by exposure of terminal galactose on the glycan chains.",
          "offsetInBeginSection": 968,
          "offsetInEndSection": 1088,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18488037",
        "http://www.ncbi.nlm.nih.gov/pubmed/27207430",
        "http://www.ncbi.nlm.nih.gov/pubmed/20816169"
      ]
    },
    {
      "id": "6429e17657b1c7a315000007",
      "type": "list",
      "body": "What histone marks are indicative of enhancers in the chromatin landscape of a given cell?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35801925",
          "text": " regulator of histone epigenetic writers KMT2D (H3K4 methyltransferase) and p300 (histone acetyltransferase). DBC1 is required for establishing the la",
          "offsetInBeginSection": 549,
          "offsetInEndSection": 699,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28916725",
          "text": "Here we use ChIP sequencing (ChIP-seq) to identify domains enriched for the histone marks histone H3 lysine 4 trimethylation, histone H3 lysine 4 monomethylation, and histone H3 lysine 27 acetylation (H3K4me3, H3K4me1, and H3K27ac) and define, for the first time, the super enhancers and typical enhancers active in primary human corneal epithelial cells.",
          "offsetInBeginSection": 421,
          "offsetInEndSection": 776,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30755522",
          "text": "oadly mapped. We have analyzed 6 histone marks (H3K4me1, H3K4me3, H3K27ac, H3K27me3, K3H9me3, H3K36me3) across 121 human cell types and tissues from t",
          "offsetInBeginSection": 371,
          "offsetInEndSection": 521,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29089515",
          "text": "These elements are characterized by distinct epigenomic profiles, such as expanded deposition of histone marks H3K27ac for super enhancers and H3K4me3 for broad domains, however little is known about how they interact with each other and the rest of the genome in three-dimensional chromatin space.",
          "offsetInBeginSection": 152,
          "offsetInEndSection": 450,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35198065",
          "text": "Methods: We performed chromatin immunoprecipitation sequencing to analyze histone mark changes (H3K4me1, H3K4me3, H3K9me3, H3K27ac, H3K27me3 and H3K36me3) on 16 HMCLs.",
          "offsetInBeginSection": 407,
          "offsetInEndSection": 574,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19129543",
          "text": "tin conformation linked to a shift of the epigenetic signature toward repressive histone marks. Importantly, these sites are not correlated with gene ",
          "offsetInBeginSection": 581,
          "offsetInEndSection": 731,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27089178",
          "text": "Here we show that acetylation of lysine residues in the globular domain of histone H3 (lysine 64 (H3K64ac) and lysine 122 (H3K122ac)) marks active gene promoters and also a subset of active enhancers.",
          "offsetInBeginSection": 559,
          "offsetInEndSection": 759,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29754476",
          "text": " DNA and are densely occupied by transcription factors, active histone marks, and co-activators. Accumulating evidence points to the critical role tha",
          "offsetInBeginSection": 441,
          "offsetInEndSection": 591,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22593555",
          "text": "romatin landscape marked by histone H3 lysine 4 mono-methylation (H3K4me1) and histone H3 lysine 27 acetylation (H3K27ac). Nevertheless, little is kno",
          "offsetInBeginSection": 391,
          "offsetInEndSection": 541,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24038352",
          "text": "Although certain chromatin features, such as the histone acetyltransferase P300 and the histone modification H3K4me1, indicate the presence of enhancers, only a fraction of enhancers are functionally active.",
          "offsetInBeginSection": 79,
          "offsetInEndSection": 286,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19129543",
        "http://www.ncbi.nlm.nih.gov/pubmed/27089178",
        "http://www.ncbi.nlm.nih.gov/pubmed/30755522",
        "http://www.ncbi.nlm.nih.gov/pubmed/35198065",
        "http://www.ncbi.nlm.nih.gov/pubmed/25128499",
        "http://www.ncbi.nlm.nih.gov/pubmed/28916725",
        "http://www.ncbi.nlm.nih.gov/pubmed/29089515",
        "http://www.ncbi.nlm.nih.gov/pubmed/35801925",
        "http://www.ncbi.nlm.nih.gov/pubmed/22328731",
        "http://www.ncbi.nlm.nih.gov/pubmed/28981749"
      ]
    },
    {
      "id": "643306cc57b1c7a315000027",
      "type": "yesno",
      "body": "Can CRISPR/Cas12a be used for the detection of EGFR mutations in circulating DNA?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35180538",
          "text": "The CRISPR/Cas12a technology can be widely used for sensitive, rapid, and stable detection of ochratoxin A.",
          "offsetInBeginSection": 472,
          "offsetInEndSection": 579,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32093010",
          "text": "The CRISPR-Cas12a system can detect both L858R and T790M with a limit of detection of 0.005% in less than three hours.",
          "offsetInBeginSection": 673,
          "offsetInEndSection": 791,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32093010",
          "text": "The CRISPR-Cas12a system can detect both L858R and T790M with a limit of detection of 0.005% in less than three hours. ddPCR detects the mutations with a limit of detection of 0.05% for more than five hours. Plasma samples of 28 lung cancer patients and 20 cancer-free individuals are tested for the EGFR mutations by CRISPR-Cas12a system and ddPCR. The CRISPR-Cas12a system could detect L858R in plasma of two lung cancer patients whose tissue biopsies are positive for L858R, and one plasma sample of three lung cancer patients whose tissue biopsies are positive for T790M. ddPCR detects L858R in the same two plasm samples, however, does not detect T790M in any of the plasma samples. This proof of principle study demonstrates that the CRISPR-Cas12a system could rapidly and sensitively detect circulating EGFR mutations",
          "offsetInBeginSection": 673,
          "offsetInEndSection": 1497,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34087725",
          "text": "We show that our strategy can allow the detection of an EGFR gene mutation in sub-femtomolar concentrations up to 0.1% variant allele frequency using either fluorescence or electrochemical readouts.",
          "offsetInBeginSection": 921,
          "offsetInEndSection": 1119,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31413315",
          "text": "Besides genome editing, CRISPR-Cas12a has recently been used for DNA detection applications with attomolar sensitivity but, to our knowledge, it has not been used for the detection of small molecules.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35132857",
          "text": "Herein, we developed a novel, simple, and highly sensitive naked-eye assay utilizing CRISPR/Cas12a-triggered no-nonspecific nucleic acid amplification (NAA) with rolling circle amplification (RCA) as a model for EGFR 19del detection.",
          "offsetInBeginSection": 359,
          "offsetInEndSection": 592,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33467412",
          "text": "CRISPR-Cas12a and PCR can specifically detect 0.01% and 0.1% mutant KRAS DNA in the presence of wild-type KRAS DNA, respectively.",
          "offsetInBeginSection": 694,
          "offsetInEndSection": 823,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36318259",
          "text": "only two CRISPR activation modes (single and double stranded) are available, and they have specificity and universality bottlenecks that limit the application of CRISPR technology in high-precision molecular recognition. Herein, we proposed a novel CRISPR/Cas12a unrestricted activation mode to greatly improve its performance. The new mode totally eliminates the need for a protospacer adjacent motif and accurately activates Cas12a through toehold-mediated strand displacement and branch migration, which is highly universal and ultra-specific. With this mode, we discriminated all mismatch types and detected the EGFR T790M and L858R mutations in very low abundance",
          "offsetInBeginSection": 211,
          "offsetInEndSection": 879,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33991961",
          "text": "CRISPR-Cas12a (Cpf1) trans-cleaves ssDNA and this feature has been widely harnessed for nucleic acid detection.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34087725",
        "http://www.ncbi.nlm.nih.gov/pubmed/35180538",
        "http://www.ncbi.nlm.nih.gov/pubmed/32093010",
        "http://www.ncbi.nlm.nih.gov/pubmed/31413315",
        "http://www.ncbi.nlm.nih.gov/pubmed/36318259",
        "http://www.ncbi.nlm.nih.gov/pubmed/35132857",
        "http://www.ncbi.nlm.nih.gov/pubmed/33467412",
        "http://www.ncbi.nlm.nih.gov/pubmed/33991961"
      ]
    },
    {
      "id": "64178ffb690f196b51000029",
      "type": "factoid",
      "body": "What type of DMD can casimersen be used for?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34569969",
          "text": "ies -Eteplirsen, Golodirsen, Viltolarsen, and Casimersen -for Duchenne Muscular Dystrophy (DMD). However, these treatments have only demonstrated vari",
          "offsetInBeginSection": 102,
          "offsetInEndSection": 252,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30171533",
          "text": "Antisense-mediated exon skipping is most extensively studied in Duchenne muscular dystrophy (DMD) and has developed from in vitro proof-of-concept studies to clinical trials targeting various single exons such as exon 45 (casimersen), exon 53 (NS-065/NCNP-01, golodirsen), and exon 51 (eteplirsen).",
          "offsetInBeginSection": 351,
          "offsetInEndSection": 649,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29791760",
          "text": "of dystrophin-deficient muscle. We tested the hypothesis that Duchenne muscular dystrophy (DMD) patients would have elevated levels of the macrophage-",
          "offsetInBeginSection": 882,
          "offsetInEndSection": 1032,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29579701",
          "text": "BACKGROUND\nAlthough prolonged ambulation is considered important in children with Duchenne muscular dystrophy (DMD), articles describing gait deviations in DMD are scarce.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23637366",
          "text": "A digital micromirror device (DMD) is an array of individually switchable mirrors that can be used in many advanced optical systems as a rapid spatial light modulator.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34097287",
          "text": "The debilitating neuromuscular disorders Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA), which harm 1 in 5000 newborn males and 1 in 11,000 newborns, respectively, are marked by progressive muscle wasting among other complications.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 252,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25198739",
          "text": "In DMD, angiotensin converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) are used as the first line drugs.",
          "offsetInBeginSection": 461,
          "offsetInEndSection": 600,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34105177",
          "text": "Casimersen was well tolerated in participants with DMD amenable to exon 45 skipping. Most TEAEs were mild, nonserious, and unrelated to casimersen. Pl",
          "offsetInBeginSection": 1478,
          "offsetInEndSection": 1628,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12692454",
          "text": "This study examined Three Wishes (a projective technique commonly used with children) in boys with Duchenne muscular dystrophy (DMD), a fatal, progressive illness (n = 74).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401026",
          "text": "om childhood, the earlier treatment is preferred. The canine X-linked muscular dystrophy in Japan (CXMDj), a dog model of DMD, produces no dystrophin ",
          "offsetInBeginSection": 557,
          "offsetInEndSection": 707,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34105177",
        "http://www.ncbi.nlm.nih.gov/pubmed/12692454",
        "http://www.ncbi.nlm.nih.gov/pubmed/36449321",
        "http://www.ncbi.nlm.nih.gov/pubmed/26972252",
        "http://www.ncbi.nlm.nih.gov/pubmed/30171533",
        "http://www.ncbi.nlm.nih.gov/pubmed/34097287",
        "http://www.ncbi.nlm.nih.gov/pubmed/33861387",
        "http://www.ncbi.nlm.nih.gov/pubmed/26594036",
        "http://www.ncbi.nlm.nih.gov/pubmed/25198739",
        "http://www.ncbi.nlm.nih.gov/pubmed/1971151"
      ]
    },
    {
      "id": "63eeefc5f36125a426000009",
      "type": "factoid",
      "body": "What is targeted by CIS43LS?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33684697",
          "text": "Collectively, these data indicate that episomal double-stranded DNA is targeted by STING-mediated cell defense.",
          "offsetInBeginSection": 1187,
          "offsetInEndSection": 1298,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33332286",
          "text": "CIS43 is a potent neutralizing human mAb that targets a highly conserved \"junctional\" epitope in the Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33684697",
        "http://www.ncbi.nlm.nih.gov/pubmed/33332286"
      ]
    },
    {
      "id": "6415b422690f196b5100000a",
      "type": "summary",
      "body": "What does Cal-light do?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28650460",
          "text": "We present a dual-protein switch system, Cal-Light, that translates neuronal-activity-mediated calcium signaling into gene expression in a light-dependent manner.",
          "offsetInBeginSection": 130,
          "offsetInEndSection": 292,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34195978",
          "text": "But the light switch cannot just be turned on, everything is solved, and life goes back to normal.",
          "offsetInBeginSection": 820,
          "offsetInEndSection": 918,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34195978",
        "http://www.ncbi.nlm.nih.gov/pubmed/28650460"
      ]
    },
    {
      "id": "64172bb2690f196b5100001e",
      "type": "factoid",
      "body": "To which region of a gene does an RNA polymerase bind to initiate transcription?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9603525",
          "text": "Initiation of transcription of a gene from a core promoter region by RNA polymerase II requires the assembly of several initiation factors to form a preinitiation complex.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6194892",
          "text": "A sensitive hybridization technique was used to demonstrate that the purified polymerase, even when supplemented with a transcription factor that binds specifically to the 5S RNA gene internal control region, is unable to initiate synthesis at the start site of the 5S RNA gene.",
          "offsetInBeginSection": 246,
          "offsetInEndSection": 524,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31863129",
          "text": "RNA polymerases (RNAPs) differ from other polymerases in that they can bind promoter sequences and initiate transcription de novo and this promoter recognition requires the presence of specific DNA binding domains in the polymerase.",
          "offsetInBeginSection": 131,
          "offsetInEndSection": 363,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3380786",
          "text": "kurstaki HD-1-Dipel that directs transcription from the promoter region of an insecticidal crystal protein gene.",
          "offsetInBeginSection": 101,
          "offsetInEndSection": 213,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2648001",
          "text": " facilitates binding of the RNA polymerase to the proper region of the promoter. The Ada protein possesses two known methyl acceptor sites, Cys69 and ",
          "offsetInBeginSection": 1617,
          "offsetInEndSection": 1767,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24600005",
          "text": " a reduced ability of RNA polymerase II to be recruited to the promoter-proximal regions of these genes. In contrast, depletion of hPaf1 reduces the o",
          "offsetInBeginSection": 643,
          "offsetInEndSection": 793,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6382259",
          "text": "The RNA polymerase from bacteriophage T4-infected Escherichia coli, which specifically initiates transcription at phage T4 late promoters, is extensively modified by ADP-ribosylation of core subunits and by binding several virus-encoded subunits.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 246,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3465670",
          "text": "We conclude that RNA polymerase II can initiate transcription at the cap site in isolated nuclei.",
          "offsetInBeginSection": 1097,
          "offsetInEndSection": 1194,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2648001",
          "text": "RNA polymerase did bind to the promoter once the methylated Ada protein had bound to the upstream sequence.",
          "offsetInBeginSection": 980,
          "offsetInEndSection": 1087,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6263495",
          "text": "ta beta alpha 2-sigma able selectively to initiate transcription at promoter sites. It is proposed that beta beta' alpha 2-nusA and beta beta' alpha 2",
          "offsetInBeginSection": 610,
          "offsetInEndSection": 760,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22999857",
        "http://www.ncbi.nlm.nih.gov/pubmed/9603525",
        "http://www.ncbi.nlm.nih.gov/pubmed/6382259",
        "http://www.ncbi.nlm.nih.gov/pubmed/9526497",
        "http://www.ncbi.nlm.nih.gov/pubmed/6537904",
        "http://www.ncbi.nlm.nih.gov/pubmed/7226225",
        "http://www.ncbi.nlm.nih.gov/pubmed/3865211",
        "http://www.ncbi.nlm.nih.gov/pubmed/384366",
        "http://www.ncbi.nlm.nih.gov/pubmed/20300884",
        "http://www.ncbi.nlm.nih.gov/pubmed/6194892"
      ]
    },
    {
      "id": "63f9ccdc33942b094c00000f",
      "type": "yesno",
      "body": "Is PRP-40 involved in microexon splicing?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34348142",
          "text": "PRP-40 is particularly required for inclusion of neuronal microexons, and our data indicate that PRP-40 is a central regulator of microexon splicing.",
          "offsetInBeginSection": 485,
          "offsetInEndSection": 634,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34348142",
          "text": "PRP-40 is particularly required for inclusion of neuronal microexons, and our data indicate that PRP-40 is a central regulator of microexon splicing.",
          "offsetInBeginSection": 485,
          "offsetInEndSection": 634,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34348142"
      ]
    },
    {
      "id": "641790d6690f196b5100002d",
      "type": "factoid",
      "body": "At what range of ages usually occurs the loss of independent ambulation in Duchenne muscular dystrophy?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12363102",
          "text": "nsuing year that resulted in loss of independent ambulation at the age of 10. Both boys remained around the 50th centile for height and weight, and sh",
          "offsetInBeginSection": 622,
          "offsetInEndSection": 772,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21784636",
          "text": "Patients with Duchenne muscular dystrophy (DMD) lose ambulation by age 12. Long-term steroids have lengthened ambulation by 2-5 years. Ischial weight-",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29067658",
          "text": "Dystrophinopathies are multi-systems disorders that are characterized by severe skeletal muscle wasting, with loss of independent ambulation in the early teenage years, followed by cardio-respiratory complications and premature death.",
          "offsetInBeginSection": 178,
          "offsetInEndSection": 412,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26022172",
          "text": "it disturbance, and historically has led to the loss of ambulation by age 12. It is important for the practicing pediatrician, however, to be aware of",
          "offsetInBeginSection": 226,
          "offsetInEndSection": 376,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35549789",
          "text": "Those with oedema had a greater time since the loss of ambulation (8.4\u00a0years versus 3.5\u00a0years; p = 0.004), higher body mass index (28.3 versus 24.8; p = 0.014), and lower frequency of deflazacort use (67% versus 89%; p = 0.008).",
          "offsetInBeginSection": 689,
          "offsetInEndSection": 917,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21038378",
          "text": "Changes in 6MWD depended on stride length and age; improvements usually occurred by 7-8 years of age; older DBMD subjects worsened, whereas older healthy subjects were stable.",
          "offsetInBeginSection": 664,
          "offsetInEndSection": 839,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3198893",
          "text": "ot orthoses at the point of loss of ambulation, between the ages of 6 and 12 years. There was an inverse relationship between the severity of the scol",
          "offsetInBeginSection": 152,
          "offsetInEndSection": 302,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33215271",
          "text": "childhood with loss of ambulation usually occurring around the age of 9-11\u00a0years.\n\n\nOBJECTIVE, MATERIAL AND METHODS\nBased on current guidelines and cl",
          "offsetInBeginSection": 99,
          "offsetInEndSection": 249,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16322188",
          "text": " by progressive skeletal muscle weakness with loss of ambulation by 12 years of age. Death occurs in early adulthood secondary to respiratory or cardi",
          "offsetInBeginSection": 214,
          "offsetInEndSection": 364,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27382620",
          "text": "Duchenne muscular dystrophy is a progressive disease with loss of ambulation at around 9-10 years of age, followed, if untreated, by development of scoliosis, respiratory insufficiency, and death in the second decade of life.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25643053",
        "http://www.ncbi.nlm.nih.gov/pubmed/18974549",
        "http://www.ncbi.nlm.nih.gov/pubmed/25635234",
        "http://www.ncbi.nlm.nih.gov/pubmed/19834452",
        "http://www.ncbi.nlm.nih.gov/pubmed/27382620",
        "http://www.ncbi.nlm.nih.gov/pubmed/21784636",
        "http://www.ncbi.nlm.nih.gov/pubmed/10382913",
        "http://www.ncbi.nlm.nih.gov/pubmed/31922454",
        "http://www.ncbi.nlm.nih.gov/pubmed/28645460",
        "http://www.ncbi.nlm.nih.gov/pubmed/12026233"
      ]
    },
    {
      "id": "6404199d201352f04a000019",
      "type": "yesno",
      "body": "Is ocrelizumab effective for primary progressive multiple sclerosis?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30160679",
          "text": "Its clinical-MRI efficacy in MS with relapses as well in primary progressive MS (PPMS) was proved by three phase III clinical studies.",
          "offsetInBeginSection": 134,
          "offsetInEndSection": 268,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32477559",
          "text": "It is indicated in the treatment of both relapsing-remitting multiple sclerosis and primary progressive multiple sclerosis.",
          "offsetInBeginSection": 106,
          "offsetInEndSection": 229,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30008443",
          "text": "osis.1,2 It is the first drug to be licensed for use in early primary progressive multiple sclerosis and relapsing forms of multiple sclerosis. Here, ",
          "offsetInBeginSection": 183,
          "offsetInEndSection": 333,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36454397",
          "text": "In RMS, ocrelizumab was revealed to be either cost-saving or have costs-per-QALY likely below commonly accepted cost-effectiveness thresholds.",
          "offsetInBeginSection": 1668,
          "offsetInEndSection": 1810,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32524163",
          "text": "Recently published phase\u00a03 studies confirmed that ocrelizumab is effective in the treatment of both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).",
          "offsetInBeginSection": 175,
          "offsetInEndSection": 360,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29881971",
          "text": "After the approval of cladribine and ocrelizumab in Europe, two new drugs are now available with ocrelizumab being the first approved option for treatment of primary progressive multiple sclerosis; however, the increased use of highly effective therapies is accompanied by a\u00a0rise in severe side effects.",
          "offsetInBeginSection": 104,
          "offsetInEndSection": 407,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33948072",
          "text": "Ocrelizumab is an intravenous anti-CD20 monoclonal antibody, approved for use in primary progressive multiple sclerosis due to its selective depletion of B-lymphocytes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35079395",
          "text": "We report a case of severe late-onset neutropenia in a patient with primary progressive multiple sclerosis treated with ocrelizumab with neutropenia occurring 3\u00a0months after the last dose received treated with empirical broad-spectrum intravenous antibiotics and filgrastim.",
          "offsetInBeginSection": 369,
          "offsetInEndSection": 643,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35964555",
          "text": "\nOcrelizumab is an effective treatment for relapsing and primary-progressive multiple sclerosis (MS). However, the effect of ocrelizumab on leptomeningeal (LM) inflammation is unknown.",
          "offsetInBeginSection": 10,
          "offsetInEndSection": 194,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32777270",
          "text": "Ocrelizumab is a novel humanized anti-CD20 antibody used for treatment of relapsing remitting and primary progressive multiple sclerosis with evidence of inflammatory activity.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35741088",
        "http://www.ncbi.nlm.nih.gov/pubmed/35964555",
        "http://www.ncbi.nlm.nih.gov/pubmed/32607256",
        "http://www.ncbi.nlm.nih.gov/pubmed/33352355",
        "http://www.ncbi.nlm.nih.gov/pubmed/35079395",
        "http://www.ncbi.nlm.nih.gov/pubmed/32477559",
        "http://www.ncbi.nlm.nih.gov/pubmed/32653735",
        "http://www.ncbi.nlm.nih.gov/pubmed/28523586",
        "http://www.ncbi.nlm.nih.gov/pubmed/33948072",
        "http://www.ncbi.nlm.nih.gov/pubmed/30008443"
      ]
    },
    {
      "id": "641b7bba690f196b5100003e",
      "type": "summary",
      "body": "How is Indocyanine green (ICG) used?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33965600",
          "text": "We describe a case using indocyanine green (ICG) fluorescence imaging for diagnosis of postoperative gastrointestinal fistula.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31129192",
          "text": "Indocyanine green (ICG) is a dye used for fluorescent-guided surgery. This review article addresses the recent surge in reported uses of ICG in variou",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19065196",
          "text": "Indocyanine green (ICG) is a fluorescent probe used in clinical imaging. However, its utility remains limited by optical instability, rapid circulatio",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34589458",
          "text": "Conclusion: Indocyanine green fluorescence angiography is a safe imaging technology and its use is increasing rapidly in pediatric surgical specialties.",
          "offsetInBeginSection": 1633,
          "offsetInEndSection": 1785,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12880353",
          "text": "Its complex spectral behavior and low quantum yield limits some applications.",
          "offsetInBeginSection": 71,
          "offsetInEndSection": 148,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35874138",
          "text": "s an operation burdened with severe postoperative complications. Fluorescence imaging, particularly using indocyanine green (ICG), offers the ability ",
          "offsetInBeginSection": 112,
          "offsetInEndSection": 262,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15871512",
          "text": "OBJECT\nRecently, intraoperative fluorescence angiography in which indocyanine green (ICG) is used as a tracer has been introduced as a novel technique to confirm successful aneurysm clipping.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 191,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35662771",
          "text": "Using indocyanine green (ICG), a standard reagent used in liver function tests, bile leaks from exfoliated liver sections can be detected with higher sensitivity than naked-eye observation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11351215",
          "text": "INTRODUCTION\nSince early 90th, infra-red angiography using indocyanine green, is an additional examination done after fluorescein angiography (FA) very often used in ARMD allowing deep retinal layers and choroid analysis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 221,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28316935",
          "text": "Indocyanine Green (ICG) is frequently used during urologic robotic procedures and is generally considered to be safe.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35874138",
        "http://www.ncbi.nlm.nih.gov/pubmed/24848167",
        "http://www.ncbi.nlm.nih.gov/pubmed/32360873",
        "http://www.ncbi.nlm.nih.gov/pubmed/11351215",
        "http://www.ncbi.nlm.nih.gov/pubmed/19790157",
        "http://www.ncbi.nlm.nih.gov/pubmed/33884231",
        "http://www.ncbi.nlm.nih.gov/pubmed/9018428",
        "http://www.ncbi.nlm.nih.gov/pubmed/36055879",
        "http://www.ncbi.nlm.nih.gov/pubmed/28477043",
        "http://www.ncbi.nlm.nih.gov/pubmed/19065196"
      ]
    },
    {
      "id": "6428da74690f196b51000052",
      "type": "factoid",
      "body": "What is the process that generates multiple transcripts from the same gene?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35269461",
          "text": "ntia, Huntington's disease, progressive supranuclear palsy, etc. Alternative splicing is a physiological process by which cells generate several trans",
          "offsetInBeginSection": 252,
          "offsetInEndSection": 402,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28402429",
          "text": "Alternative splicing generates multiple transcript and protein isoforms from the same gene and thus is important in gene expression regulation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35821097",
          "text": "at give rise to phenotypic diversity in multicellular organisms. Alternative splicing generates multiple transcripts from a single gene, enriching the",
          "offsetInBeginSection": 79,
          "offsetInEndSection": 229,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24955028",
          "text": "The completion of the Human Genome Project aroused renewed interest in alternative splicing, an efficient and widespread mechanism that generates multiple protein isoforms from individual genes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 194,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29368663",
          "text": "ranscriptional regulation of gene expression. Selection of transcript cleavage and polyadenylation sites is a dynamic process that produces multiple t",
          "offsetInBeginSection": 82,
          "offsetInEndSection": 232,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29074233",
          "text": "Alternative splicing, which generates multiple transcripts from the same gene, is an important modulator of gene expression that can increase proteome diversity and regulate mRNA levels.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32880830",
          "text": "Through the process of alternative splicing, proteins with distinct biological functions and localisations are generated from a single gene.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18817741",
          "text": "Alternative splicing of messenger RNA (mRNA) precursors generates multiple transcripts from a single primary transcript.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11868989",
          "text": "ervening noncoding sequences, introns, from primary transcripts. Alternative splicing generates an enormous repertoire of functional diversity by prod",
          "offsetInBeginSection": 182,
          "offsetInEndSection": 332,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34383135",
          "text": "Alternative splicing is a widespread phenomenon, which generates multiple isoforms of the gene product.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34440445",
        "http://www.ncbi.nlm.nih.gov/pubmed/18817741",
        "http://www.ncbi.nlm.nih.gov/pubmed/33434218",
        "http://www.ncbi.nlm.nih.gov/pubmed/35821097",
        "http://www.ncbi.nlm.nih.gov/pubmed/28064309",
        "http://www.ncbi.nlm.nih.gov/pubmed/24955028",
        "http://www.ncbi.nlm.nih.gov/pubmed/35269461",
        "http://www.ncbi.nlm.nih.gov/pubmed/34383135",
        "http://www.ncbi.nlm.nih.gov/pubmed/33793927",
        "http://www.ncbi.nlm.nih.gov/pubmed/11868989"
      ]
    },
    {
      "id": "63f9cdcc33942b094c000013",
      "type": "yesno",
      "body": "Does silencing of SRRM4 inhibit tumor growth across cancers?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20698994",
          "text": "In nude mice bearing PC-3M xenografts, survivin knockdown synergizes with selenium in inhibiting tumor growth.",
          "offsetInBeginSection": 2113,
          "offsetInEndSection": 2223,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16888408",
          "text": "een associated with cell growth and proliferation. Downregulation of ODC may inhibit tumor cell growth. To verify this hypothesis, ODC gene silencing ",
          "offsetInBeginSection": 89,
          "offsetInEndSection": 239,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26258795",
          "text": "In these cancers, silencing miR-221/222 could represent a novel anti-tumor approach to inhibit tumor growth and metastasis.",
          "offsetInBeginSection": 287,
          "offsetInEndSection": 410,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23319807",
          "text": "This gene has been found to be mutated frequently in breast and prostate cancers and to inhibit tumor cell growth, but its functional significance in DNA repair has not been studied.",
          "offsetInBeginSection": 97,
          "offsetInEndSection": 279,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26162838",
          "text": "Importantly, in preclinical models of these cancers, either pharmacological inhibition or genetic silencing of CBS was shown to be sufficient to suppress cancer cell bioenergetics in vitro, inhibit tumor growth and metastasis in vivo, and enhance the antitumor efficacy of frontline chemotherapeutic agents, providing a strong rationale for the development of CBS-targeted inhibitors as anticancer therapies.",
          "offsetInBeginSection": 578,
          "offsetInEndSection": 986,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29381393",
          "text": "Consistently, silencing SATB1 with small interfering RNA inhibits the growth and invasion of some kinds of tumors.",
          "offsetInBeginSection": 304,
          "offsetInEndSection": 418,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20698994",
          "text": "Several studies have shown that selenium compounds inhibit the growth of prostate cancer cells.",
          "offsetInBeginSection": 459,
          "offsetInEndSection": 554,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29393472",
          "text": "The in\u00a0vivo study demonstrated that tumor growth was markedly inhibited following siRNA\u2011MTA2 treatment.",
          "offsetInBeginSection": 1526,
          "offsetInEndSection": 1629,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31371983",
          "text": "Furthermore, the results of animal experiments also demonstrated that intake too much fructose could prominently increase tumor volume, and silencing GLUT5 could significantly inhibit tumor proliferation.",
          "offsetInBeginSection": 1118,
          "offsetInEndSection": 1322,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25706396",
          "text": "These results suggest that silencing Biot2 in CT26 cells by RNA interference can inhibit cell growth in vitro and in vivo.",
          "offsetInBeginSection": 937,
          "offsetInEndSection": 1059,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21725599",
        "http://www.ncbi.nlm.nih.gov/pubmed/29381393",
        "http://www.ncbi.nlm.nih.gov/pubmed/25706396",
        "http://www.ncbi.nlm.nih.gov/pubmed/26162838",
        "http://www.ncbi.nlm.nih.gov/pubmed/26496979",
        "http://www.ncbi.nlm.nih.gov/pubmed/33621242",
        "http://www.ncbi.nlm.nih.gov/pubmed/26258795",
        "http://www.ncbi.nlm.nih.gov/pubmed/15788898",
        "http://www.ncbi.nlm.nih.gov/pubmed/27346347",
        "http://www.ncbi.nlm.nih.gov/pubmed/35611828"
      ]
    },
    {
      "id": "64179aac690f196b51000037",
      "type": "factoid",
      "body": "What is the life expectancy for Duchenne muscular dystrophy patients?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21482750",
          "text": "Caregivers (21 mothers and 6 fathers; mean age, 40.04 years) of 27 Duchenne muscular dystrophy patients (mean age, 11.26 years) completed the validated Children Health Questionnaire-Parent Form 50 and the Family Strain Questionnaire.",
          "offsetInBeginSection": 286,
          "offsetInEndSection": 519,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11929208",
          "text": "ife, cease walking at the beginning of the second decade, and usually die by age 20 years. Until treatment of the basic genetic defect is available, m",
          "offsetInBeginSection": 168,
          "offsetInEndSection": 318,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33075081",
          "text": "rophy (DMD) is a childhood onset muscular dystrophy leading to shortened life expectancy. There are gaps in published DMD care guidelines regarding re",
          "offsetInBeginSection": 35,
          "offsetInEndSection": 185,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1450492",
          "text": "ife span of the patients with progressive muscular dystrophy from 15.8 years to 20.4 years over the last 20 years. Various new drug trials for muscula",
          "offsetInBeginSection": 67,
          "offsetInEndSection": 217,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27234309",
          "text": "Our results indicate that boys with Duchenne muscular dystrophy have quite a satisfactory quality of life.",
          "offsetInBeginSection": 876,
          "offsetInEndSection": 982,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34645707",
          "text": "Median life expectancy was 22.0 years (95% confidence interval [CI] 21.2, 22.4).",
          "offsetInBeginSection": 1005,
          "offsetInEndSection": 1085,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30275245",
          "text": "Life expectancy has improved from mid-teenage years to mid-20s with the use of glucocorticoids and beyond the third decade with ventilator support and multidisciplinary care.",
          "offsetInBeginSection": 281,
          "offsetInEndSection": 455,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10193393",
          "text": "eath in patients with Duchenne muscular dystrophy (DMD). Life expectancy is less than one year once diurnal hypercapnia develops. This study examines ",
          "offsetInBeginSection": 58,
          "offsetInEndSection": 208,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34417099",
          "text": "on and early respiratory complications). Respiratory complications reduce the life expectancy of those affected. There is no treatment that modifies i",
          "offsetInBeginSection": 374,
          "offsetInEndSection": 524,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28099279",
          "text": "and clinical history of Duchenne muscular dystrophy who is currently 53 years old. Because of improvements in cardiopulmonary care, there has been a g",
          "offsetInBeginSection": 45,
          "offsetInEndSection": 195,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/6696607",
        "http://www.ncbi.nlm.nih.gov/pubmed/30275245",
        "http://www.ncbi.nlm.nih.gov/pubmed/28744411",
        "http://www.ncbi.nlm.nih.gov/pubmed/21482750",
        "http://www.ncbi.nlm.nih.gov/pubmed/25752877",
        "http://www.ncbi.nlm.nih.gov/pubmed/27234309",
        "http://www.ncbi.nlm.nih.gov/pubmed/1450492",
        "http://www.ncbi.nlm.nih.gov/pubmed/28099279",
        "http://www.ncbi.nlm.nih.gov/pubmed/20581335",
        "http://www.ncbi.nlm.nih.gov/pubmed/3694224"
      ]
    },
    {
      "id": "64041e97201352f04a00001e",
      "type": "yesno",
      "body": "Is daridorexant effective for insomnia?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32778207",
          "text": "Daridorexant successfully passed first pivotal phase 3 clinical trial in April 2020 for the treatment of insomnia disorder [3] (\"Good things come to those who wait\").",
          "offsetInBeginSection": 587,
          "offsetInEndSection": 753,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36045942",
          "text": "It was shown to be effective in reducing insomnia symptoms, increasing daytime functioning, and improving the overall quality of sleep.",
          "offsetInBeginSection": 759,
          "offsetInEndSection": 894,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31953863",
          "text": "INTERPRETATION\nDaridorexant induced a dose-dependent reduction in wake time after sleep onset in subjects with insomnia disorder (Clinicaltrials.gov NCT02839200).",
          "offsetInBeginSection": 1576,
          "offsetInEndSection": 1738,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31953863",
          "text": "OBJECTIVE\nTo evaluate the dose-response relationship of daridorexant, a new dual orexin receptor antagonist, on sleep variables in subjects with insomnia disorder.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32134851",
          "text": "PURPOSE/BACKGROUND\nDaridorexant is a dual orexin receptor antagonist in development for the treatment of sleep disorders.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33205362",
          "text": "BACKGROUND\nDaridorexant\u00a0(ACT-541468) is a potent dual orexin receptor antagonist under development for the treatment of sleep disorders.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34121345",
          "text": "The aim of this study was to evaluate the impact of renal impairment on the pharmacokinetics (PKs), safety, and tolerability of daridorexant, a dual orexin receptor antagonist intended for the treatment of insomnia.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 215,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32341187",
          "text": "OBJECTIVE\nTo assess the dose-response of daridorexant, a new dual orexin receptor antagonist, on wake after sleep onset (WASO).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35843245",
          "text": "Many licensed drugs (including benzodiazepines, daridorexant, suvorexant, and trazodone) can be effective in the acute treatment of insomnia but are associated with poor tolerability, or information about long-term effects is not available.",
          "offsetInBeginSection": 3896,
          "offsetInEndSection": 4136,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32901578",
          "text": "Dual orexin receptor antagonists (DORAs) have been approved for the treatment of insomnia disorders (suvorexant, lemborexant) and drugs with a distinctive profile (daridorexant) or orexin-2 receptor selectivity (seltorexant) are in development.",
          "offsetInBeginSection": 179,
          "offsetInEndSection": 423,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31953863",
        "http://www.ncbi.nlm.nih.gov/pubmed/36098936",
        "http://www.ncbi.nlm.nih.gov/pubmed/34331678",
        "http://www.ncbi.nlm.nih.gov/pubmed/32937014",
        "http://www.ncbi.nlm.nih.gov/pubmed/35065036",
        "http://www.ncbi.nlm.nih.gov/pubmed/35306405",
        "http://www.ncbi.nlm.nih.gov/pubmed/32134851",
        "http://www.ncbi.nlm.nih.gov/pubmed/32603512",
        "http://www.ncbi.nlm.nih.gov/pubmed/36144776",
        "http://www.ncbi.nlm.nih.gov/pubmed/36045942"
      ]
    },
    {
      "id": "6422ee03690f196b51000046",
      "type": "factoid",
      "body": "What cells produce erythroferrone?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31808893",
          "text": "Furthermore, hepcidin regulation by erythropoiesis is attributed in large part to a bone marrow-derived hormone erythroferrone.",
          "offsetInBeginSection": 494,
          "offsetInEndSection": 621,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25267320",
          "text": "We hypothesize that in pathological situations associated with erythroid precursor suppression (erythroblastopenia), anemia is the result of two major mechanisms: (1) direct erythroblast suppression leading to decreased production of red cells and (2) low iron availability due to high hepcidin levels arising as a result of low erythroferrone production.",
          "offsetInBeginSection": 699,
          "offsetInEndSection": 1054,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34827208",
          "text": "Intense physical activity contributes to an increased demand for red blood cells, which transport oxygen to working muscles.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35464433",
          "text": "Erythroferrone is a recently identified erythroid regulator produced by erythroblasts in the mammalian bone marrow and extramedullary sites, known to be induced in conditions of anemia or blood loss.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31649559",
          "text": "The paradigm is non-transfusion-dependent thalassemia where the release of erythroferrone from the expanded pool of immature erythroid cells results in hepcidin suppression and secondary iron overload that in turn worsens ineffective erythropoiesis and anemia.",
          "offsetInBeginSection": 1704,
          "offsetInEndSection": 1964,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33372284",
          "text": "When the release of erythropoietin from the kidney stimulates the production of new red blood cells, it also increases the synthesis of ERFE in bone marrow erythroblasts.",
          "offsetInBeginSection": 143,
          "offsetInEndSection": 313,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31723763",
          "text": "Here the hormone erythroferrone, produced by erythroblasts, acts on hepatocytes to suppress hepcidin production, and thereby increase dietary iron absorption and mobilization from stores.",
          "offsetInBeginSection": 825,
          "offsetInEndSection": 1012,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35628152",
          "text": "d iron export from both duodenal absorptive cells and reticuloendothelial cells that process old and/or damaged red blood cells. Erythroferrone, a fac",
          "offsetInBeginSection": 765,
          "offsetInEndSection": 915,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28666715",
          "text": "oiesis, body iron needs to increase to enable the production of new red blood cells. In the 1950s, the observation of an increased digestive iron abso",
          "offsetInBeginSection": 19,
          "offsetInEndSection": 169,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28629515",
          "text": "Among the number of factors proposed as mediators linking erythropoiesis with liver hepcidin suppression, erythroferrone, a hormone produced and secreted by erythroid precursors, appears the best candidate.",
          "offsetInBeginSection": 1033,
          "offsetInEndSection": 1239,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33372284",
        "http://www.ncbi.nlm.nih.gov/pubmed/34827208",
        "http://www.ncbi.nlm.nih.gov/pubmed/35464433",
        "http://www.ncbi.nlm.nih.gov/pubmed/31808893",
        "http://www.ncbi.nlm.nih.gov/pubmed/31723763",
        "http://www.ncbi.nlm.nih.gov/pubmed/28666715",
        "http://www.ncbi.nlm.nih.gov/pubmed/25267320",
        "http://www.ncbi.nlm.nih.gov/pubmed/28629515",
        "http://www.ncbi.nlm.nih.gov/pubmed/31649559",
        "http://www.ncbi.nlm.nih.gov/pubmed/35628152"
      ]
    },
    {
      "id": "6429f86657b1c7a31500000d",
      "type": "summary",
      "body": "What is the role of the Mediator in gene expression?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21854862",
          "text": "forming a link between gene-specific transcription factors and RNA polymerase II. Most protein-coding genes therefore require Mediator complex activity for transcriptional regulation. Given the essential functions performed by Mediator complex proteins in gene regulation, it is not surprising that mutations in Mediator complex genes disrupt animal and plant development. What is more intriguing is that the phenotypes of individual Mediator complex mutants are distinct from each other, demonstrating that certain developmental processes have a greater requirement for specific Mediator complex genes. Additionally, the range of developmental processes that are altered in Mediator complex mutants is broad, affecting a variety of cell types and physiological systems. Gene expression defects in Mediator complex mutants reveal distinct roles for individual Mediator proteins in transcriptional regulation, suggesting that the deletion of one Mediator complex protein does not interfere with transcription in general, but instead alters the expression of specific target genes",
          "offsetInBeginSection": 67,
          "offsetInEndSection": 1145,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21854862"
      ]
    },
    {
      "id": "6415c0df690f196b51000010",
      "type": "factoid",
      "body": "What does FBDD stand for?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18061882",
          "text": "With more than 10 years of practical experience and theoretical analysis, fragment-based drug discovery (FBDD) has entered the mainstream of the pharmaceutical and biotech industries.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23480433",
          "text": "BACKGROUND\nFragment-based drug discovery (FBDD) has been established as a powerful alternative and complement to traditional high-throughput screening techniques for identifying drug leads.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30386766",
          "text": "Fragment-based drug discovery (FBDD) is a well-established approach for the discovery of novel medicines, illustrated by the approval of two FBBD-derived drugs.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29087197",
          "text": "The popularity of fragment-based drug discovery (FBDD) is demonstrated by the number of recent successful fragment-to-lead (F2L) publications.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19028598",
          "text": "Fragment-based drug discovery (FBDD) is complementary to high-throughput screening.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32592867",
          "text": "Fragment-based drug discovery (FBDD) is an innovative approach, progressively more applied in the academic and industrial context, to enhance hit identification for previously considered undruggable biological targets.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21695633",
          "text": "Fragment-based drug discovery (FBDD) has emerged in the past decade as a powerful tool for discovering drug leads.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20190516",
          "text": "Fragment-Based Drug Discovery (FBDD) has been recognized as a newly emerging lead discovery methodology that involves biophysical fragment screening and chemistry-driven fragment-to-lead stages.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 194,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22827744",
          "text": "IMPORTANCE OF THE FIELD\nIn silico fragment-based drug design (FBDD) is a relatively new approach inspired by the success of the biophysical fragment-based drug discovery field.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21378847",
          "text": " traced back, in part, to the quality of the chemical leads. Fragment-based drug discovery (FBDD) is a new approach, increasingly used in the pharmace",
          "offsetInBeginSection": 179,
          "offsetInEndSection": 329,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32592867",
        "http://www.ncbi.nlm.nih.gov/pubmed/19028598",
        "http://www.ncbi.nlm.nih.gov/pubmed/29087197",
        "http://www.ncbi.nlm.nih.gov/pubmed/20190516",
        "http://www.ncbi.nlm.nih.gov/pubmed/21378847",
        "http://www.ncbi.nlm.nih.gov/pubmed/19443265",
        "http://www.ncbi.nlm.nih.gov/pubmed/30386766",
        "http://www.ncbi.nlm.nih.gov/pubmed/21695633",
        "http://www.ncbi.nlm.nih.gov/pubmed/32133344",
        "http://www.ncbi.nlm.nih.gov/pubmed/18061882"
      ]
    },
    {
      "id": "64041dae201352f04a00001d",
      "type": "yesno",
      "body": "Is deucravacitinib effective for psoriasis?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35820547",
          "text": "CONCLUSION\nDeucravacitinib was superior to placebo and apremilast across multiple efficacy endpoints and was well tolerated in moderate to severe psoriasis.",
          "offsetInBeginSection": 1191,
          "offsetInEndSection": 1347,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34471993",
          "text": "TYK2 versus the closely related Janus kinases (JAKs) 1/2/3. Deucravacitinib was efficacious in phase 2 and 3 psoriasis trials, without clinical or lab",
          "offsetInBeginSection": 276,
          "offsetInEndSection": 426,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36115523",
          "text": "CONCLUSION\nDeucravacitinib demonstrated superiority versus placebo and apremilast and was well tolerated in adults with moderate to severe plaque psoriasis.",
          "offsetInBeginSection": 1200,
          "offsetInEndSection": 1356,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35025062",
          "text": "INTRODUCTION\nDeucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that demonstrated therapeutic benefit in a Phase 2 clinical trial of adults with moderate to severe plaque psoriasis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15090021",
          "text": "CONCLUSION\nInfliximab is not only an effective agent in the treatment of psoriasis but appears to have a very rapid onset of action.",
          "offsetInBeginSection": 950,
          "offsetInEndSection": 1082,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31548750",
          "text": "According to clinical trials, tildrakizumab is an effective and safe drug for use in adult patients in the treatment of moderate to severe psoriasis.",
          "offsetInBeginSection": 763,
          "offsetInEndSection": 912,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19998529",
          "text": "Even though acitretin is less effective as a monotherapy for chronic plaque psoriasis, combination therapy with other agents, especially UVB or psoralen plus UVA phototherapy, can enhance efficacy.",
          "offsetInBeginSection": 619,
          "offsetInEndSection": 816,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35960487",
          "text": "Despite advances in the treatment of psoriasis, namely among biologic agents, an oral, effective and safe new drug can bring several advantages to prescribers and patients.",
          "offsetInBeginSection": 1443,
          "offsetInEndSection": 1615,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401743",
          "text": "The Marketing Authorisation Application for deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis has been validated in the EU, and clinical development of the drug for the treatment of multiple immune-mediated diseases is underway in numerous countries worldwide.",
          "offsetInBeginSection": 853,
          "offsetInEndSection": 1148,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18624682",
          "text": "\nAcitretin is effective as monotherapy for pustular and erythrodermic psoriasis and for plaque psoriasis (with other systemic agents). Side effects of acitretin use occur more commonly with high doses. Hence, acitretin is safe and effective for psoriasis",
          "offsetInBeginSection": 681,
          "offsetInEndSection": 935,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16485887",
        "http://www.ncbi.nlm.nih.gov/pubmed/34224773",
        "http://www.ncbi.nlm.nih.gov/pubmed/35566756",
        "http://www.ncbi.nlm.nih.gov/pubmed/36469536",
        "http://www.ncbi.nlm.nih.gov/pubmed/26267735",
        "http://www.ncbi.nlm.nih.gov/pubmed/30050284",
        "http://www.ncbi.nlm.nih.gov/pubmed/35025062",
        "http://www.ncbi.nlm.nih.gov/pubmed/19998529",
        "http://www.ncbi.nlm.nih.gov/pubmed/34767869",
        "http://www.ncbi.nlm.nih.gov/pubmed/36115523"
      ]
    },
    {
      "id": "6415b6eb690f196b5100000b",
      "type": "list",
      "body": "What processes do orexin/hypocretin neurons regulate?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15978010",
          "text": "Orexin/hypocretin neurons in the lateral hypothalamus and adjacent perifornical area (LH/PFA) innervate midbrain dopamine (DA) neurons that project to corticolimbic sites and subserve psychostimulant-induced locomotor activity.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 227,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11532254",
          "text": "In this way, hypocretin, which is implicated in feeding, energy metabolism and wakefulness, serves to influence cognitive processes critical for the animal's survival.",
          "offsetInBeginSection": 1882,
          "offsetInEndSection": 2049,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34052808",
          "text": "However, cellular-resolution calcium imaging and optogenetic studies show that orexin neurons regulate self-generated and sensory-evoked movement on rapid, subsecond timescales.",
          "offsetInBeginSection": 233,
          "offsetInEndSection": 410,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28620314",
          "text": "Orexin neurons are \"multi-tasking\" neurons regulating a set of vital body functions, including sleep/wake states, feeding behavior, energy homeostasis, reward systems, cognition and mood.",
          "offsetInBeginSection": 303,
          "offsetInEndSection": 490,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28025809",
          "text": "ntral nervous system to control sleep and arousal, circadian rhythms, metabolism, reward pathways, and other behaviors. Dysfunction of orexin/hypocret",
          "offsetInBeginSection": 298,
          "offsetInEndSection": 448,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11532254",
          "text": "This peptide is believed to be involved in regulating feeding and wakefulness.",
          "offsetInBeginSection": 264,
          "offsetInEndSection": 342,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30348769",
          "text": "in the hypothalamus play an essential role in sleep-wake control, feeding, reward, and energy homeostasis. The likelihood of anesthesia and sleep shar",
          "offsetInBeginSection": 42,
          "offsetInEndSection": 192,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16054072",
          "text": "d orexin) neurons have emerged as instrumental in triggering arousal and regulating energy metabolism. The lack of hypocretin signaling is the cause o",
          "offsetInBeginSection": 47,
          "offsetInEndSection": 197,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36457878",
          "text": " role for the lateral hypothalamus (LH) in driving the reward pathway, sleep and awake circuits, decision making and psychotic disorders. But our know",
          "offsetInBeginSection": 1907,
          "offsetInEndSection": 2057,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22813966",
          "text": "hrough interactions with neuronal systems that regulate emotion, reward, and energy homeostasis. Here, we briefly summarize the progress of orexin/hyp",
          "offsetInBeginSection": 437,
          "offsetInEndSection": 587,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36457878",
        "http://www.ncbi.nlm.nih.gov/pubmed/20467915",
        "http://www.ncbi.nlm.nih.gov/pubmed/10624957",
        "http://www.ncbi.nlm.nih.gov/pubmed/20307612",
        "http://www.ncbi.nlm.nih.gov/pubmed/15848807",
        "http://www.ncbi.nlm.nih.gov/pubmed/32804153",
        "http://www.ncbi.nlm.nih.gov/pubmed/9920670",
        "http://www.ncbi.nlm.nih.gov/pubmed/27227052",
        "http://www.ncbi.nlm.nih.gov/pubmed/22430644",
        "http://www.ncbi.nlm.nih.gov/pubmed/15978010"
      ]
    },
    {
      "id": "6428da47690f196b51000051",
      "type": "yesno",
      "body": "Can the epigenetic status of introns affect gene expression?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18319396",
          "text": "However, not all introns affect gene expression, and direct testing is currently the only way to identify stimulatory introns.",
          "offsetInBeginSection": 86,
          "offsetInEndSection": 212,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32187179",
          "text": "Although TE-bearing introns are widely observed in eukaryotic genomes, their epigenetic states, impacts on gene regulation and function, and their contributions to genetic diversity and evolution, remain poorly understood.",
          "offsetInBeginSection": 235,
          "offsetInEndSection": 457,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12702819",
          "text": "lly different expression profiles. Introns and the act of their removal by the spliceosome can affect gene expression at many different levels, includ",
          "offsetInBeginSection": 114,
          "offsetInEndSection": 264,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18287520",
          "text": "itness. Together, our results show that although the presence of introns may optimize gene expression and provide benefit under stress, a majority of ",
          "offsetInBeginSection": 840,
          "offsetInEndSection": 990,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21913084",
          "text": "Transcription factors can also affect gene transcription through binding of the key transcriptional machinery to the gene promoter.",
          "offsetInBeginSection": 120,
          "offsetInEndSection": 251,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30010918",
          "text": "Epigenetic modulation of intragenic TEs often contributes to gene regulation, phenotypic expression, and genome evolution.",
          "offsetInBeginSection": 635,
          "offsetInEndSection": 757,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24455281",
          "text": "modifications can affect the long-term gene expression without any change in nucleotide sequence of the DNA. Epigenetic processes intervene in the cell differentiation, chromatin structure, and activity of genes since the embryonic period. However, disorders in genes' epigenetic pattern can affect the mechanisms such as cell division, apoptosis, and response to the environmental stimuli which may lead to the incidence of different diseases and cancers.",
          "offsetInBeginSection": 11,
          "offsetInEndSection": 467,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25191382",
          "text": " heritable changes that affect gene expression without altering the DNA sequence. Epigenetic regulation of gene expression is facilitated through different mechanisms such as DNA methylation, histone modifications and RNA-associated silencing by small non-coding RNAs. All these mechanisms are crucial for normal development, differentiation and tissue-specific gene expression. These three systems interact and stabilize one another and can initiate and sustain epigenetic silencing, thus determining heritable changes in gene expression",
          "offsetInBeginSection": 25,
          "offsetInEndSection": 563,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15673716",
          "text": "The nucleosome formation potential of introns, intergenic spacers and exons of human genes is shown here to negatively correlate with among-tissues breadth of gene expression.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 175,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28768481",
          "text": "It has been observed that the methylation status of certain CpG sites close to or within a gene can directly affect its expression, either by silencing or, in some cases, up-regulating transcription.",
          "offsetInBeginSection": 92,
          "offsetInEndSection": 291,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31945283",
        "http://www.ncbi.nlm.nih.gov/pubmed/12702819",
        "http://www.ncbi.nlm.nih.gov/pubmed/28673892",
        "http://www.ncbi.nlm.nih.gov/pubmed/15673716",
        "http://www.ncbi.nlm.nih.gov/pubmed/25191382",
        "http://www.ncbi.nlm.nih.gov/pubmed/18630758",
        "http://www.ncbi.nlm.nih.gov/pubmed/28768481",
        "http://www.ncbi.nlm.nih.gov/pubmed/21913084",
        "http://www.ncbi.nlm.nih.gov/pubmed/23593031",
        "http://www.ncbi.nlm.nih.gov/pubmed/18319396"
      ]
    },
    {
      "id": "6415c5d4690f196b51000014",
      "type": "list",
      "body": "What was Keytruda originally approved for by the FDA?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12179363",
          "text": "The fact that this IUD is approved for 6 years makes it an even more attractive option for women choosing a contraceptive method.\"",
          "offsetInBeginSection": 1104,
          "offsetInEndSection": 1234,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17280539",
          "text": "Thus, while the circulatory support was initially tolerated for short periods to permit recovery of cardiac function, this technology eventually provided effective circulatory support for increasing periods that permitted the FDA to approve devices for bridging patients in end-stage cardiac failure awaiting transplant and eventually a device for destination therapy where patients in end-stage heart failure are not cardiac transplant candidates.",
          "offsetInBeginSection": 685,
          "offsetInEndSection": 1133,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34647523",
          "text": "and Drug Administration (FDA) for use in pediatric patients with relapsed or refractory classical Hodgkin's lymphoma. However, there is currently no p",
          "offsetInBeginSection": 215,
          "offsetInEndSection": 365,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21792346",
          "text": " refractory to or intolerant of imatinib, dasatinib and nilotinib are now also FDA approved in the first-line setting. The choice of tyrosine kinase i",
          "offsetInBeginSection": 437,
          "offsetInEndSection": 587,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29209918",
          "text": "FDA previously approved Keytruda for treatment of several types of malignancies, such as metastatic melanoma, metastatic non-small-cell lung cancer, recurrent or metastatic head and neck cancer, refractory Hodgkin lymphoma, and urothelial carcinoma, all of which carry positive programmed death-1/programmed death-ligand 1 biomarkers.",
          "offsetInBeginSection": 335,
          "offsetInEndSection": 669,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34156377",
          "text": "Pembrolizumab (Keytruda) has been approved to treat metastatic or locally advanced esophageal or gastroesophageal junction cancer.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32645193",
          "text": "The FDA approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 296,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17280539",
          "text": " the US FDA first approved a mechanical device to provide the circulatory support lacking from a failing heart. Devices are presently approved for mar",
          "offsetInBeginSection": 96,
          "offsetInEndSection": 246,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28235882",
          "text": "On September 4, 2014, the FDA approved pembrolizumab (KEYTRUDA; Merck Sharp & Dohme Corp.) with a recommended dose of 2 mg/kg every 3 weeks by intravenous infusion for the treatment of patients with unresectable or metastatic melanoma who have progressed following treatment with ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 345,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29758342",
          "text": "r companion diagnostics (MSK-IMPACT\u2122) and the first drug targeting a genetic signature rather than a disease (Keytruda\u00ae). We envision that population-",
          "offsetInBeginSection": 350,
          "offsetInEndSection": 500,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29209918",
        "http://www.ncbi.nlm.nih.gov/pubmed/17280539",
        "http://www.ncbi.nlm.nih.gov/pubmed/21792346",
        "http://www.ncbi.nlm.nih.gov/pubmed/34156377",
        "http://www.ncbi.nlm.nih.gov/pubmed/12179363",
        "http://www.ncbi.nlm.nih.gov/pubmed/28235882",
        "http://www.ncbi.nlm.nih.gov/pubmed/34647523",
        "http://www.ncbi.nlm.nih.gov/pubmed/32645193",
        "http://www.ncbi.nlm.nih.gov/pubmed/29758342"
      ]
    },
    {
      "id": "63f5713733942b094c000003",
      "type": "summary",
      "body": "What are clinical features of the Achard-Thiers syndrome?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31400053",
          "text": "Coffin-Lowry syndrome (CLS) is a well-described syndrome characterized by intellectual disability, growth retardation, recognizable dysmorphic features, and skeletal changes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27562837",
          "text": "The condition features characteristic face, short stature, skeletal anomalies, muscle pseudohypertrophy, restricted joint mobility, stiff and thick skin, and variable intellectual disability.",
          "offsetInBeginSection": 187,
          "offsetInEndSection": 378,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1695555",
          "text": "Diagnosis is based on the presence of typical clinical features, striking nail changes, lymphedema, and pleural effusions of undetermined etiology.",
          "offsetInBeginSection": 73,
          "offsetInEndSection": 220,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34232366",
          "text": "Kabuki syndrome (KS) is a well-recognized disorder characterized by postnatal growth deficiency, dysmorphic facial features, skeletal anomalies, and intellectual disability.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1201353",
          "text": "The Achard syndrome is a well-defined clinical entity consisting of widespread dysostoses and increased ligament laxity.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33043631",
          "text": "Developmental milestones are delayed and a mild to moderate cognitive impairment is present in all patients, variably associated with features of autism spectrum disorder, behavioral disturb, and sleep disturb.",
          "offsetInBeginSection": 643,
          "offsetInEndSection": 853,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31608744",
          "text": "This article summarizes the clinical features of Tourette syndrome, including major diagnostic criteria, unique features of tics, and key aspects that differentiate tics from common mimics and chameleons.",
          "offsetInBeginSection": 1177,
          "offsetInEndSection": 1381,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3958872",
          "text": "The features studied were primary position deviation, face turn, anomalous vertical movements, divergence in midline vertical gaze, anisometropia, and amblyopia.",
          "offsetInBeginSection": 311,
          "offsetInEndSection": 472,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31608744",
          "text": "This article summarizes the clinical features of Tourette syndrome, including major diagnostic criteria, unique features of tics, and key aspects that differentiate tics from common mimics and chameleons.",
          "offsetInBeginSection": 1177,
          "offsetInEndSection": 1381,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29948256",
          "text": "All patients with Noonan syndrome showed multiple abnormalities in the categories of vision and refraction, external ocular features, ocular alignment and motility, anterior ocular segment, and posterior ocular segment.",
          "offsetInBeginSection": 410,
          "offsetInEndSection": 629,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/2682933",
        "http://www.ncbi.nlm.nih.gov/pubmed/29948256",
        "http://www.ncbi.nlm.nih.gov/pubmed/11505871",
        "http://www.ncbi.nlm.nih.gov/pubmed/10560599",
        "http://www.ncbi.nlm.nih.gov/pubmed/27562837",
        "http://www.ncbi.nlm.nih.gov/pubmed/31400053",
        "http://www.ncbi.nlm.nih.gov/pubmed/33960620",
        "http://www.ncbi.nlm.nih.gov/pubmed/33043631",
        "http://www.ncbi.nlm.nih.gov/pubmed/34232366",
        "http://www.ncbi.nlm.nih.gov/pubmed/31608744"
      ]
    },
    {
      "id": "642d4c9b57b1c7a315000013",
      "type": "yesno",
      "body": "Are Luminopsins a fusion proteins of luminol and Rhodopsin ?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29414245",
          "text": "To support bradykinin (BK) B2 receptor (B2R) detection and therapeutic stimulation, we developed and characterized fusion proteins consisting of the BK homolog maximakinin (MK), or variants, positioned at the C-terminus of functional proteins (enhanced green fluorescent protein (EGFP), the peroxidase APEX2, or human serum albumin (HSA)).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 339,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34281270",
          "text": "Bioluminescent optogenetics (BL-OG) uses luminopsins, fusion proteins of light-generating luciferase and light-sensing ion channels that could be used to increase neuronal excitability if exposed to a suitable substrate.",
          "offsetInBeginSection": 321,
          "offsetInEndSection": 541,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9809429",
          "text": "These fusion proteins preserved the intrinsic functions of each component, bacteriorhodopsin and GFP, were expressed in H. salinarum under conditions with an extremely high salt concentration, and were proved to be properly localized in its plasma membrane.",
          "offsetInBeginSection": 290,
          "offsetInEndSection": 547,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25378153",
          "text": "Expression of EGFP-rab11a fusion proteins in Xenopus laevis photoreceptors revealed that the nucleotide binding status of rab11a affects its subcellular localization, with GTP-locked mutants concentrated in the inner segment and GDP-locked mutants concentrated in the outer segment.",
          "offsetInBeginSection": 492,
          "offsetInEndSection": 774,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10988291",
          "text": "phy procedure. Biochemical studies show that some of the fusion proteins effectively mimic the activated conformation(s) of rhodopsin in stimulating G",
          "offsetInBeginSection": 944,
          "offsetInEndSection": 1094,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10988291",
          "text": "Biochemical studies show that some of the fusion proteins effectively mimic the activated conformation(s) of rhodopsin in stimulating G-protein or competing with the light-activated rhodopsin/G-protein interaction, in supporting phosphorylation of the carboxyl-terminal opsin fragment by rhodopsin kinase, and/or phosphopeptide-stimulated arrestin binding.",
          "offsetInBeginSection": 959,
          "offsetInEndSection": 1315,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30954887",
          "text": "Currently, three different types of these fusion proteins with an N-terminal type-1 rhodopsin and a C-terminal enzyme domain have been identified, but their physiological relevance is mostly unknown.",
          "offsetInBeginSection": 129,
          "offsetInEndSection": 328,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35836081",
          "text": "BL-OG is realized through opsin-luciferase fusion proteins called luminopsins (LMOs).",
          "offsetInBeginSection": 499,
          "offsetInEndSection": 584,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11134067",
          "text": "Various green fluorescent protein (GFP)/rhodopsin COOH-terminal fusion proteins were expressed specifically in the major red rod photoreceptors of transgenic Xenopus laevis under the control of the Xenopus opsin promoter.",
          "offsetInBeginSection": 269,
          "offsetInEndSection": 490,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29414245",
          "text": "Fusion protein ligands of the B2R are stable but subjected to slow intracellular inactivation, strong species specificity, and possible steric hindrance between the receptor and large proteins.",
          "offsetInBeginSection": 1273,
          "offsetInEndSection": 1466,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/11134067",
        "http://www.ncbi.nlm.nih.gov/pubmed/34281270",
        "http://www.ncbi.nlm.nih.gov/pubmed/30954887",
        "http://www.ncbi.nlm.nih.gov/pubmed/25378153",
        "http://www.ncbi.nlm.nih.gov/pubmed/9809429",
        "http://www.ncbi.nlm.nih.gov/pubmed/10988291",
        "http://www.ncbi.nlm.nih.gov/pubmed/35836081",
        "http://www.ncbi.nlm.nih.gov/pubmed/29414245"
      ]
    },
    {
      "id": "6429fe4e57b1c7a31500000f",
      "type": "summary",
      "body": "What are coactivators?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17476305",
          "text": "development and physiology. These coactivators are nuclear proteins and transcription co-regulators that function to facilitate the transcription init",
          "offsetInBeginSection": 70,
          "offsetInEndSection": 220,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11893487",
          "text": "Coactivators are diverse and multifunctional proteins that act downstream of DNA-binding activators to stimulate transcription.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11108858",
          "text": "Coactivators are a diverse group of molecules that bring multiple structural and enzymatic functions to the promoter.",
          "offsetInBeginSection": 287,
          "offsetInEndSection": 404,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11306337",
          "text": "The emerging picture shows coactivators as flexible, but precise, coordinators of complex and dynamic networks, in which transcriptional regulation by GR and other NRs is linked to other signaling pathways.",
          "offsetInBeginSection": 752,
          "offsetInEndSection": 958,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21664237",
          "text": "Coactivators are a diverse group of non-DNA binding proteins that induce structural changes in agonist-bound nuclear receptors (NRs) that are essential for NR-mediated transcriptional activation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9806345",
          "text": "ent and indicates a dual role for coactivators as bridging factors and chromatin remodeling proteins. The opposites of coactivators are corepressors, ",
          "offsetInBeginSection": 879,
          "offsetInEndSection": 1029,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8571454",
          "text": "Coactivators are a novel class of transcriptional activator required at many eukaryotic promoters.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26201947",
          "text": "ogen-sensitive and -insensitive prostate cancer cells. Coactivators p300 and SRC-1 are required for AR activation by interleukin-6 (IL-6), a cytokine ",
          "offsetInBeginSection": 1188,
          "offsetInEndSection": 1338,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14690606",
          "text": "160, p300, and CARM1 coactivators. We identified a coactivator, coiled-coil coactivator (CoCoA), which binds to this domain and thereby enhances trans",
          "offsetInBeginSection": 413,
          "offsetInEndSection": 563,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25024406",
          "text": "Transcriptional coactivators have evolved as an important new class of functional proteins that participate with virtually all transcription factors and nuclear receptors (NRs) to intricately regulate gene expression in response to a wide variety of environmental cues.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 269,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17046230",
        "http://www.ncbi.nlm.nih.gov/pubmed/26201947",
        "http://www.ncbi.nlm.nih.gov/pubmed/32410572",
        "http://www.ncbi.nlm.nih.gov/pubmed/14766010",
        "http://www.ncbi.nlm.nih.gov/pubmed/10454563",
        "http://www.ncbi.nlm.nih.gov/pubmed/11306337",
        "http://www.ncbi.nlm.nih.gov/pubmed/11893487",
        "http://www.ncbi.nlm.nih.gov/pubmed/16604175",
        "http://www.ncbi.nlm.nih.gov/pubmed/17476305",
        "http://www.ncbi.nlm.nih.gov/pubmed/27654711"
      ]
    },
    {
      "id": "6412331b201352f04a000038",
      "type": "factoid",
      "body": "What are PROTACs?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30706727",
          "text": "y reducing or eliminating disease-causing proteins. PROTACs are bifunctional molecules that consist of a target protein ligand, a linker and an E3 lig",
          "offsetInBeginSection": 92,
          "offsetInEndSection": 242,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33369705",
          "text": "PROteolysis Targeting Chimeras (PROTACs) are a family of heterobifunctional small molecules that specifically target cellular proteins for degradation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35589670",
          "text": "ive technology for targeted protein degradation. PROTACs are heterobifunctional molecules that can trigger the polyubiquitination of proteins of inter",
          "offsetInBeginSection": 74,
          "offsetInEndSection": 224,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32270707",
          "text": "uitin-proteasome system. PROTAC molecules (PROTACs) are a class of heterobifunctional molecules, which contain a ligand targeting the protein of inter",
          "offsetInBeginSection": 106,
          "offsetInEndSection": 256,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34034148",
          "text": "Chemical knockdown of therapeutic targets using proteolysis targeting chimeras (PROTACs) is a rapidly developing field in drug discovery, but PROTACs are bifunctional molecules that generally show poor bioavailability due to their relatively high molecular weight.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 264,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32718354",
          "text": "Proteolysis targeting chimeras (PROTACs) are heterobifunctional small molecules that utilize the ubiquitin proteasome system (UPS) to degrade proteins of interest (POI).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36120561",
          "text": "PROTACs are small molecule, protein degraders that function by hijacking the built-in Ubiquitin-Proteasome pathway.",
          "offsetInBeginSection": 254,
          "offsetInEndSection": 369,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33081540",
          "text": "INTRODUCTION\nPROTACs represent a novel class of heterobifunctional molecules that simultaneously bind to a target protein and to an E3 ligase complex, resulting in the transfer of ubiquitin and initiating a process ultimately causing the proteasomal degradation of the target protein.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 284,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31064868",
          "text": "Proteolysis-targeting chimeras (PROTAC) are bifunctional molecules that hijack endogenous E3 ubiquitin ligases to induce ubiquitination and subsequent degradation of protein of interest.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35418290",
          "text": "to selectively deplete their respective targets. PROTACs act as bifunctional degraders that comprise ubiquitin E3 ligase- and target-binding moieties ",
          "offsetInBeginSection": 144,
          "offsetInEndSection": 294,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32270707",
        "http://www.ncbi.nlm.nih.gov/pubmed/35589670",
        "http://www.ncbi.nlm.nih.gov/pubmed/35418290",
        "http://www.ncbi.nlm.nih.gov/pubmed/36041010",
        "http://www.ncbi.nlm.nih.gov/pubmed/35533582",
        "http://www.ncbi.nlm.nih.gov/pubmed/32718354",
        "http://www.ncbi.nlm.nih.gov/pubmed/33369705",
        "http://www.ncbi.nlm.nih.gov/pubmed/34034148",
        "http://www.ncbi.nlm.nih.gov/pubmed/36232374",
        "http://www.ncbi.nlm.nih.gov/pubmed/32698111"
      ]
    },
    {
      "id": "62008022c9dfcb9c0900001b",
      "type": "list",
      "body": "Which variables are included in the ALBI grade?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32411593",
          "text": "Multivariate analysis suggested that the ALBI grade, AAPR, CA19-9, tumor number, and microvascular invasion were independent prognostic predictors for OS.",
          "offsetInBeginSection": 1048,
          "offsetInEndSection": 1202,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35703648",
          "text": "groups based on ALBI scores: grade 1 (\u2264 -2.60, n = 113), grade 2 (-2.60 to -1.39, n = 835), and grade 3 (> -1.39, n = 77). The association of ALBI sco",
          "offsetInBeginSection": 405,
          "offsetInEndSection": 555,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31046687",
          "text": "For liver function assessment, Child-Pugh class, ALBI grade, MELD, ALP-to-platelet ratio and albumin-to-ALP ratio were derived.",
          "offsetInBeginSection": 1068,
          "offsetInEndSection": 1195,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29168098",
          "text": "orodeoxyglucose-positron emission tomography (18F-FDG-PET) and the albumin-bilirubin (ALBI) grade.\n\n\nMETHODS\nThis study included 207 consecutive patie",
          "offsetInBeginSection": 349,
          "offsetInEndSection": 499,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31191834",
          "text": "Patient's age, gender, cause of cirrhosis, ALBI Grade along with the site, size and number of tumors were recorded.",
          "offsetInBeginSection": 497,
          "offsetInEndSection": 612,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36411535",
          "text": "BACKGROUND\nAlbumin-bilirubin (ALBI) grade is an index of liver function based on total bilirubin (T-BIL) and albumin levels, and its usefulness has been widely reported.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33788758",
          "text": "RESULTS\nALBI grade 2/3 was significantly associated with older age, male sex, advanced pT status, and histological type.",
          "offsetInBeginSection": 556,
          "offsetInEndSection": 676,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36291867",
          "text": "The modified ALBI (mALBI) grades were: an ALBI score \u2264-3.02 for mALBI grade 1, an ALBI score &gt;-3.02 to \u2264-2.08 for mALBI grade 2, and an ALBI score &gt;-2.08 for mALBI grade 3.",
          "offsetInBeginSection": 688,
          "offsetInEndSection": 866,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33442542",
          "text": "Unlike the Child-Pugh score, the ALBI score uses only objective parameters, albumin (Alb) and total bilirubin (T.Bil), enabling a better evaluation.",
          "offsetInBeginSection": 151,
          "offsetInEndSection": 299,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31191834",
          "text": "Patient's age, gender, cause of cirrhosis, ALBI Grade along with the site, size and number of tumors were recorded.",
          "offsetInBeginSection": 497,
          "offsetInEndSection": 612,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35703648",
        "http://www.ncbi.nlm.nih.gov/pubmed/31046687",
        "http://www.ncbi.nlm.nih.gov/pubmed/31191834",
        "http://www.ncbi.nlm.nih.gov/pubmed/31335351",
        "http://www.ncbi.nlm.nih.gov/pubmed/32411593",
        "http://www.ncbi.nlm.nih.gov/pubmed/33788758",
        "http://www.ncbi.nlm.nih.gov/pubmed/33442542",
        "http://www.ncbi.nlm.nih.gov/pubmed/27214151",
        "http://www.ncbi.nlm.nih.gov/pubmed/35297807",
        "http://www.ncbi.nlm.nih.gov/pubmed/29976502"
      ]
    },
    {
      "id": "64240f33690f196b51000049",
      "type": "list",
      "body": "What drugs are used to treat FIP, Feline Infectious Peritonitis in cats?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8588340",
          "text": "Feline infectious peritonitis (FIP) virus antigen was demonstrated after methanol, ethanol or formalin fixation in paraffin-embedded tissues by means of monoclonal and polyclonal antibodies.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22092616",
          "text": "All cats received additional treatment with glucocorticoids, antibiotics, and low molecular weight heparin according to methods.",
          "offsetInBeginSection": 569,
          "offsetInEndSection": 697,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36016355",
          "text": "This study shows that ionophore antibiotics, including valinomycin, salinomycin, and nigericin, inhibit FCoV proliferation in vitro in a dose-dependent manner.",
          "offsetInBeginSection": 842,
          "offsetInEndSection": 1001,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36387398",
          "text": "Objectives\nThe main objectives of this study were to investigate the efficacy of the nucleotide analog GS-441524 in combination with the 3C-like protease inhibitor GC376 for the treatment of naturally aquired feline infectious peritonitis (FIP) and to test whether their combination shortens the dosing period and improves the cure rate.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 337,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18196725",
          "text": "All cats received adjunctive treatment with glucocorticoids and antibiotics and passive immunization with Feliserin.",
          "offsetInBeginSection": 620,
          "offsetInEndSection": 736,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33799985",
          "text": "ed, and most of the affected cats die or are euthanized. Anecdotally, doxycycline has been used to treat FIP-affected cats, but there are currently no",
          "offsetInBeginSection": 191,
          "offsetInEndSection": 341,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32456286",
          "text": "Our study suggested that HCQ and rfIFN-\u03c9 are applicable for treatment of FIP.",
          "offsetInBeginSection": 882,
          "offsetInEndSection": 959,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18395801",
          "text": "Immune suppressive drugs such as prednisone or cyclophosphamide may slow disease progression but do not produce a cure.",
          "offsetInBeginSection": 287,
          "offsetInEndSection": 406,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27264736",
          "text": "rmed to have fTNF-alpha neutralization activity. Purified mouse mAb 2-4 and chimeric mAb 2-4 were repeatedly administered to cats, and the changes in ",
          "offsetInBeginSection": 703,
          "offsetInEndSection": 853,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15123155",
          "text": "ritonitis (FIP) were treated with a combination of recombinant feline interferon and glucocorticoid. A complete remission (over 2 years) and a partial",
          "offsetInBeginSection": 78,
          "offsetInEndSection": 228,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18196725",
        "http://www.ncbi.nlm.nih.gov/pubmed/26656689",
        "http://www.ncbi.nlm.nih.gov/pubmed/9637307",
        "http://www.ncbi.nlm.nih.gov/pubmed/19482534",
        "http://www.ncbi.nlm.nih.gov/pubmed/33799985",
        "http://www.ncbi.nlm.nih.gov/pubmed/32441826",
        "http://www.ncbi.nlm.nih.gov/pubmed/24458025",
        "http://www.ncbi.nlm.nih.gov/pubmed/36387398",
        "http://www.ncbi.nlm.nih.gov/pubmed/36297266",
        "http://www.ncbi.nlm.nih.gov/pubmed/30342822"
      ]
    },
    {
      "id": "6428da98690f196b51000053",
      "type": "yesno",
      "body": "Is there a way to distinguish COVID-19 clinically from other respiratory illnesses, such as influenza?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34111501",
          "text": "Although COVID-19 is often compared to other respiratory viral illnesses, few formal comparisons of these viruses on kidney health exist.",
          "offsetInBeginSection": 169,
          "offsetInEndSection": 306,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35603380",
          "text": "Influenza and COVID-19 are contagious respiratory illnesses that are caused by different pathogenic viruses but appeared with similar initial presentations.",
          "offsetInBeginSection": 366,
          "offsetInEndSection": 522,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33135801",
          "text": "It is difficult to distinguish coronavirus disease-2019 (COVID-19) from other viral respiratory tract infections owing to the similarities in clinical and radiological findings.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33995342",
          "text": "Although COVID-19 has been extensively characterized clinically, the factors distinguishing SARS-CoV-2 from other respiratory viruses are unknown.",
          "offsetInBeginSection": 224,
          "offsetInEndSection": 370,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34590732",
          "text": "The success and efficacy of vaccination campaigns for other respiratory illnesses, such as influenza, may help inform messaging around COVID-19 vaccinations.",
          "offsetInBeginSection": 141,
          "offsetInEndSection": 298,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33947345",
          "text": "However, it is important to distinguish COVID-19 from other respiratory infectious diseases, such as influenza.",
          "offsetInBeginSection": 147,
          "offsetInEndSection": 258,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32482366",
          "text": "Clinicians can neither rule out other co-infections caused by respiratory pathogens by diagnosing SARS-CoV-2 infection nor rule out COVID-19 by detection of non-SARS-CoV-2 respiratory pathogens.",
          "offsetInBeginSection": 1544,
          "offsetInEndSection": 1738,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34981695",
          "text": "However, the differences between the groups were not substantial enough and would probably not suffice to distinguish between the viral illnesses in the emergency department.",
          "offsetInBeginSection": 1190,
          "offsetInEndSection": 1364,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33090987",
          "text": "Data that examine all in-hospital complications of COVID-19 and that compare these complications with those associated with other viral respiratory pathogens, such as influenza, are lacking.",
          "offsetInBeginSection": 214,
          "offsetInEndSection": 404,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33901185",
          "text": "At clinical presentation, nine basic clinical and epidemiological indicators may help to distinguish COVID-19 or dengue from each other and other febrile illnesses.",
          "offsetInBeginSection": 2027,
          "offsetInEndSection": 2191,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33901185",
        "http://www.ncbi.nlm.nih.gov/pubmed/32511543",
        "http://www.ncbi.nlm.nih.gov/pubmed/34981695",
        "http://www.ncbi.nlm.nih.gov/pubmed/33947345",
        "http://www.ncbi.nlm.nih.gov/pubmed/36362465",
        "http://www.ncbi.nlm.nih.gov/pubmed/32881022",
        "http://www.ncbi.nlm.nih.gov/pubmed/34728719",
        "http://www.ncbi.nlm.nih.gov/pubmed/33090987",
        "http://www.ncbi.nlm.nih.gov/pubmed/33615750",
        "http://www.ncbi.nlm.nih.gov/pubmed/33933115"
      ]
    },
    {
      "id": "6415c8f1690f196b51000017",
      "type": "factoid",
      "body": "Which form of cancer have paclitaxel, docetaxel, doxorubicin, and epirubicin been approved for?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11432615",
          "text": "BACKGROUND\nTreatment of metastatic breast cancer (MBC) with paclitaxel (T) and doxorubicin has yielded high response rates but the regimen is associated with significant cardiac toxicity.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10426454",
          "text": "re among the most active cytotoxic agents for the treatment of metastatic breast cancer. Given their activity, relative non-cross-resistance, partiall",
          "offsetInBeginSection": 106,
          "offsetInEndSection": 256,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11552225",
          "text": "While both paclitaxel and docetaxel may be effectively combined with doxorubicin in the treatment of metastatic breast cancer, the drug-drug interaction between paclitaxel and doxorubicin (but not of docetaxel and doxorubicin) warrants that certain restrictions be followed for safe use.",
          "offsetInBeginSection": 1324,
          "offsetInEndSection": 1611,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12473512",
          "text": "apeutic agents for the first-line and second-line treatment of metastatic breast cancer, and their clinical use is widespread. However, for women whos",
          "offsetInBeginSection": 112,
          "offsetInEndSection": 262,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11970739",
          "text": "The taxanes are emerging as the most powerful compounds in breast cancer. Both compounds, paclitaxel and docetaxel, have been evaluated in the metasta",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8629032",
          "text": "We conclude that the combination paclitaxel/epirubicin is safe for patients with metastatic breast cancer and, at this early evaluation, shows promising antitumor activity.",
          "offsetInBeginSection": 1939,
          "offsetInEndSection": 2111,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14499011",
          "text": "he 1990s, the taxanes have emerged as the most powerful compounds in breast cancer. Paclitaxel and docetaxel have been evaluated in the metastatic set",
          "offsetInBeginSection": 54,
          "offsetInEndSection": 204,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11346678",
          "text": "he 1990s, the taxanes have emerged as the most powerful compounds in breast cancer. Both compounds, paclitaxel and docetaxel, have been evaluated in m",
          "offsetInBeginSection": 54,
          "offsetInEndSection": 204,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9865708",
          "text": "her doxorubicin or epirubicin has significant activity against metastatic breast cancer. However, the optimal schedule in terms of activity and toxici",
          "offsetInBeginSection": 90,
          "offsetInEndSection": 240,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11396360",
          "text": "Doxorubicin/paclitaxel (Taxol) combinations are very active in advanced breast cancer, with objective response rates up to 90%, but have shown a high incidence of cardiotoxicity.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/10426454",
        "http://www.ncbi.nlm.nih.gov/pubmed/11706529",
        "http://www.ncbi.nlm.nih.gov/pubmed/9865686",
        "http://www.ncbi.nlm.nih.gov/pubmed/9463787",
        "http://www.ncbi.nlm.nih.gov/pubmed/9322878",
        "http://www.ncbi.nlm.nih.gov/pubmed/11552229",
        "http://www.ncbi.nlm.nih.gov/pubmed/9516602",
        "http://www.ncbi.nlm.nih.gov/pubmed/28614979",
        "http://www.ncbi.nlm.nih.gov/pubmed/9865708",
        "http://www.ncbi.nlm.nih.gov/pubmed/11970739"
      ]
    },
    {
      "id": "63eeec79f36125a426000006",
      "type": "factoid",
      "body": "Talquetamab was developed for treatment of which disease?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36464766",
          "text": "CASE REPORT\nWe present the case of a 77-year-old male who received T cell redirecting bispecific antibody therapy with talquetamab for relapsed/refractory multiple myeloma (RRMM) and developed CRS with concurrent ICANS after receiving a second dose of talquetamab.",
          "offsetInBeginSection": 451,
          "offsetInEndSection": 715,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26179525",
          "text": " developed aortitis during treatment with adalimumab (ADA) for ileocolic Crohn's disease (CD). The patient complained of a high fever, abdominal pain,",
          "offsetInBeginSection": 19,
          "offsetInEndSection": 169,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8100702",
          "text": "OBJECTIVES\nThe objectives were to assess (a) the comparative merits of commonly used disease modifying drugs in the treatment of rheumatoid arthritis (RA) and (b) the influence of age, gender, and disease duration on the outcome of treatment.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 242,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18673132",
          "text": "Subjects with nonalcoholic fatty liver disease are at risk of progressive liver failure.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28203197",
          "text": "Syphilitic uveitis was suspected, so we administered treatment for syphilis, anticoagulant treatment for retinal vasculitis, steroids for intraocular inflammation, and photocoagulation for the retinal nonperfusion area.",
          "offsetInBeginSection": 660,
          "offsetInEndSection": 879,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36462062",
          "text": "From a historic lens, treatment for patients with relapsed/refractory multiple myeloma (R/R MM) has advanced significantly since the advent of immunomodulatory agents (IMiDs) in the 1990s, proteasome inhibitors in the 2000s, monoclonal antibodies in the 2010s, and CAR-T treatments in the 2020s.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 295,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10584579",
          "text": "se in which UFT was effective as a preoperative treatment for stage II b cervical cancer. The patient was a 66-year-old female whose chief complaint w",
          "offsetInBeginSection": 14,
          "offsetInEndSection": 164,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9545827",
          "text": "A 40-year-old man with chronic myelogenous leukemia in chronic phase received an allogeneic marrow graft from his HLA identical brother.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36464766",
        "http://www.ncbi.nlm.nih.gov/pubmed/18673132",
        "http://www.ncbi.nlm.nih.gov/pubmed/28203197",
        "http://www.ncbi.nlm.nih.gov/pubmed/8100702",
        "http://www.ncbi.nlm.nih.gov/pubmed/10584579",
        "http://www.ncbi.nlm.nih.gov/pubmed/26179525",
        "http://www.ncbi.nlm.nih.gov/pubmed/9545827",
        "http://www.ncbi.nlm.nih.gov/pubmed/36462062"
      ]
    },
    {
      "id": "642321a5690f196b51000047",
      "type": "summary",
      "body": "Please summarize Feline Spongiform Encephalopathy(FSE",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12296404",
          "text": "Feline spongiform encephalopathy (FSE) is thought to have resulted from consumption of food contaminated with bovine spongiform encephalopathy and the latter is believed to result from the consumption of food contaminated with scrapie.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 235,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22505359",
          "text": " in zoological gardens, and feline spongiform encephalopathy in domestic cats.  This short review summarizes the history of the research to find the n",
          "offsetInBeginSection": 526,
          "offsetInEndSection": 676,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14522860",
          "text": "These include feline spongiform encephalopathy of zoological and domestic cats (FSE) and transmissible spongiform encephalopathy (TSE) of zoological ruminants and non-human primates, as well as chronic wasting disease of deer and elk (CWD) and transmissible mink encephalopathy of farmed mink (TME).",
          "offsetInBeginSection": 150,
          "offsetInEndSection": 449,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19335885",
          "text": "BACKGROUND\nTwo domestic shorthair cats presenting with progressive hind-limb ataxia and increased aggressiveness were necropsied and a post mortem diagnosis of Feline Spongiform Encephalopathy (FSE) was made.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19738899",
          "text": "Feline spongiform encephalopathy (FSE) is considered to be related to bovine spongiform encephalopathy (BSE) and has been reported in domestic cats as well as in captive wild cats including cheetahs, first in the United Kingdom (UK) and then in other European countries.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 270,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18725465",
          "text": "Feline spongiform encephalopathy (FSE) is a transmissible spongiform encephalopathy associated with the consumption of feedstuffs contaminated with tissue from bovine spongiform encephalopathy-affected cattle and characterized by the accumulation in the central nervous system of an abnormal isoform of the prion protein (PrP(sc)).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 331,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23236066",
          "text": "form encephalopathy (FSE), almost certainly caused by consumption of bovine spongiform encephalopathy (BSE)-contaminated meat. Because domestic and fr",
          "offsetInBeginSection": 80,
          "offsetInEndSection": 230,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15276850",
          "text": "lopathy (FSE), which may have occurred before it was first recognized in 1990. The following six categories of disease were identified: congenital; de",
          "offsetInBeginSection": 140,
          "offsetInEndSection": 290,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20660146",
          "text": "Feline spongiform encephalopathy (FSE) is a transmissible spongiform encephalopathy that affects domestic cats (Felis catus) and captive wild members of the family Felidae.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12442705",
          "text": "Feline spongiform encephalopathy was confirmed by histological brain examination and positive immunohistochemistry for PrPSc.",
          "offsetInBeginSection": 514,
          "offsetInEndSection": 639,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/12442705",
        "http://www.ncbi.nlm.nih.gov/pubmed/18725465",
        "http://www.ncbi.nlm.nih.gov/pubmed/23236066",
        "http://www.ncbi.nlm.nih.gov/pubmed/14522860",
        "http://www.ncbi.nlm.nih.gov/pubmed/15276850",
        "http://www.ncbi.nlm.nih.gov/pubmed/20660146",
        "http://www.ncbi.nlm.nih.gov/pubmed/22505359",
        "http://www.ncbi.nlm.nih.gov/pubmed/19738899",
        "http://www.ncbi.nlm.nih.gov/pubmed/12783238",
        "http://www.ncbi.nlm.nih.gov/pubmed/11338713"
      ]
    },
    {
      "id": "6428d7da690f196b51000050",
      "type": "yesno",
      "body": "Can untranslated regions (UTRs) regulate gene expression?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18615019",
          "text": "Structured RNAs embedded in the untranslated regions (UTRs) of messenger RNAs can regulate gene expression.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985357",
          "text": "Many studies using reporter assays have demonstrated that 3' untranslated regions (3'-UTRs) regulate gene expression by controlling mRNA stability and translation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31234415",
          "text": "Single nucleotide polymorphisms located in 5' untranslated regions (5'UTRs) can regulate gene expression and have clinical impact.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18631145",
          "text": "Post-transcriptional regulation, via 5'-UTRs (5'-untranslated regions), plays an important role in the control of eukaryotic gene expression.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22846368",
          "text": "Untranslated regions (UTRs) in eukaryotes play a significant role in the regulation of translation and mRNA half-life, as well as interacting with specific RNA-binding proteins.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33821006",
          "text": "Endogenous deletion of conserved elements within these 5' UTRs decreased gene expression, and extremely conserved 5' UTRs possess cis-regulatory elements that promote cell-type-specific regulation of translation.",
          "offsetInBeginSection": 359,
          "offsetInEndSection": 571,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20720301",
          "text": "Untranslated regions (UTRs) of eukaryotic mRNAs play crucial roles in post-transcriptional regulation of gene expression via the modulation of nucleocytoplasmic mRNA transport, translation efficiency, subcellular localization, and message stability.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 249,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24067953",
          "text": "3' untranslated regions (UTRs) are known to play an important role in posttranscriptional regulation of gene expression.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16430990",
          "text": "Tissue-specific expression of transcripts that have different untranslated regions (UTRs) can control protein expression enabling developmental, physiological and pathological regulation.",
          "offsetInBeginSection": 243,
          "offsetInEndSection": 430,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7662369",
          "text": "The 3' untranslated region (3' UTR) can control gene expression by affecting the localization, stability and translation of mRNAs.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18631145",
        "http://www.ncbi.nlm.nih.gov/pubmed/21543795",
        "http://www.ncbi.nlm.nih.gov/pubmed/33821006",
        "http://www.ncbi.nlm.nih.gov/pubmed/20563548",
        "http://www.ncbi.nlm.nih.gov/pubmed/25577389",
        "http://www.ncbi.nlm.nih.gov/pubmed/32995550",
        "http://www.ncbi.nlm.nih.gov/pubmed/31234415",
        "http://www.ncbi.nlm.nih.gov/pubmed/16430990",
        "http://www.ncbi.nlm.nih.gov/pubmed/19372383",
        "http://www.ncbi.nlm.nih.gov/pubmed/7662369"
      ]
    },
    {
      "id": "63f9cbb433942b094c00000c",
      "type": "yesno",
      "body": "Is alternative splicing associated with heart disease?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26116573",
          "text": "We found that loss of rbfox1 led to progressive cardiac contractile dysfunction and heart failure.",
          "offsetInBeginSection": 441,
          "offsetInEndSection": 539,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30051286",
          "text": "Here, we review our current knowledge of alternative splicing in the heart, with a particular focus on the factors controlling cardiac alternative splicing and their role in cardiomyopathies and subsequent heart failure.",
          "offsetInBeginSection": 757,
          "offsetInEndSection": 977,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24552714",
          "text": "Collectively, the present results suggest that chronic pressure-overload hypertrophy is closely associated with distinct alternative splicing due to altered expression of splicing factors.",
          "offsetInBeginSection": 1287,
          "offsetInEndSection": 1475,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21859973",
          "text": "A number of human diseases are associated with alternative mRNA splicing, which has received comparatively little attention in the study of cardiac disease.",
          "offsetInBeginSection": 279,
          "offsetInEndSection": 435,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30468920",
          "text": "assembly of the contractile apparatus. Recently, FHOD3 mutations have been found associated with heart diseases. We identified novel FHOD3 splicing va",
          "offsetInBeginSection": 753,
          "offsetInEndSection": 903,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27825848",
          "text": "In the heart of human, mis-regulation of alternative splicing has been associated with heart failure.",
          "offsetInBeginSection": 367,
          "offsetInEndSection": 468,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30468920",
          "text": "These results indicate that RBM20 and PTBP1 play a role in the actin filament functional organization mediated by FHOD3 isoforms and suggest their possible involvement in heart diseases.",
          "offsetInBeginSection": 1190,
          "offsetInEndSection": 1376,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35938400",
          "text": "ve been reported in human heart defects. Defects in alternative splicing are associated with many heart diseases, yet relatively little is known about",
          "offsetInBeginSection": 212,
          "offsetInEndSection": 362,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34273561",
          "text": "In humans, cardiac mRNA splicing is involved in the pathophysiology of heart failure.",
          "offsetInBeginSection": 94,
          "offsetInEndSection": 179,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35938400",
          "text": "Several genes that have splicing regulated by GATA4 have functional consequences and many are associated with dilated cardiomyopathy, suggesting a novel role for GATA4 in achieving the necessary cardiac proteome in normal and stress-responsive conditions.",
          "offsetInBeginSection": 2062,
          "offsetInEndSection": 2317,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34651015",
        "http://www.ncbi.nlm.nih.gov/pubmed/35938400",
        "http://www.ncbi.nlm.nih.gov/pubmed/24552714",
        "http://www.ncbi.nlm.nih.gov/pubmed/27825848",
        "http://www.ncbi.nlm.nih.gov/pubmed/26846640",
        "http://www.ncbi.nlm.nih.gov/pubmed/22939879",
        "http://www.ncbi.nlm.nih.gov/pubmed/34573439",
        "http://www.ncbi.nlm.nih.gov/pubmed/21859973",
        "http://www.ncbi.nlm.nih.gov/pubmed/35862102",
        "http://www.ncbi.nlm.nih.gov/pubmed/33671899"
      ]
    },
    {
      "id": "61fa941ec9dfcb9c09000005",
      "type": "yesno",
      "body": "Should Intepirdine be used for Alzheimer's disease?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28253832",
          "text": "Expert opinion: If current Phase-3 trials are positive, 5-HT6 antagonists such as Idalopirdine and Intepirdine may be considered as supplementary treatments to ChEI's and NMDA receptor antagonists for the symptomatic treatment of AD.",
          "offsetInBeginSection": 1152,
          "offsetInEndSection": 1385,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9179132",
          "text": "CONCLUSION\nResults of this study indicate that pupil measurement after instillation of tropicamide cannot be used as a reliable diagnostic test for Alzheimer's disease.",
          "offsetInBeginSection": 1424,
          "offsetInEndSection": 1592,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34189249",
          "text": "INTRODUCTION\nA phase 2b clinical trial, HEADWAY-DLB, was performed to assess treatment with intepirdine, a serotonin receptor antagonist, in patients with dementia with Lewy bodies (DLB).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32321414",
          "text": "It is predicted that some FDA-approved drugs, such as Paracetamol, Risperidone, Escitalopram, Simvastatin, Cilostazoand, and Ritalin-SR, could also be used in off-label ways for AD.",
          "offsetInBeginSection": 1829,
          "offsetInEndSection": 2010,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29848076",
          "text": "Cholinesterase inhibitors and the NMDA-receptor antagonist memantine are currently the two approved symptomatic treatments for AD.",
          "offsetInBeginSection": 124,
          "offsetInEndSection": 254,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31554608",
          "text": "ce to the average patient with major depressive disorder. Antidepressants should not be used for adults with major depressive disorder before valid ev",
          "offsetInBeginSection": 1190,
          "offsetInEndSection": 1340,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32321414",
        "http://www.ncbi.nlm.nih.gov/pubmed/9179132",
        "http://www.ncbi.nlm.nih.gov/pubmed/28253832",
        "http://www.ncbi.nlm.nih.gov/pubmed/31554608",
        "http://www.ncbi.nlm.nih.gov/pubmed/29848076",
        "http://www.ncbi.nlm.nih.gov/pubmed/34189249"
      ]
    },
    {
      "id": "6422e2f1690f196b51000043",
      "type": "factoid",
      "body": "What human cells are usually targeted with a Gal-Nac conjugated siRNA or ASO",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20964335",
          "text": "In conclusion, these siRNA conjugates have the potential for targeted delivery of siRNAs to hepatocytes and hepatic stellate cells for efficient gene silencing in vivo.",
          "offsetInBeginSection": 1273,
          "offsetInEndSection": 1441,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24992960",
          "text": "GalNAc conjugation also enhanced potency and duration of the effect of two ASOs targeting human apolipoprotein C-III and human transthyretin (TTR) in transgenic mice.",
          "offsetInBeginSection": 940,
          "offsetInEndSection": 1106,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20964335",
          "text": "lycol) (M6P-PEG) for targeted delivery of siRNAs to hepatocytes and hepatic stellate cells (HSCs), respectively. These siRNA conjugates were purified ",
          "offsetInBeginSection": 299,
          "offsetInEndSection": 449,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26546271",
          "text": "Atx complex formation with ASOs or siRNA was achieved via the in-frame fusion of either Saccharomyces cerevisiae GAL4 or Homo sapien sapien PKR (respectively) to a truncation of Atx lethal factor (LFn), which were used with Atx protective antigen (PA).",
          "offsetInBeginSection": 475,
          "offsetInEndSection": 727,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24992960",
          "text": " of the effect of two ASOs targeting human apolipoprotein C-III and human transthyretin (TTR) in transgenic mice. The unconjugated ASOs are currently ",
          "offsetInBeginSection": 993,
          "offsetInEndSection": 1143,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22443209",
          "text": "njugates were taken up by cancer cells but not normal mammary epithelial cells or human blood monocytes. By 120 min of incubation, most of the cells h",
          "offsetInBeginSection": 511,
          "offsetInEndSection": 661,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26546271",
        "http://www.ncbi.nlm.nih.gov/pubmed/22443209",
        "http://www.ncbi.nlm.nih.gov/pubmed/24992960",
        "http://www.ncbi.nlm.nih.gov/pubmed/20964335"
      ]
    },
    {
      "id": "64299fa957b1c7a315000002",
      "type": "summary",
      "body": "What is rebound COVID-19?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35345769",
          "text": "00 daily cases, from May 6 to August 14, 2020) and a rebound phase (>100 daily cases, from August 15 to December 31, 2020).\n\n\nResults\nArea-level socio",
          "offsetInBeginSection": 842,
          "offsetInEndSection": 992,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35073672",
          "text": "The dynamic COVID-zero strategy is to follow the premise of \"external prevention of import, internal prevention of rebound\" prevention and control strategy, when the emergence of local COVID-19 cases, to take effective comprehensive prevention and control measures, and to \"find one, extinguish one\", to quickly cut off the chain of epidemic transmission, so that each epidemic is terminated in a timely manner, achieving maximum effectiveness with minimum cost.",
          "offsetInBeginSection": 356,
          "offsetInEndSection": 818,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35982673",
          "text": " BA.2.12.1 cohort: rebound infections (Hazard Ratio or HR: 1.32, 95% CI: 1.06-1.66), rebound symptoms (HR: 1.32, 95% CI: 1.04-1.68). As SARS-CoV-2 evo",
          "offsetInBeginSection": 1154,
          "offsetInEndSection": 1304,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36472873",
          "text": "Main Outcomes and Measures\nViral rebound, defined as a Ct value greater than 40 that decreased to 40 or less.",
          "offsetInBeginSection": 921,
          "offsetInEndSection": 1030,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36181334",
          "text": " infection is rebound COVID-19, which occurs between five and eight days following the cessation of antiviral treatment. Most case reports of rebound ",
          "offsetInBeginSection": 72,
          "offsetInEndSection": 222,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33864970",
          "text": "A rebound effect in transmission could occur after several years and this situation depends on the intensity of reinfection force.",
          "offsetInBeginSection": 1102,
          "offsetInEndSection": 1232,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35794889",
          "text": "Conclusions and Relevance\nCOVID-19 rebound occurred both after Paxlovid and Molnupiravir, especially in patients with underlying medical conditions.",
          "offsetInBeginSection": 2377,
          "offsetInEndSection": 2525,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35982673",
          "text": "The risks of both COVID-19 rebound infections and symptoms 2-8 days after Paxlovid treatment were higher in the BA.5 cohort than in the propensity-score matched BA.2.12.1 cohort: rebound infections (Hazard Ratio or HR: 1.32, 95% CI: 1.06-1.66), rebound symptoms (HR: 1.32, 95% CI: 1.04-1.68).",
          "offsetInBeginSection": 994,
          "offsetInEndSection": 1286,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35982660",
          "text": "viral RNA and symptom rebound in people with COVID-19 treated with nirmatrelvir/ritonavir. Since the natural course of viral and symptom trajectories of COVID-19 has not been well described, we evaluated the incidence of viral and symptom rebound in untreated outpatients with mild-moderate COVID-19.\n\n\nMethods\nThe study population included 568 participants enrolled in the ACTIV-2/A5401 platform trial who received placebo. Anterior nasal swabs were collected for SARS-CoV-2 RNA testing on days 0-14, 21 and 28. Participants recorded the severity of 13 targeted symptoms daily from day 0 to 28. Viral rebound was defined as \u22650.5 log10 viral RNA copies/mL increase and symptom rebound was defined as a 4-point total symptom score increase from baseline",
          "offsetInBeginSection": 32,
          "offsetInEndSection": 784,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33864970",
          "text": "A rebound effect in transmission could occur after several years and this situation depends on the intensity of reinfection force.",
          "offsetInBeginSection": 1102,
          "offsetInEndSection": 1232,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36181334",
        "http://www.ncbi.nlm.nih.gov/pubmed/35073672",
        "http://www.ncbi.nlm.nih.gov/pubmed/35982673",
        "http://www.ncbi.nlm.nih.gov/pubmed/35794889",
        "http://www.ncbi.nlm.nih.gov/pubmed/32388934",
        "http://www.ncbi.nlm.nih.gov/pubmed/35734093",
        "http://www.ncbi.nlm.nih.gov/pubmed/36472873",
        "http://www.ncbi.nlm.nih.gov/pubmed/35345769",
        "http://www.ncbi.nlm.nih.gov/pubmed/35982660",
        "http://www.ncbi.nlm.nih.gov/pubmed/33864970"
      ]
    },
    {
      "id": "6432fb1957b1c7a31500001e",
      "type": "list",
      "body": "What clinical applications is Zanubrutinib approved for in the United States?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36252483",
          "text": "oved for the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). While its role in pulmon",
          "offsetInBeginSection": 611,
          "offsetInEndSection": 761,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
          "text": "In the United States, zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle cell lymphoma who have received at least one prior therapy, for adults with Waldenstr\u00f6m macroglobulinemia, and for adults with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based therapy.",
          "offsetInBeginSection": 543,
          "offsetInEndSection": 890,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32869675",
          "text": "Zanubrutinib is currently approved for the treatment of patients with relapsed mantle cell lymphoma and has demonstrated an impressive safety and efficacy profile.",
          "offsetInBeginSection": 701,
          "offsetInEndSection": 864,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
          "text": "Zanubrutinib is currently approved for use for treatment of adult patients with MCL who have received at least one prior therapy, for adults with WM, and for adults with MZL who have received at least one anti-CD20-based therapy.",
          "offsetInBeginSection": 3210,
          "offsetInEndSection": 3439,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35306909",
          "text": "BTK) approved for the treatment of Waldenstr\u00f6m's macroglobulinemia, mantle cell lymphoma, and marginal zone lymphoma. As a class, BTKs have been linke",
          "offsetInBeginSection": 112,
          "offsetInEndSection": 262,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
          "text": "Zanubrutinib is currently approved for use for treatment of adult patients with MCL who have received at least one prior therapy, for adults with WM, and for adults with MZL who have received at least one anti-CD20-based therapy.",
          "offsetInBeginSection": 3210,
          "offsetInEndSection": 3439,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33539089",
          "text": "Many kinase inhibitors, including baricitinib, ruxolitinib, imatinib, tofacitinib, pacritinib, zanubrutinib, and ibrutinib, are under clinical investigation for COVID-19.",
          "offsetInBeginSection": 766,
          "offsetInEndSection": 936,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33777941",
          "text": "n the United States and in Europe, and zanubrutinib also in China, while tirabrutinib is currently only registered in Japan. In most cases, these comp",
          "offsetInBeginSection": 569,
          "offsetInEndSection": 719,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32753893",
          "text": "otherapy or those with chemoresistant disease. In addition to ibrutinib and acalabrutinib, the FDA recently approved zanubrutinib for the treatment of",
          "offsetInBeginSection": 367,
          "offsetInEndSection": 517,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35950210",
          "text": "ond-generation inhibitor, was recently approved in treatment-naive and refractory/relapsed patients. Here, we review the use of BTK inhibitors in WM i",
          "offsetInBeginSection": 363,
          "offsetInEndSection": 513,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35950210",
        "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
        "http://www.ncbi.nlm.nih.gov/pubmed/33539089",
        "http://www.ncbi.nlm.nih.gov/pubmed/32753893",
        "http://www.ncbi.nlm.nih.gov/pubmed/11842397",
        "http://www.ncbi.nlm.nih.gov/pubmed/33306268",
        "http://www.ncbi.nlm.nih.gov/pubmed/32861286",
        "http://www.ncbi.nlm.nih.gov/pubmed/34558376",
        "http://www.ncbi.nlm.nih.gov/pubmed/32869675",
        "http://www.ncbi.nlm.nih.gov/pubmed/34664792"
      ]
    },
    {
      "id": "61f7cb37882a024a10000029",
      "type": "yesno",
      "body": "Is rilonacept effective for pericarditis?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34599390",
          "text": "Colchicine, an inhibitor of NLRP3 inflammasome formation, and IL-1-targeted therapies, such as anakinra and rilonacept, were found to effectively blunt the acute inflammation and reduce the risk for recurrences.",
          "offsetInBeginSection": 1048,
          "offsetInEndSection": 1259,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35639340",
          "text": "Both anakinra and rilonacept have demonstrated efficacy in randomized trials of patients with recurrent pericarditis.",
          "offsetInBeginSection": 663,
          "offsetInEndSection": 780,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36277322",
          "text": "Rilonacept significantly reduced symptoms, inflammatory markers and recurrent episodes, and increased successful withdrawal of steroids.",
          "offsetInBeginSection": 717,
          "offsetInEndSection": 853,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34008144",
          "text": "Recent randomized trials indicate the efficacy of the interleukin-1 inhibitors anakinra and rilonacept in recurrent pericarditis, including colchicine-resistant and corticosteroid-dependent cases.",
          "offsetInBeginSection": 277,
          "offsetInEndSection": 473,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36398320",
          "text": "It is safe and efficacious in the treatment of recurrent pericarditis in the RHAPSODY II and III trials.",
          "offsetInBeginSection": 780,
          "offsetInEndSection": 884,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19649332",
          "text": "It is yet to be determined whether rilonacept would be an effective treatment for other chronic inflammatory conditions such as gout, familial Mediterranean fever and systemic juvenile idiopathic arthritis.",
          "offsetInBeginSection": 1993,
          "offsetInEndSection": 2199,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35350578",
          "text": "In the era of tailored medicine, anti-IL-1 agents such as anakinra and rilonacept have been demonstrated highly effective in patients with recurrent pericarditis associated with an inflammatory phenotype.",
          "offsetInBeginSection": 2149,
          "offsetInEndSection": 2353,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23754188",
          "text": "Treatment with rilonacept had a substantial steroid-sparing effect and was generally well-tolerated.",
          "offsetInBeginSection": 2062,
          "offsetInEndSection": 2162,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34156376",
          "text": "Rilonacept (Araclyst) has been approved to treat recurrent pericarditis and to reduce the risk of recurrence in adults and children 12 years of age and older.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36398320",
          "text": "It is safe and efficacious in the treatment of recurrent pericarditis in the RHAPSODY II and III trials.",
          "offsetInBeginSection": 780,
          "offsetInEndSection": 884,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36250662",
        "http://www.ncbi.nlm.nih.gov/pubmed/33200890",
        "http://www.ncbi.nlm.nih.gov/pubmed/36398320",
        "http://www.ncbi.nlm.nih.gov/pubmed/36277322",
        "http://www.ncbi.nlm.nih.gov/pubmed/19649332",
        "http://www.ncbi.nlm.nih.gov/pubmed/32562029",
        "http://www.ncbi.nlm.nih.gov/pubmed/34459270",
        "http://www.ncbi.nlm.nih.gov/pubmed/35350578",
        "http://www.ncbi.nlm.nih.gov/pubmed/34528670",
        "http://www.ncbi.nlm.nih.gov/pubmed/35639340"
      ]
    },
    {
      "id": "6413712a201352f04a00003e",
      "type": "list",
      "body": "The 1p19q co-deletion is associated with what types of tumors?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20446099",
          "text": "The authors describe a case wherein a 1p19q deletion in a disseminated tumor with mixed immunohistochemical features of oligodendroglioma and neurocytoma was encountered and treated.",
          "offsetInBeginSection": 158,
          "offsetInEndSection": 340,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18710393",
          "text": "Co-deletion of chromosome arms 1p and 19q, characteristic of oligodendroglial tumors, was recently found to be mediated by t(1;19)(q10;p10).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24197863",
          "text": "The lack of CIC expression was detected in 13 cases (68\u00a0%) of oligodendroglial tumors with the 1p/19q co-deletion, and in only 1 case of oligodendroglial tumors without the 1p/19q co-deletion (5\u00a0%, P\u00a0<\u00a00.0001).",
          "offsetInBeginSection": 660,
          "offsetInEndSection": 870,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25971646",
          "text": "1p19q co-deletion is a chromosomal alteration associated with primary brain tumours of oligodendroglial histology.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24197863",
          "text": "Combined immunohistochemical analysis assessed by INA expression and/or the lack of CIC expression was strongly associated with the 1p/19q co-deletion in oligodendroglial tumors, indicating a potential surrogate marker of the 1p/19q state.",
          "offsetInBeginSection": 871,
          "offsetInEndSection": 1110,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20587495",
          "text": "RESULTS\nTumors associated with the 1p19q codeletion were predominantly located in the frontal lobe (p=0.044).",
          "offsetInBeginSection": 572,
          "offsetInEndSection": 681,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20587495",
          "text": "RESULTS\nTumors associated with the 1p19q codeletion were predominantly located in the frontal lobe (p=0.044).",
          "offsetInBeginSection": 572,
          "offsetInEndSection": 681,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29550880",
          "text": "If our cohort had only used IDH status and IHC-based ATRX expression for diagnosis, 78 tumors would have been subtyped as 48 oligodendroglial tumors, 16 IDH-mutant astrocytic tumors, and 14 IDH-wildtype astrocytic tumors.",
          "offsetInBeginSection": 613,
          "offsetInEndSection": 834,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20035368",
          "text": "It has been reported recently that oligodendroglial tumors arising in the insula rarely harbor co-deletions of chromosomes 1p and 19q, a molecular signature which is associated with a good prognosis and increased responsiveness to radiation and chemotherapy compared with tumors in which 1p and/or 19q is intact.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 312,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28340142",
          "text": "Tumor purity was found to be significantly decreased in high-risk IDH-mutant with 1p/19q co-deletion gliomas and IDH-wild-type glioblastomas but not in IDH-wild-type lower grade or IDH-mutant, non-co-deleted gliomas.",
          "offsetInBeginSection": 1342,
          "offsetInEndSection": 1558,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20587495",
        "http://www.ncbi.nlm.nih.gov/pubmed/24197863",
        "http://www.ncbi.nlm.nih.gov/pubmed/31157866",
        "http://www.ncbi.nlm.nih.gov/pubmed/25971646",
        "http://www.ncbi.nlm.nih.gov/pubmed/24608451",
        "http://www.ncbi.nlm.nih.gov/pubmed/30371623",
        "http://www.ncbi.nlm.nih.gov/pubmed/18565359",
        "http://www.ncbi.nlm.nih.gov/pubmed/20446099",
        "http://www.ncbi.nlm.nih.gov/pubmed/29550880",
        "http://www.ncbi.nlm.nih.gov/pubmed/22661585"
      ]
    },
    {
      "id": "6429ad3857b1c7a315000003",
      "type": "factoid",
      "body": "The X-inactive specific transcript (Xist) gene is responsible for mediating the X-chromosome inactivation in females, where one X-chromosome is silenced and transcriptionally inactivated. What does Xist encode?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12123576",
          "text": "The process is initiated by a cis-acting RNA, the X inactive specific transcript (Xist).",
          "offsetInBeginSection": 225,
          "offsetInEndSection": 313,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32482714",
          "text": "gulator of X chromosome inactivation in mammals. Xist produces a long noncoding (lnc)RNA that accumulates over the entire length of the chromosome fro",
          "offsetInBeginSection": 63,
          "offsetInEndSection": 213,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17333537",
          "text": "In eutherian mammals X inactivation is regulated by the X-inactive specific transcript (Xist), a cis-acting non-coding RNA that triggers silencing of the chromosome from which it is transcribed.",
          "offsetInBeginSection": 166,
          "offsetInEndSection": 360,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12900551",
          "text": "X inactivation is effected by a large CIS-acting RNA molecule termed the X inactive specific transcript (XIST).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23166390",
          "text": "e master regulator of X-inactivation. The Xist gene produces a non-coding RNA that functions as the primary switch for X-inactivation, coating the X c",
          "offsetInBeginSection": 432,
          "offsetInEndSection": 582,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21626138",
          "text": "Central to XCI is the long non-coding RNA Xist, which is highly and specifically expressed from the inactive X chromosome.",
          "offsetInBeginSection": 187,
          "offsetInEndSection": 309,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9722171",
          "text": "The Xist transcript does not encode a protein but remains sequestered within the nucleus and co-localises with the inactive X chromosome.",
          "offsetInBeginSection": 367,
          "offsetInEndSection": 504,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30539545",
          "text": "X-inactive specific transcript (Xist) is a long noncoding RNA that is essential for initiating and maintaining epigenetic silencing of one copy of the X chromosome in mammalian females.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21613321",
          "text": "X chromosome inactivation (X-inactivation) in female mammals is triggered by differential upregulation of the Xist gene on one of the two X chromosomes and subsequent coating of the X in cis with its non-coding transcripts.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 223,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25000994",
          "text": "The Xist transcript triggers gene silencing in cis by coating the future inactive X chromosome.",
          "offsetInBeginSection": 331,
          "offsetInEndSection": 426,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32482714",
        "http://www.ncbi.nlm.nih.gov/pubmed/12900551",
        "http://www.ncbi.nlm.nih.gov/pubmed/23166390",
        "http://www.ncbi.nlm.nih.gov/pubmed/12123576",
        "http://www.ncbi.nlm.nih.gov/pubmed/21613321",
        "http://www.ncbi.nlm.nih.gov/pubmed/30539545",
        "http://www.ncbi.nlm.nih.gov/pubmed/9722171",
        "http://www.ncbi.nlm.nih.gov/pubmed/17333537",
        "http://www.ncbi.nlm.nih.gov/pubmed/21626138",
        "http://www.ncbi.nlm.nih.gov/pubmed/25000994"
      ]
    },
    {
      "id": "63f92fd033942b094c00000b",
      "type": "summary",
      "body": "What are microexons?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34346508",
          "text": "The splicing of microexons (very small exons) is frequently dysregulated in the brain of individuals with autism spectrum disorder.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10805741",
          "text": "ns six copies of the simple sequence GGGGCUG. The enhancer activates heterologous microexons and will work when located either upstream or downstream ",
          "offsetInBeginSection": 716,
          "offsetInEndSection": 866,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35895262",
          "text": "However, the analysis of RNAs-seq data for detection and quantification of microexons, extremely short exons of length up to 30\u00a0nt, require specialized computational workflows.",
          "offsetInBeginSection": 196,
          "offsetInEndSection": 372,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33859668",
          "text": "Exons with a length \u2264 30 nt are defined as microexons that are unique in identification.",
          "offsetInBeginSection": 155,
          "offsetInEndSection": 243,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34836511",
          "text": "BACKGROUND\nMicroexons are a particular kind of exon of less than 30 nucleotides in length.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32535349",
          "text": "The discovery and characterization of a network of highly conserved neuronal microexons has provided fundamental new insight into mechanisms underlying nervous system development and function, as well as an important basis for pathway convergence in autism spectrum disorder.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 275,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34155820",
          "text": "Microexons are small sized (\u226451\u2009bp) exons which undergo extensive alternative splicing in neurons, microglia, embryonic stem cells, and cancer cells, giving rise to cell type specific protein isoforms.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33482885",
          "text": "BACKGROUND\nMicroexons, exons that are \u2264\u200930 nucleotides, are a highly conserved and dynamically regulated set of cassette exons.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27502555",
          "text": "We discover a conserved AS program comprising hundreds of alternative exons, microexons and introns that is differentially regulated in planarian stem cells, and comprehensively identify its regulators.",
          "offsetInBeginSection": 396,
          "offsetInEndSection": 598,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31999954",
          "text": "Microexons represent the most highly conserved class of alternative splicing, yet their functions are poorly understood.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34155820",
        "http://www.ncbi.nlm.nih.gov/pubmed/34836511",
        "http://www.ncbi.nlm.nih.gov/pubmed/33482885",
        "http://www.ncbi.nlm.nih.gov/pubmed/28188674",
        "http://www.ncbi.nlm.nih.gov/pubmed/33621242",
        "http://www.ncbi.nlm.nih.gov/pubmed/31999954",
        "http://www.ncbi.nlm.nih.gov/pubmed/27502555",
        "http://www.ncbi.nlm.nih.gov/pubmed/31559909",
        "http://www.ncbi.nlm.nih.gov/pubmed/25525873",
        "http://www.ncbi.nlm.nih.gov/pubmed/35895262"
      ]
    },
    {
      "id": "64041f38201352f04a00001f",
      "type": "yesno",
      "body": "Is tebentafusp effective for uveal melanoma?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34885078",
          "text": "Unlike cutaneous melanoma, treatment with kinase inhibitors or immune checkpoint inhibitors is not effective.",
          "offsetInBeginSection": 81,
          "offsetInEndSection": 190,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29692251",
          "text": "So far, there have been no effective targeted therapeutic agents in patients with uveal melanoma.",
          "offsetInBeginSection": 87,
          "offsetInEndSection": 184,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35060440",
          "text": "Recent evidence suggests this drug may become the standard of care for first-line treatment of metastatic uveal melanoma.",
          "offsetInBeginSection": 226,
          "offsetInEndSection": 347,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16489097",
          "text": "Conventional chemotherapy, being the only therapeutic option today against metastatic uveal melanoma, has not proved to be effective.",
          "offsetInBeginSection": 142,
          "offsetInEndSection": 275,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33839690",
          "text": "If approved, tebentafusp could become the standard of care for metastatic uveal melanoma-but only for those patients with a particular HLA allele.",
          "offsetInBeginSection": 172,
          "offsetInEndSection": 318,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31336704",
          "text": "In contrast to cutaneous melanoma, kinase inhibitors and immune checkpoint inhibitors are usually ineffective in patients with metastatic uveal melanoma.",
          "offsetInBeginSection": 178,
          "offsetInEndSection": 331,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36442912",
          "text": "While uveal melanoma is most common in Caucasian populations, other HLA-restricted cancer therapeutics are being developed for indications with more diverse patient populations, such as cervical cancer.We advocate for proactive consideration of the populations eligible for each HLA-restricted therapeutic in development to ensure this emerging therapeutic class does not compound long-standing health disparities.",
          "offsetInBeginSection": 748,
          "offsetInEndSection": 1162,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32273508",
          "text": "Although UM metastases are less responsive than cutaneous melanoma to chemotherapy or immune checkpoint inhibitors, encouraging results have been reported with partial hepatectomy for solitary metastases, with percutaneous hepatic perfusion with melphalan or with tebentafusp.",
          "offsetInBeginSection": 917,
          "offsetInEndSection": 1193,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36229663",
          "text": "Our findings indicate that tebentafusp has promising clinical activity with an acceptable safety profile in patients with previously treated metastatic uveal melanoma, and data suggesting ctDNA as an early indicator of clinical benefit from tebentafusp need confirmation in a randomized trial.",
          "offsetInBeginSection": 1324,
          "offsetInEndSection": 1617,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19032679",
          "text": "Conventional chemotherapy being the only therapeutic option today against metastatic uveal melanoma, has not proved to be effective.",
          "offsetInBeginSection": 141,
          "offsetInEndSection": 273,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36094043",
        "http://www.ncbi.nlm.nih.gov/pubmed/1589858",
        "http://www.ncbi.nlm.nih.gov/pubmed/35172589",
        "http://www.ncbi.nlm.nih.gov/pubmed/31336704",
        "http://www.ncbi.nlm.nih.gov/pubmed/32273508",
        "http://www.ncbi.nlm.nih.gov/pubmed/35236927",
        "http://www.ncbi.nlm.nih.gov/pubmed/29692251",
        "http://www.ncbi.nlm.nih.gov/pubmed/36229663",
        "http://www.ncbi.nlm.nih.gov/pubmed/35716258",
        "http://www.ncbi.nlm.nih.gov/pubmed/36442912"
      ]
    },
    {
      "id": "6426bb49690f196b5100004d",
      "type": "summary",
      "body": "What is the Fenton reaction",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32369069",
          "text": "The Fenton reaction is regarded as an advanced oxidation process that can efficiently remediate environmental pollutants.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36080218",
          "text": "The Fenton reaction is the reaction between iron and hydrogen peroxide, generating hydroxyl radical, which is highly reactive and highly toxic to living cells.",
          "offsetInBeginSection": 150,
          "offsetInEndSection": 309,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25496478",
          "text": "INTRODUCTION\nFenton reaction is the main source of free radicals in biological systems.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32668496",
          "text": "The Fenton reaction generates highly reactive HO\u2022, which has been applied effectively.",
          "offsetInBeginSection": 131,
          "offsetInEndSection": 217,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31343117",
          "text": "Here, the Fenton reaction is used to prepare silk hydrogels through oxidation of tyrosine residues in silk fibroin, leading to dityrosine crosslinking.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17166556",
          "text": "Fenton reaction is a powerful oxidation technology used for the oxidation of groundwater pollutants.",
          "offsetInBeginSection": 134,
          "offsetInEndSection": 234,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26899649",
          "text": "The heterogeneous Fenton reaction can generate highly reactive hydroxyl radicals (OH) from reactions between recyclable solid catalysts and H2O2 at acidic or even circumneutral pH.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35395600",
          "text": "s in aqueous environments. The Fenton reaction, as an effective organic pollution treatment technology, is particularly suitable for the treatment of ",
          "offsetInBeginSection": 291,
          "offsetInEndSection": 441,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19806722",
          "text": "The photo-Fenton reaction, oxidation of photoproduced ferrous iron by hydrogen peroxide, produces reactive oxidants that may be important to degradation of biologically and chemically recalcitrant organic compounds in surface waters at circum-neutral pH.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 254,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28531840",
          "text": "The Fenton process, one of several advanced oxidation processes, describes the reaction of Fe(II) with hydrogen peroxide.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32668496",
        "http://www.ncbi.nlm.nih.gov/pubmed/31259456",
        "http://www.ncbi.nlm.nih.gov/pubmed/36080218",
        "http://www.ncbi.nlm.nih.gov/pubmed/25496478",
        "http://www.ncbi.nlm.nih.gov/pubmed/26899649",
        "http://www.ncbi.nlm.nih.gov/pubmed/34190261",
        "http://www.ncbi.nlm.nih.gov/pubmed/19806722",
        "http://www.ncbi.nlm.nih.gov/pubmed/30991337",
        "http://www.ncbi.nlm.nih.gov/pubmed/16504301",
        "http://www.ncbi.nlm.nih.gov/pubmed/26948406"
      ]
    }
  ]
}